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ABSTRACT 
 Glucocorticoids (GC) are used widely for the treatment of a large number of 
inflammatory conditions. A loss in muscle mass and increases in muscle weakness are 
common complications of GC therapy. Androgen therapy has been suggested to reverse 
GC-associated muscle loss (GAML), but evidence of its effectiveness is inconsistent. 
Herein, I established a mouse model of GAML. Young adult male mice receiving 10 
mg/(kg day) of the GC dexamethasone (Dexa) s.c. daily, for a week, lost 3% of their total 
body weight. Based on NMR lean body mass quantification and muscle dissection, more 
than 10% of their muscle mass was lost. More than half of the Dexa-induced muscle loss 
could be reversed by co-administration of 35 mg/(kg day) of testosterone (Testo). To my 
knowledge, this is the first mouse model of GAML demonstrating alleviation by Testo. 
 Dexa-upregulated intramuscular atrogene expression and proteasome catalytic 
activity were suppressed by Testo co-administration. Dexa downregulated cathepsin L 
enzymatic activity and beclin expression, indicating that lysosome was not a major 
effector of GAML. Changes in calpain 1 and in translation factors 4E-BP, eIF3f and 
eIF2, following Testo treatment, were inconclusive. The changes in proteasome activity 
  vii 
and atrogene expression were correlated with changes in expression of Foxo 1, 3a, and 4. 
Pro-catabolic factors REDD1 and Klf15 were repressed by Testo co-administration. 
 C2C12 differentiated myotubes were used to model GAML in vitro. Myotube 
diameter and total protein were reduced by Dexa, and restored by Testo co-
administration. Changes in C2C12 total protein were correlated with changes in protein 
degradation. Dexa-induced proteolysis was inhibited by the proteasome inhibitor MG132. 
 In vivo, Dexa reduced intramuscular IGF-I expression, an effect reversed by Testo 
co-administration. In C2C12, inhibition of IGF-1R signaling with picropodophyllin did 
not modify Testo protective effect. Mechanisms potentially explaining these observations 
are discussed. 
 In summary, my model demonstrates that Testo protective effect in GAML is 
mainly anti-catabolic, through the reversal of proteasome upregulation induced by Dexa. 
In vivo, Testo stimulates a potentially protective intramuscular IGF-I response. The roles 
of protein synthesis and IGF-I in anabolic myoprotection could not be addressed in these 
models, and require further investigations. 
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CLINICAL QUESTIONS AND EVIDENCE 
Cushing’s syndrome and hints of an atrophy mechanism 
Maintenance of muscle mass and force is dependent on the well-adjusted 
endocrine system. The first evidence for this muscle-hormones interaction came from 
diseases, interpreted as natural experiments. Interestingly, the role of adrenal hormones in 
muscle homeostasis was deduced from perturbations of another gland, the pituitary. 
Through the detailed case series written by Harvey Cushing [3], the scientific and 
medical community became aware of an otherwise rare disease, which bears his name. 
Unlike the earlier and better-studied deficiencies of the thyroid and pancreas, pituitary 
defects are more variable in manifestation and therefore harder to unify in a single 
clinical entity. Even when macroscopic hypertrophy of pituitary was localized to a gland 
subdomain, pathological mechanisms were ambiguous. Symptoms could have been 
attributed to a hypersecretion from the hypertrophied sector, or to a deficiency in the 
neighboring compressed structures. Pituitary extracts caused multiple, and even opposite 
effects, in animal models [4], further proving the heterogeneous nature of pituitary 
secretion. 
Among 50 cases described by Cushing, about five stood out due to the 
involvement of other glands. In each of them, and, to a lesser extent, in a few more cases, 
“hyperadrenalism” was blamed for asthenia, hyperpigmentation of skin, low blood 
pressure, and hypoglycemia. Histopathology tests localized the adrenal abnormalities to 
the zona fasciculata of the cortex. Cushing wrote that some of these abnormalities reflect 
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current adrenal hypoactivity, caused by exhaustion after preceding intense stimulation 
and hyperactivity. 
Twenty years later, Cushing narrowed the focus in an updated case series of 
combined pituitary-adrenal pathology [5]. Cushing noted that basophile adenomata of the 
pituitary and hypertrophy of the adrenal glands often coexisted. Based on the curative 
effect of pituitary surgery, he hypothesized that the adrenal defect is secondary to the 
pituitary abnormality. In turn, he inferred that the adrenal changes mediate the disease 
phenotype, which includes obesity with ectopic adipose deposits, kyphosis, amenorrhea / 
impotence, hypertrichosis, lineae atrophicae, fatigability and weakness. Among these 
disease manifestations, muscle impairment was a serious, if variable, component. 
Cushing considered intense muscle loss the cause of death for one of these cases. 
Cushing’s work did little to elucidate mechanisms leading to the phenotype. The 
variability in pituitary changes between the cases he described meant that many scientists 
rejected his hypothesis of pituitary primacy. A group at the Mayo Clinic was actively 
pursuing the opposite hypothesis, with the adrenal as the primary site of impairment in 
adrenal-pituitary combined afflictions [6]. On the clinical side, it was noted that some of 
Cushing’s patients lacked observable pituitary changes. Moreover, some of the Mayo 
patients were cured by adrenal surgery. From a theoretical perspective, the adrenal 
hypothesis was more tempting because the adrenal deficiency (termed Addison’s disease) 
and its reversal by administration of adrenal cortex extracts were better known than 
pituitary pathology [7]. 
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Today, we know that the truth was more nuanced. Hypersecretion of the adrenal 
cortex hormones cortisol and / or corticosterone is termed hypercortisolism. One or more 
clinical signs classically described by Cushing (listed above) suggest to the practitioner 
the activation of the hypothalamic - pituitary - adrenal (HPA) axis. Cushing’s syndrome 
(CS) comprises clinical manifestations of hypercortisolism attributable to HP 
hyperactivity and biochemical confirmation by an increase of urine free cortisol 
measurements, or by the effacement of the evening trough in circulating cortisol [8]. 
Some hypercortisolism cases, termed pseudo-Cushing’s syndrome, are ascribed to causes 
outside the HPA axis, such as in depression, morbid obesity, uncontrolled diabetes 
mellitus, and sleep apnea (reviewed in [9]). 
True CS cases are further classified based on the role of the adrenal-stimulating 
pituitary hormone corticotropin (adrenocorticotropic hormone; ACTH). In some CS 
patients, hypercortisolism is paralleled by an increase in ACTH. Their adrenals are 
usually responsive to further ACTH stimulation tests, indicating that previously intact 
adrenals underwent hyperplasia in response to a pathological overstimulation with 
ACTH. When attributed to the pituitary, such ACTH hypersecretion, followed by 
secondary hypercortisolism, is termed Cushing’s disease (reviewed in [10]). Cushing’s 
disease remains a staple of physiology textbooks, because it provides an excellent 
didactic example of a hormone hierarchy. 
The remainder of CS cases consists of hypercortisolism despite low ACTH. In 
primary hypercortisolism, ACTH is typically suppressed by negative feedback. Adrenal 
neoplasms are the most frequent cause of primary hypercortisolism. Ectopic or diffuse 
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unregulated sources of ACTH or cortisol may cause hypercortisolism. In recent decades, 
overdose with synthetic derivatives of cortisol became the most important cause of low-
intensity CS (discussed in the next section). 
Although CS may originate in various HPA pathologies, muscle impairment is 
one of its most common, unifying features. 
Glucocorticoid therapy 
A series of serendipitous decisions brought impressive knowledge about CS of 
non-pituitary etiology (reviewed in [11]). First, during World War II, US intelligence 
learned that Germans were importing large quantities of adrenal glands from neutral 
Argentina. This reignited US government interest in corticoadrenal research, despite the 
lackluster results with earlier adrenal extracts. At the end of the war, only a few grams of 
pure adrenal steroids were manufactured, from endogenous sources and at a high cost. 
The second opportunity was in the allocation of those scarce steroids. One of them, 
cortisone, made by Merck, was shared by a few clinical researchers, including Phillip 
Hench. Hench’s request was based on his previous work on rheumatoid arthritis. He 
observed that rheumatoid arthritis was alleviated in jaundice, and hypothesized the 
existence of a steroidal “anti-rheumatoid factor.” Third, Hench’s choice of dose and route 
elicited an extraordinary reversal in arthritic pain and dysfunction. In 1949, after treating 
only five patients [12], impressive improvements in those cases reordered priorities in 
corticosteroid research. 
Previous work described multiple effects for adrenal extracts. In fact, adrenal 
research was considered a dead end prior to cortisone purification, because less pure 
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extracts combined antagonistic hormones in variable doses, seemingly lacking defined 
pharmacological or endocrine relevance. Even with purified cortisone, Hench saw a very 
diverse set of consequences for cortisone administration [13]. However, Hench’s 
observations were replicable, demonstrating the complex and vital role of the adrenal. 
First, cortisone’s action on metabolism was accessible even to the less 
sophisticated clinical measurements used 60 years ago. Patients receiving cortisone gain 
weight. Chronic cortisone therapy leads to accumulation of adipose tissue, often in 
ectopic locations, such as the interscapular “buffalo hump.” Cortisone also induces 
hyperglycemia, and subsequent glycosuria. For this reason, cortisone and its endogenous 
and synthetic analogs are grouped in the glucocorticoid (GC) family. 
Hench and collaborators hypothesized that cortisone’s protective action is not 
limited to rheumatoid arthritis. In his 1950 Nobel lecture, Hench envisaged a role for 
alleviation of most inflammatory diseases. GCs share the ability to reduce inflammation 
(reviewed in [14, 15]). Some of these anti-inflammatory effects, such as reduction in the 
number of circulating white blood cells, are ample and robust. Other aspects of GC action 
remain under active study, facilitated by the rapid progress of immunology. The 
questions still open illustrate the convoluted ways in which GC signals are relayed in the 
cell. For example, GCs are often acting in a manner shared with all steroid hormones, by 
binding and activating the glucocorticoid receptor (GR). Activated GR translocates from 
cytosol to the nucleus, where it dimerizes on specific DNA sequences, termed 
glucocorticoid responsive-elements (GRE) [16]. The classical effect of the GRE-GR 
interaction is increased transcription for target genes in the proximity of GRE 
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(transactivation), as it is the case in polymorphonucleate cells for interleukin 1 (IL-1) 
receptor type II (IL-1RII) [17], a decoy inhibitor for the pro-inflammatory IL-1. In other 
circumstances, the activated receptor inhibits transcription directly (transrepression), or 
by interfering with transcription factors. For example, in human T lymphocytes, GCs 
inhibit the transcription factor activator protein 1 (AP-1), thus causing a reduction in their 
ability to synthesize pro-inflammatory interleukin 2 (IL-2) [18]. GCs employ 
nongenomic mechanisms, such as mRNA stability and enzymatic activity modulations. In 
airway epithelia, GCs reduce the half-life of the mRNA for interleukin 8 (IL-8), the major 
chemoattractant for neutrophils [19]. Within minutes, GC administration induces 
vasodilation, through direct, nongenomic activation of endothelial phosphatidylinositol 3-
kinase (PI3K) leading to activation of endothelial nitric oxide synthase (eNOS) [20]. 
Some GC effects may be limited to a range of doses, durations, and frequencies of 
administration. Moreover, the example of adrenalectomized rats re-supplemented with 
corticosterone, their most abundant endogenous GC, illustrates how, at times, the same 
GC can induce or repress the same cellular response, depending on the dose. A lower 5 
mg/kg dose enhanced the immune skin delayed-type hypersensitivity, while a 40 mg/kg 
dose yielded the opposite, expected immunosuppressive response [21]. This biphasic 
behavior, suggestive of a U- (or inverted-U) shaped curve, poses great challenges, both to 
the investigative scientist, and to the clinician attempting to establish a therapeutic 
regimen. 
In 1950, naturally occurring GCs corticosterone and cortisol, were synthesized at 
Merck [22], thus lowering the price and creating the opportunity for large-scale trials. 
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The Empire Rheumatism Council organized a randomized trial comparing cortisone with 
acetylsalicylate, and concluded that there is no benefit in cortisone [23]. While 
participants receiving cortisone claimed an improvement in subjective well-being, they 
were afflicted more often with deleterious side effects, including edema and 
hypertension. In retrospect, a comparison between two palliative symptomatic therapies 
using cure-indicating outcomes was likely misleading. Nevertheless, cortisone was 
deemed unfit for therapeutic purposes, at least in Britain. This failure initiated a race for 
designing synthetic novel GCs (reviewed in [24]). While synthesizing esters with a better 
half-life, Schering chemists introduced a double bond in the A ring of cortisone, thus 
discovering prednisone, the first widely used oral GC [25]. Prednisone was a better anti-
inflammatory than cortisone, but had a lower ability to cause edema. This was the first 
suggestion that the many GC effects could be separated by chemical modifications. In 
1955, NIH researchers synthesized and characterized prednisone’s active metabolite, 
prednisolone [26]. In a trial of prednisolone versus acetylsalicylate in rheumatoid 
arthritis, the GC provided better functional protection to the articulations [27], thus 
establishing prednisolone as a standard of care and making GCs even more interesting for 
chemists. 
Further improvements were made at Squibb, where it was found that insertion of a 
halogen atom improves GCs anti-inflammatory effect [28, 29]. In 1958, Merck chemists 
led by Arth modified cortisol with the unsaturated A ring (Δ1 ), the fluoride addition at 
position 9α, and with a methyl group on the 16α position to obtain dexamethasone (Dexa) 
[30, 31]. Dexa is the most effective and specific therapeutic synthetic GC to date, with 
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170 times higher ability to inhibit the immune reaction to subcutaneous foreign bodies 
(granuloma) compared to cortisol [32]. The other benefit of Dexa is its virtual inability to 
cause edema and electrolyte imbalance. 
In addition to being a strong anti-inflammatory, Dexa is 52 times more potent in 
suppressing endogenous GC secretion, and 35 times more potent in causing 
hyperglycemia compared to cortisone [33, 34]. Efforts to synthesize steroids with anti-
inflammatory action that do not interfere with metabolism have failed. Compounds such 
as A276575 [35] and RU 24858 [36] failed in preclinical studies. Mapracorat [37] did not 
progress beyond phase II clinical trials. These facts demonstrate that the anti-
inflammatory and hyperglycemic actions are intermediated by the same specific, Dexa-
sensitive receptor, whereas electrolyte changes are caused by cortisol through a different 
pathway. Clinicians prescribing GCs in these five decades had to balance therapeutic 
benefit with metabolic side effects, and, in the case of less specific GCs, with the water 
retention. 
Edema is an example of non-specific GC effect, caused by a less typical 
interaction of the hormone with the mineralocorticoid receptor (MR). The GC family 
spans tens of active principles and thousands of formulations, from weak GCs with lower 
specificity, such as cortisone, to strong, specific GCs, such as Dexa. When strong GR 
activation is desired, clinicians have to use Dexa in order to avoid MR activation. When 
safety is desired, such as in over-the-counter products, low-activity, low-specificity 
compounds are preferred. 
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Chronic GC therapy causes glucose metabolism disturbance, osteoporosis, and 
muscle loss, suggesting that their therapeutic use is limited. However, their efficacy 
makes them some of the most commonly used drugs. The trivial case for using GC 
therapy is in hormone replacement, such as in adrenocortical insufficiency (reviewed in 
[38]). In addition, many other diseases are alleviated by GCs to a degree that deleterious 
effects are outweighed. Based on their ability to lower white blood cell count, GC are an 
important adjuvant in the palliative and even etiologic treatment of leukemias and 
lymphomas [39, 40, 41]. On the balance of benefits and drawbacks, GCs are 
recommended for many life threatening or impairing immune reactions, such as 
polymyositis (reviewed in [42]), severe sarcoidosis (reviewed in [43]), and disseminated 
pulmonary tuberculosis. GCs are relatively safe in topical applications in dermatological 
conditions (pemphigus, psoriasis, most types of dermatitis; reviewed in [44]). Similarly, 
GCs are commonly used in eye inflammatory conditions [45, 46], such as diffuse 
posterior uveitis and optical neuritis. GC therapy is suitable for brief administration in 
acute immune or allergic conditions, such as seasonal rhinitis (reviewed in [38]). In 
chronic diseases, GCs are recommended for short-term alleviation of exacerbations. 
Short-term GC therapy is recommended for rheumatoid arthritis, gouty arthritis, psoriatic 
arthritis, ankylosing spondylitis, asthma [47, 48], ulcerative colitis [49, 50], and 
idiopathic nephrotic syndrome [51]. 
As envisaged by Hench in his Nobel Lecture, GCs do not address disease causes, 
and are recommended for temporary respite. For many immune diseases, more specific 
therapeutic alternatives have been developed. The list of Food and Drug Administration 
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(FDA)-approved indications for cortisone, Dexa, and prednisone is often narrowed by 
additional precautions, and by newly discovered drugs [52, 53, 54]. Nevertheless, off-
label use of GCs is very frequent. For example, GCs are perceived by physicians as a 
fallback therapeutic alternative for cerebral hypertensive conditions, despite scarce 
evidence for efficacy in any specific conditions. Small trials suggest GCs reduce 
vasogenic cerebral edema [55] and prevent acute mountain sickness [56]. These studies 
have been carried although earlier systematic reviews showed that, in fact, GCs worsen 
outcomes for acute brain trauma victims [57]. This example illustrates how strongly 
rooted are off-label uses of GCs. 
A similar, paradoxical situation is seen in ongoing clinical research. As of 2015, 
the patent-free status of the GCs discourages trials for new indications, while their de 
facto standard-of-care status makes them a common comparator in clinical trials. The 
National Cancer Institute sponsors 311 ongoing clinical studies employing Dexa, mainly 
in the standard-of-care arm, thus providing a plethora of data that have been, and may 
still be, misconstrued as support for the use of GCs. Everyday practice may drift further 
apart for the officially sanctioned label, thus providing new opportunities for unjustifiable 
overdose. 
This wide array of uses make GCs some of the most prescribed and used drugs. 
Despite the low prevalence of the conditions proven to benefit from GC therapy, every 
year, about 1% of the Americans and British receive some form of GC [58, 59]. GCs are 
likely even more prescribed in the developing world, due to affordability and lack of 
alternatives, poor access to health care notwithstanding. Dexa and cortisol are the only 
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drugs listed five times in the World Health Organization’s List of Essential Medicines 
[60]. Due to their widespread use, GCs are likely to cause covert iatrogenic CS in a large 
population, impairing muscle mass and quality of life to a certain and understudied 
degree. 
Hypercortisolism-induced muscle loss 
Primary and secondary endogenous hypercortisolism are rare diseases (1-2 cases 
per million and year each [61]), despite a recent boost from incidental imaging diagnoses. 
The symptomatology is non-specific, meaning that, even today in the developed world, 
an average of 6 years pass from signs onset until diagnosis is made and treatment is 
initiated [62]. Endogenous hypercortisolism is a life-threatening disease, with untreated 
patients having a median survival rate of 5 years after diagnosis [63]. Some of the 
changes occurring in Cushing’s disease are irreversible, especially at the level of brain, 
bone, adipose tissue, and liver levels (reviewed in [64]). Even after surgical adjustments 
of the hyperactive pituitary, the quality of life for CS patients lags behind that of the 
unaffected population. 
About two thirds of patients with Cushing’s syndrome acknowledge muscular 
problems at presentation, with similar incidence among pituitary and adrenal conditions 
[65]. Among patients diagnosed with endogenous CS, one fifth are referred to the 
endocrinologist due to muscle weakness [66]. Two fifths of those whose endogenous 
hypercortisolism is successfully corrected by surgery still complain of fatigue [67]. 
On the other hand, therapy-induced (iatrogenic) CS is common. The glut of GC 
indications and off-label uses makes them some of the most used drugs in the developed 
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countries, as described earlier. In most cases, the cause of iatrogenic CS can be identified 
by careful history taking and medication reviews. However, an increasing number of 
cases are not as easily diagnosed, because the excess GC is not from prescription 
medicine. In United States, FDA approved in 1979 over-the-counter sale of 0.5% 
hydrocortisone cream for itching and minor skin inflammation. In 1990, 1% 
hydrocortisone creams were also permitted [68]. In 1987, hydrocortisone creams became 
over-the-counter in Great Britain. Regulated over-the-counter GC creams rarely cause CS 
on their own, but have been frequently suspected to lower the threshold for CS in patients 
who are also prescribed oral GC. Unregulated, mislabeled, overdosing GC creams sold as 
skin-bleaching products pose a great CS risk to patients from ethnic groups with darker 
skin. Half of the respondents in a Nigeria poll admitted using GC-based skin bleaching 
products [69]. In 2015, the Ivory Coast government made illegal skin bleaching products, 
due to worries about GC overdose side effects [70]. The side effects of skin bleaching are 
well recognized by the sub-Saharan medical community. Paradoxically, CS caused by 
bleaching products may be less identifiable to practitioners who care for the African 
diaspora in the developed world, where bleaching is more frequent, due to improved 
financial access and social pressures [71, 72]. 
Other, less frequent causes of iatrogenic CS include the interaction between low 
dose GC therapy and cytochrome P450 3A4 inhibitors, such as the antiretroviral ritonavir 
[73]. Other steroid drugs may interact with GR and cause CS when overdosed, as it is the 
case with the synthetic progestin megestrol acetate [74]. 
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Due to its insidious and erratic symptomatology, iatrogenic CS is often diagnosed 
years after onset or completely unrecognized [62]. The incidence of iatrogenic CS is 
difficult to estimate, because there is no reporting requirement. In the developed world, 
iatrogenic CS could be as frequent as one case per thousand and year [75]. 
Signs of iatrogenic CS are as varied as those of Cushing’s disease. In a cohort of 
patients receiving for three months more than 0.4 mg/(kg d) prednisone, the most 
common signs were development of ectopic adipose deposits (50%), hyperphagia (47%), 
and muscle cramps (32%) [76]. In the same cohort, 15% complained of muscle weakness. 
Patients stated that the most distressing signs of hypercortisolism were, in order, body 
shape changes, neuropsychiatric disorders, muscle cramps, and hand tremor. In 1982, the 
most common cause of iatrogenic muscle weakness was GC therapy [77]. 
There are differences between GC-induced cardiovascular changes, depending on 
the nature of the GC. Endogenous GCs, such as cortisol, have hypertensive effects, while 
some synthetic GCs, Dexa included, lack such non-specific MR-dependent action. 
Nevertheless, excess exogenous and endogenous GC causes the same disabling effects on 
muscle [78], indicating that muscle damage is mediated by GR. GCs differ quantitatively 
in their ability to cause myopathy. Myopathy is invariably induced in two weeks by either 
0.2 mg/(kg d) Dexa [79], or by 0.5 mg/(kg d) prednisone [80]. Based on animal studies, it 
is likely that the catabolic potency ratio is even more tilted towards Dexa than the 
referenced studies indicate. Modern human pharmacodynamics and epidemiological 
studies are needed, in order to establish actual safety thresholds. 
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In their 1958 case series, Muller and Kugelberg were the first to describe muscle 
changes associated with long-term Cushing’s disease [81]. In their mixed, primary and 
secondary, endogenous hypercortisolic cohort, they found that complaints of muscle 
weakness were primarily localized on the thigh. Objective loss of muscle force was 
correlated with histopathological changes indicative of a muscle fiber defect, such as 
degenerated fibers, at times hyalinized or with loss of striation, muscle replacement with 
fat and connective tissue, and rare hypertrophic fibers. Through electromyography, they 
established that the number of motor units is unaffected. Together with lack of changes in 
reflexes, their work negated a neurological component of CS. Muller and Kugelberg 
noted that hypercortisolism is correlated with faster extinction of the action potential, 
which is typically caused by a reduction in the number of muscle fibers, or by fiber 
atrophy [82]. Based on the evidence that CS is a muscle fiber disease, they coined the 
phrase “steroid myopathy” (in opposition to a hypothetical “neuropathy”). Similar 
electromyography changes are induced by long-term GC therapy [83], making some 
authors reserve the term “steroid myopathy” to muscle complaints of iatrogenic etiology. 
In 1966, D’Agostino and Chiga, confirming histological fiber changes in a rabbit model 
of iatrogenic CS, formulated the more precise, yet less commonly used “glucocorticoid 
myopathy” [84]. Owing to the fact that glucocorticoid myopathy is not a standalone 
disease or syndrome, terminology has never been standardized. In the present work, the 
human condition will be designated glucocorticoid myopathy, while its animal models 
will be termed GC-associated muscle loss (GAML). 
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In exogenous CS, GC excess can be better quantified. In a population with 
neurological maladies receiving long-term Dexa, the threshold for manifest 
glucocorticoid myopathy appears to be 50 µg/(kg d) [85]. However, the most significant 
predictor of clinical GAML is total dose [79, 86]. When GAML develops, the amplitude 
of electromyography changes (that is, the reduction in action potential duration) is 
proportional with the total GC dose [87]. These findings imply that glucocorticoid 
myopathy can be induced in shorter periods, if the GC dose is extremely high. Foye and 
colleagues drew a distinction between “classic” or “chronic” glucocorticoid myopathy, 
induced “within weeks to years,” and “acute” glucocorticoid myopathy, induced in 5-7 
days of high-dose GC [88]. However, their description of the two forms of GAML is 
almost identical, suggesting that the two clinical entities are largely overlapping. 
In a comparative study of patients receiving GC therapy for asthma, half of the 
patients receiving more than 0.2 mg/(kg d) prednisone exhibited a reduction in hip flexor 
strength of 2 SD or more, compared with healthy age- and sex-matched controls [80]. In 
a study of adults with brain or spine cancer, 60% of the participants experienced loss of 
iliopsoas muscle force in response to GC therapy for cerebral edema [79]. In a small 
cohort, 6 months of 0.16 mg/(kg d) prednisone treatment was associated with a 20% 
reduction in thigh muscle force, compared to healthy controls [89]. Such findings suggest 
that GC-induced weakness has functional consequences. 
In a post-hoc analysis of a chronic obstructive pulmonary disease (COPD) trial, 
the placebo arm was stratified in GC-treated and GC-naive groups [90]. The maximal 
inspiratory mouth pressure, a proxy measurement for respiratory muscle strength, was 
  
16 
significantly better maintained over the 8 weeks of the trial in the GC-naive, compared to 
GC-treated participants. Involvement of partly-involuntary muscles further proves that 
glucocorticoid myopathy is caused by an objective muscle disorder, and negate the 
alternative, neuropsychiatric etiology. 
Another investigative direction in the study of GC-induced muscle weakness 
focused on muscle mass and volume. Although correlated, muscle force, mass, and 
volume are not completely reflecting each other. The most accessible proxy 
measurements of muscle mass, such as mid upper-arm or thigh circumference, are not 
sensitive enough in monitoring GC-induced muscle loss, even after subtracting skin fold, 
because GC stimulate intramuscular adipose deposits [91]. The advent of modern 
imaging allowed non-invasive muscle measurements. Chronic prednisone administration 
causes a 20% reduction in mid-thigh muscle area measured by computed tomography, 
and a 36% increase in the ratio of fat-to-muscle areas (CT) [92]. Psoas muscle area and 
density, measured by computed tomography, are inversely correlated with GC levels 
indicated by 24-hour urine cortisol (24HUC) [93]. 
Muscle fibers are classified in types, based on their adaptation to either endurance 
or brief strong bursts. Fast-twitch fibers are further classified based on their propensity 
for aerobic or anaerobic (glycolytic) metabolism. Differential effects on fiber types and 
inter-type conversions have been observed in many muscle-afflicting maladies. For 
example, gains in the ratio fast-to-slow twitch fibers are associated with insulin resistance 
[94]. In contrast, aging is correlated with preferential loss of fast fibers [95]. Reports of 
type-specific effects of GC are inconclusive. In one study, women with CS had an 
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increased proportion of type IIx (fast twitch, glycolytic) and a lower proportion of type I 
(slow twitch, oxidative) fibers in their vastus lateralis muscles [96]. Renal transplant 
patients receiving 25 mg/(kg d) prednisone over three months had lower cross-sectional 
area (CSA) in type IIa (slow twitch, oxidative / glycolytic) and I fibers [97]. Others found 
that all types of fibers are uniformly affected by GC [98]. This hypothesis was further 
followed in animal studies. 
A set of muscle mononucleate cells, expressing the paired-box transcription factor 
Pax7, are presumed to support muscle development and regeneration, and are termed 
satellite cells (reviewed in [99]). There are no definitive studies describing the effect of 
GC in human satellite cells. Some or all satellite cells may be activated to proliferate, 
thus becoming myoblasts. Many in vitro assays use proliferating cells from human 
muscle, at times assumed to be myoblasts. These human “myoblasts” do not proliferate in 
the absence of at least 1 µM Dexa( [100], and personal observation; data not shown). For 
comparison, maximum normal concentration of endogenous cortisol in humans is 0.78 
µM [101], that is, tens of times less potent. Therefore, it is impossible to conceive an 
experiment where human myoblasts in culture are subjected to meaningful manipulations 
of GC concentration. The fact that GCs are vital for in vitro human muscle development 
and maintenance suggests that cell lines that do not require GC may be less accurate 
models of human muscle. 
There are no published cases of increase in circulating myoglobin or creatine 
kinase in response to GC monotherapy, or as a consequence of Cushing’s disease. The 
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absence of such intramuscular protein from the blood flow suggests GC do not cause 
rhabdomyolysis, that is, loss of muscle through uncontrolled rapid membrane leakage. 
GC therapy induces a massive loss of nitrogen, a side effect seen from its first 
trial [102]. The ample increase in urinary creatine and creatinine is evidence for 
upregulated tissue protein breakdown. As little as 20 µg/kg cortisol infused over 8 hours 
increases by a quarter the rate of appearance of leucine into the bloodstream, suggestive 
of acute proteolysis upregulation [103]. Leucine’s rate of appearance is even higher when 
the GC-induced hyperinsulinemia is prevented, indicating that whole-body experiments 
do not capture the amplitude of the GC-induced proteolysis [104]. More modern mass 
spectrometric methods revealed that a single dose of 1 mg/kg prednisolone cause 
increases in all blood amino acids, presumably due to mobilization from muscle sources 
[105]. The same acute treatment causes an increase in 3-methylhistidine (3MH), a non-
recyclable degradation product specific to muscle actin and myosin [106]. Similar 
increases in 3MH are seen with control diet in chronic GC excess of endogenous or 
exogenous nature [98]. These findings demonstrate that GC-induced loss of muscle mass 
is mediated by stimulation of protein degradation. 
The last three decades brought a better understanding of protein degradative 
pathways and of muscle atrophy. Two distinct proteolytic systems, the proteasome - 
ubiquitin system and the autophagosome (discussed in later sections), have been 
discovered. Unfortunately, only one published trial investigated the action of GC in 
human muscle biopsies, at a molecular level. It failed to find a significant change in 
mRNA of ubiquitin and the C3 subunit of the proteasome [107]. The result is 
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unsurprising, given that the control of the proteasome system may be exercised in other, 
unexplored ways. In animal models, the genes most correlated with muscle loss, 
including GAML, are two E3 ubiquitin ligases, muscle atrophy F-box (MAFbx; gene 
known as Fbxo32) and muscle RING finger 1 (MuRF1; gene known as Trim63), but no 
published studies confirm or refute their modulation in humans (reviewed in [108]). 
Recently, pharmacological inhibitors of the proteasome became widely available. 
The first proteasome inhibitor, bortezomib, is recommended by the FDA for multiple 
myeloma and mantle cell lymphoma [109]. The second generation, irreversible 
proteasome blocker carfilzomib is also approved for advanced myeloma therapy [110]. In 
the light of data from the animal models of muscle loss, these drugs should have been 
useful in cachexia, but, to date, no human trials investigated their ability to prevent 
muscle atrophy. 
There are no trials comparing GC with the combination (GC + bortezomib). 
However, an indirect comparison can be made. In a trial for multiple myeloma, fatigue 
was a complaint of 32% of the participants receiving 40 mg Dexa, compared to 42% for 
bortezomib [111]. In another trial, addition of 20 mg Dexa to bortezomib lowered the rate 
of fatigue from 57% to 25% [112]. Neither finding is suggestive for superiority of that the 
combination (Dexa + bortezomib) to Dexa alone. Clinical studies directly addressing this 
comparison are recommended, given that the most commonly accepted hypothesis 
centers on the proteasome as main effector of GC-induced muscle loss. Proving a 
beneficial action of bortezomib in co-administration with GC will have major practice-
changing implications. Even proving the opposite, that bortezomib has no protective 
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action, will be very valuable in better understanding and eventually preventing GC-
induced muscle loss. 
The inhibition of the other proteolytic system, the autophagosome, is also the 
focus of clinical studies. Starting with the inexpensive antimalarials chloroquine and 
hydroxychloroquine, autophagosome inhibitors are now the focus of phase II clinical 
studies in many cancers [113]. Interestingly, hydroxychloroquine is also recommended 
for rheumatoid arthritis, where it may be prescribed for up to six months [114]. However, 
to my knowledge, no clinical trial compared hydroxychloroquine with GC. Chronic 
hydroxychloroquine therapy is known to induce muscle weakness and sporadic 
myopathy, through a distinct, vacuolar mechanism. The hydroxychloroquine-induced 
myopathy is associated with an increase in autophagosome markers in muscle, 
demonstrating the importance of autophagosome in muscle regulation [115]. In two 
separate case reports, co-administration of prednisone and hydroxychloroquine led to 
vacuolar myopathy, which could be caused by the choice of doses, or could be indicative 
of true epistasis [116, 117]. Potential benefits of anti-lysosome co-therapy in 
glucocorticoid myopathy remain the subject of speculation. 
Another putative parallel mechanism for GC-induced loss of muscle is 
downregulation of protein synthesis. Few human trials measured directly the effect of GC 
on protein synthesis in healthy volunteers. Brillion and colleagues [104] found that an 80 
mg cortisol infusion over 13 hours led to 8% increase in non-oxidative leucine uptake, 
indicating an upregulation of protein synthesis. However, using a 200 mg cortisol 
infusion in the same protocol failed to cause a detectable change in protein synthesis 
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compared to placebo, suggesting a biphasic response. Löfberg and colleagues [107] 
found that three days of 65 mg / day prednisolone caused a non-significant 21% increase 
in protein synthesis rate and a statistically significant 52% increase in the rate of protein 
degradation, based on the difference between arterial and venous levels of tritiated 
phenylalanine at leg level. Short and colleagues employed fractional synthesis rate (FSR), 
which describes the time rate of enrichment in muscle tracer, normalized to the 
circulating tracer concentration. They concluded repeatedly that, in leg muscles, 35 mg / 
day prednisone for 6 days “has no effect on [...] muscle protein metabolism or muscle 
function” [118, 119]. Some of these studies may have been underpowered (sample size n 
= 6-7) or may be troubled by the use of a small dose. Nevertheless, their validity is 
confirmed by the fact that, in each case, the expected hyperglycemic response to GC was 
observed. 
The hypothesis that GC cause muscle loss by inhibition of protein synthesis is still 
debated, due to a plethora of indirect evidence. In Löfberg’s study, biopsies revealed a 
prednisolone-induced loss of muscle polyribosomes, interpreted as evidence for decrease 
in protein synthesis rate. Even in studies where GC failed to elicit reductions in protein 
synthesis, they inhibited translation-stimulating signals in muscle from anabolic factors 
such as insulin [120], branched chain amino acids [121], and exercise [122]. 
At a molecular level, it appears that Dexa inhibits anabolic signals centered on the 
Akt / mechanistic target of rapamycin (mTOR) axis. Rather than directly repressing this 
axis, GCs appear to reduce sensitivity of this axis to upstream stimuli. One study on 
humans described how Dexa inhibits branched chain amino acids’ ability to induce 
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phosphorylation of mTOR substrates eukaryotic translation initiation factor 4E (eIF4E) 
binding protein (4E-BP) and p70-S6K [123]. In the same study, Dexa had no effect on 
another translation regulator, the α subunit of the eukaryotic initiation factor 2 (eIF2). 
More evidence has been obtained from animal models (discussed in a dedicated section). 
In addition to GC excess, muscle weakness is observed with GC withdrawal 
[124], and by GC deficiency, illustrated by the Addisonian crisis [125]. In both 
hypercortisolism and hypocortisolism, effects on human muscle remain understudied. 
Animal models have been essential for the study of GC-induced muscle loss (discussed in 
the dedicated section). Human studies agree that GC-induced loss of muscle force is an 
objective finding caused by an increased proteolytic activity. Indirect evidence indicates 
that human GAML is associated with changes in protein synthesis. Current guidelines 
suggest GC discontinuation if myopathy develops, because proven mitigating 
interventions have not been developed. 
Muscle protection with androgen therapy 
A series of historical circumstances brought anabolic androgenic steroids (AAS) 
in the attention of clinicians treating hypercortisolism in muscle. The same circumstances 
meant that utility of AAS therapy in glucocorticoid myopathy has never been fully 
explored. 
Male hormones have been considered an efficacious anabolic therapy long before 
they were purified and tested. The effects of male castration, such as reductions in 
aggressiveness and muscle force, were discovered independently by many human 
civilizations, starting more than three thousand years ago. Castration is omnipresent in 
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ancient mythology, and, more mundanely, in primitive farming. For almost as long, 
people perceived testis ingestion as a reversal of castration, thought to improve muscle 
force. Such perceptions were caused by the placebo effect alone, given that this testis 
active principle is almost completely degraded by liver. 
Testis extract benefits received more attention starting around 1889, when Brown-
Séquard published his theory about rejuvenating abilities of sperm. He thought that loss 
of sperm during aging or masturbation causes degradation in muscle and brain 
performance, and hypothesized that chemicals from sperm may pass into blood where 
they have “a most-essential use in giving strength to the nervous system and to other 
parts.” Consequently, he injected himself with a combination of sperm and testis extracts, 
which led to self-reported improvements in physical and intellectual abilities [126]. He 
describes how, at the age of 72, a single injection enables him stand for hours, or write 
longer scientific papers. Later on, he describes how testis extracts appeared to alleviate 
“serious affections of any kind,” including cachexia, pulmonary tuberculosis, cancer and 
leprosy ulcers [127]. Because the active principle in testis is made as needed, rather than 
stored in high-concentration depots, Brown-Séquard’s injections must have contained 
very little male hormones. His observations were likely caused by the placebo effect. 
The cultural context in which Brown-Séquard worked introduced multiple biases 
in his experiments and conclusions. His mistaken theses were constrained into rather low-
quality experiments, which luckily provided useful, testable, and eventually proven 
scientific hypotheses. First, the logical conclusion for Brown-Séquard’s theory would 
have been endorsement for semen therapy. Instead, due to the semen taboo, Brown-
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Séquard and his disciples resorted to surrogate interventions, such as vasectomy, believed 
to preserve sperm in the body, and injections with testis extracts. The introduction of 
injections gave a new lease of life to the therapeutic use of organ extracts, called 
“organotherapy,” which had been banished from the British Pharmacopoeia in 1788 after 
failing the test of oral administration. Some organotherapies were shams or even harmful. 
Yet a few of them provided evidence that specific parts of the body store or release into 
the blood stream chemicals, which subsequently induce changes in other specific parts of 
the body. This conjecture led the discovery of endocrine glands and the establishment of 
endocrinology as a science. In fact, androgen organotherapy provided the blueprint for 
GC discovery. 
Second, the Victorian era was an age of body rediscovery. Georgian pastimes, 
such as cock fighting, horse racing, or cricket, were replaced by more muscular sports, 
such as football, rugby, gymnastics, and swimming. Bodybuilding became fashionable, 
with the first professional competition selling out Royal Albert Hall in 1901. Brown-
Séquard’s promise of muscle without effort made testis organotherapy a widespread, 
well-earning business. When Voronoff was barred from practicing in Paris and judged as 
fraudulent by the Royal Society of Medicine, he took his testis transplant business to 
Algiers, where he received patients from all over the world (reviewed in [128]). Private 
sponsorship led to investment in androgen research, but with a focus on commercial 
rather than clinical efficacy. 
Finally, Brown-Séquard’s era tolerated unscientific theories, which ignored the 
physical and intellectual ability of women. Brown-Séquard claimed that ovary extracts 
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provide some benefits, but with “less power” than testis extracts [127]. Such conclusions 
stemmed from cultural biases rather than comparative experiments. In 1849, Berthold 
showed that, through testis implants, roosters regain male characteristics they lost 
through castration, such as aggressiveness, libido, and larger combs [129]. With 
maintenance of secondary sex characteristics as its sole ability, Berthold’s secreted agent 
was therefore androgenic. In contrast, Brown-Séquard claimed that his extract increases 
muscle force, without mentioning any virilizing side effects. Moreover, in 1935, 
Kochakian proved that urine-extracted “male hormone” stimulates muscle accretion in 
castrated dogs, that is, that it is anabolic [130]. While ultimately proven correct, the idea 
that “male hormones” were simultaneously androgenic, anabolic, and ergogenic was 
based on a cultural construct that confounded manliness and physical force, rather than 
the product of direct scientific evidence. 
The belief in a male-secreted ergogenic substance inspired many commercial 
enterprises to sponsor research in male endocrinology, through the decades where the 
evidence was confined to changes in the combs of roosters. These dark ages ended in 
1927, when McGee and Koch extracted a lipophilic virilizing mixture from rooster testis 
[131, 132]. A pure and even more androgenic chemical was extracted in 1935 from bull 
testis by Laqueur, working for Organon [133]. Laqueur named his discovery testosterone 
(Testo). Three months later, Butenandt and Ruzicka, sponsored by Schering and Ciba 
respectively, announced the development of manufacturing methods for synthetic 
testosterone, an achievement that brought them the 1939 Nobel Chemistry Prize 
(reviewed in [134]). The first beneficiaries of the new drug were hypogonadal men, that 
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is, adult males with pathological decreases in circulating Testo. At the University of 
Chicago, Kenyon tested Testo on four eunuchoid patients of testicular and pituitary 
etiology. Daily injections of 25 mg testosterone propionate (Tp) caused a doubling in 
prostate and penis size [135] after less than two weeks, thus establishing the efficacy of 
Testo replacement therapy in hypogonadal men. Except for a few, narrow exceptions, this 
population was and remains the sole generally accepted, FDA-approved indication for 
Testo therapy [136, 137, 138]. Recent Testo preparations are also recommended for some 
breast cancers, but this indication is describes as having small, unpredictable efficacy. 
Due to manufacturing costs, limited commercial target, and governments’ lack of 
interest, Testo therapy reached a very long experimental stage, which could easily be 
called “the second dark age of androgens.” Only in 1953, did the FDA give its first 
approval for an androgenic therapy, a Testo enanthate injection. Then, as now, FDA’s 
approval was based on Testo ability to restore normal levels of androgens, rather than 
other, more functional or curative, outcomes [137]. However, in 18 years of life as 
experimental drugs, androgenic steroids have been trialed in diverse diseases, including 
male functional impotence [139], unwanted lactation [140], uterine bleeding and 
dysmenorrhea [141], or osteoporosis [142]. These early studies share the extremely small 
sample size, and the scarcity of controls, blinding, and objective outcomes. For example, 
a study found that 14-35 injections of Tp (cumulative dose 255-455 mg) caused an 
improvement of acne in half of the male participants [143]. Such findings are at odds 
with more modern trials, where weekly i.m. androgen injection lead to an increase in 
absolute risk of acne by 15%, in healthy males [144], and are possibly explained by the 
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variability in the androgen arm, small sample size (n = 12), lack of blinding, and early 
stopping in the placebo arm. Nevertheless, these trials are, in many cases, the only source 
of information about the action of Testo in the normogonadal population. For example, 
early trials of oral methyltestosterone revealed its hepatic toxicity. Fifty years later, those 
limited trials are still the main factor discouraging the development of oral synthetic 
androgenic therapies. 
The second dark age of Testo was a time of poor knowledge and poor clinical 
study design. Yet in these years, androgenic steroids first gained their reputation as 
ergogenics. Kenyon noted in his studies on eunuchoid men that Testo injections helped 
them gain weight through protein accretion, as demonstrated by a reduction in urinary 
nitrogen despite fixed dietary intake. Other trials evidenced benefits from androgenic 
therapy in muscle-depleting conditions, including thyrotoxic myopathy [145] and 
muscular dystrophy [146]. By 1940, Kenyon confirmed that Tp caused nitrogen retention, 
caused by increased protein accretion, even in healthy men and women [147]. In 1942, 
Samuels and colleagues concluded that Testo does not change grip strength in healthy 
males [148]. According to a meta-analysis [149] and my literature search, no other test of 
androgens’ effect on muscle strength was published until 1968. Despite the lack of 
evidence, androgens were used as ergogenics in healthy people, starting with Olympic 
athletes around 1954 [150]. 
As exemplified by the ergogenic hypothesis, benefits of androgen therapy on men 
with Testo deficiency have been extrapolated by clinicians and theoreticians to other 
muscle-depleting conditions, and even to healthy humans. One of the conditions 
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associated with loss of muscle mass that clinicians hoped to improve was 
hypercortisolism. In 1941, Albright showed that the newly discovered Tp, in 25 mg daily 
injections, was better than estradiol benzoate, progesterone, or vitamin D in restoring 
nitrogen balance in three cases of Cushing’s disease [151]. Similarly, in 1950, the Mayo 
Clinic team who discovered cortisone remarked that, in one case, 25 mg Tp daily 
injections reduced urinary nitrogen losses caused by 200 mg cortisone administration 
[13]. Some of the aforementioned researchers publish similar case reports, sharing the 
small sample size and the use of surrogate outcomes [152]. These shortcomings do not 
prevent each investigator from subjective claims of improvements in physical function. 
During the 1950’s, AAS became part of the standard of care for endogenous 
hypercortisolism during the gap between diagnosis and curative surgery. However, this 
gap narrowed to a few weeks, due to improvements in differential diagnosis. Today, 
development of accurate cortisol assays allowed the measurement of its changes in 
response to Dexa, thus discriminating conditions where feedback mechanisms fail 
(mainly endocrine neoplasms) from cortisol-stimulating non-endocrine conditions. 
ACTH assays differentiate ACTH-independent cases (typically adrenal tumors) from the 
ACTH-dependent ones (usually localized in the pituitary). Modern imaging, including 
computed tomography of the adrenal and magnetic resonance imaging of the pituitary, 
rapidly identify the target for surgery. AAS therapy is now confined to inoperable cases, 
including unidentified ectopic sources of ACTH or cortisone. Even these cases benefit 
from more targeted interventions (see Table 1). 
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Class Medications 
ACTH inhibitors  Subtype 5 somatostatin receptor agonists: 
pasireotide (FDA-approved) [153] 
 Dopamine D2 receptor blockers: 
cabergoline 
11-β hydroxylase inhibitors Metyrapone, mitotane, ketoconazole. 
Inhibitor of 3 β-hydroxysteroid 
dehydrogenase 
Trilostane (EMA-approved, FDA-withdrawn) 
[154] 
Inhibitor of the cholesterol side-
chain cleavage enzyme 
Aminoglutethimide 
GR antagonist Mifepristone (FDA-approved) [155] 
Table 1. Pharmacological agents used in Cushing’s disease of unidentified ectopic, or diffuse 
localization (reviewed in [1, 2]) 
Similarly, the opportunities for AAS as adjuvant to GC therapy are very limited. 
Many of the diseases previously treated by high-dose GC are now treated with higher-
specificity drugs. As practitioners became more accustomed with the risks of GC therapy, 
doses and durations were reduced. With the exception of life-threatening conditions, 
typical GC prescriptions switched to lower-potency compounds, such as prednisone or 
even cortisol. In particular, practitioners became well aware of the issues of GC 
withdrawal syndrome, where adrenal atrophy is aggravated by some other, still 
undiscovered, component [124]. By mid-1970’s, it became common advice that 
“prescriptions for [glucocorticoid] steroids should not be refillable” [156]. By the time 
modern trials with AAS began, the incidence of overt hypercortisolism decreased 
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significantly. Despite potential epidemic of covert hypercortisolism, with deleterious 
effects of life quality and expectancy, the interest for studies on hypercortisolism has 
largely waned. Clinical studies investigating the benefits of AAS in hypercortisolism are 
scarce and small-scale. For example, there are no significant-size clinical studies 
analyzing the effect of AAS on the muscle strength of the endogenous CS patient. 
An unblinded trial observed AAS-induced increases in lean body mass and 
appendicular muscle mass, in men already receiving an average of 6 mg prednisone a day 
over 9 years [157]. Another, randomized, blinded, placebo-controlled trial by Crawford 
and colleagues tested the benefits of testosterone or nandrolone decanoate as an adjuvant 
to chronic GC therapy for diverse pathologies [158]. The exposure to GC was an average 
of 12 mg prednisone a day, over more than 8 years, and was already causing osteopenia, 
hyperlipidemia, hypercholesterolemia, and a reduction in quality of life compared to 
historical controls [159]. Such side effects could arguably be considered evidence for 
mild iatrogenic CS. After six months of 200 mg testosterone injections every other week, 
the AAS group had higher bone density, muscle mass and strength, and a better quality of 
life, compared to the placebo group. To date, Crawford’s study is the best evidence for 
effectiveness of AAS as adjuvant in GC therapy. 
In a subset of CS patients, androgen administration improves muscle mass and 
quality of life. There are no published human trials describing in molecular terms the 
interaction of GCs and AAS at muscle level. Most of our knowledge is derived from 
animal models (discussed later). 
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Hypercortisolism-induced changes in endogenous androgens levels 
AAS therapy does not change circulating cortisol levels [160]. However, the 
opposite interaction, where hypercortisolism interferes with endogenous AAS secretion, 
is a common finding, with a complex physiological basis. The interaction of GC with 
endogenous AAS distinguishes male from female hypercortisolism, to the point that the 
two syndromes are qualitatively different. 
A series of trials observed the effect of short-term (hours or days) 
hypercortisolism in healthy volunteers. Experimental acute hypercortisolism represses 
circulating levels of Testo, in a reversible manner, in males and, to a lesser degree, in 
females [161, 162]. The mechanisms through which acute hypercortisolism causes Testo 
downregulation, also termed hypoandrogenism, are debated. Some studies suggested that 
acute hypercortisolism downregulates the pituitary-secreted, Testo-upregulating, 
luteinizing hormone (LH) [163, 164, 165]. Others found that GC induce 
hypoandrogenism even when LH is unchanged, thus locating the repression at gonad 
level [166]. Another hypothesis is that the negative feedback loop repressing ACTH in 
hypercortisolism has a side effect of androgen suppression [167]. A few groups have 
even hypothesized the existence of another, still unknown hormone, synthesized from 
ACTH precursor, pro-opiomelanocortin (POMC), with the ability to stimulate 
androstenedione synthesis and secretion [168, 169]. GC-induced repression of POMC 
would also repress this unknown androgen-stimulating hormone, but its existence was 
never proven. 
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In males, chronic hypercortisolism is also associated with hypoandrogenism. 
Long-term prednisone therapy reduces circulating Testo levels [170]. Similar 
observations have been made in endogenous CS, where exposure is longer and, 
depending on etiology, ACTH may be higher than normal. As with acute studies, 
multiple competing explanations were suggested. A study found that hypercortisolism 
impairs hypothalamic GnRH secretion of gonadotropin-releasing hormone (GnRH), the 
main regulator of LH [171]. Others found that that CS is correlated with pathologically 
low levels of LH and of the other gonad-stimulating pituitary hormone, follicle 
stimulating hormone (FSH), despite normal GnRH secretion [172, 173]. This scenario 
suggests that hypercortisolism reduces pituitary’s GnRH responsiveness. Finally, a small 
study found that male asthma patients receiving long-term prednisone have lower 
circulating Testo levels despite increases in LH and FSH, and concluded that prednisone 
has a direct inhibitory action on the testes [174]. Despite disagreeing on the mechanism, 
all these studies agree that chronic hypercortisolism represses testicular androgen 
secretion. 
In adult women, the regulation of AAS is more complex. During reproductive age 
and a few years afterwards, the main source of androgenic stimulation is the ovary [175], 
where Testo is an intermediate product in the synthesis of estrogens (reviewed in [176]). 
A feedback loop links LH and estrogens levels, with LH directly stimulating synthesis 
and secretion of estrogens from the developing and atretic follicles [177]. The reverse 
link is more complex, with estrogens inhibiting LH for most of the menstrual cycle [178], 
with the possible exception of ovulation. In the direct link, LH must stimulate ovarian 
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Testo synthesis in order to achieve estrogen upregulation, but a reverse link, where Testo 
directly inhibits LH, is absent in women [179, 180]. Although measurement methods and 
normal ranges are still to be perfected, it appears that circulating Testo level in women 
are reflecting the menstruation-related cyclical interplay of estrogen and LH, rather than 
being independently controlled [181, 182]. 
This sexual dimorphism differentiates male and female AAS response to chronic 
hypercortisolism. Women with CS have lower muscle mass compared to general 
population [183]. Decreased libido, a sign of hypoandrogenism in both genders, is 
reported by 40% of female CS patients [65]. However, in contrast to males, females with 
CS have normal or even increased AAS synthesis and levels, compared to healthy 
controls [184, 185]. Four fifths of women with CS have menstrual irregularities, which 
has been attributed to hyperandrogenism, direct cortisol action, or depletion of LH or 
estradiol [171]. More than 75% of CS cases present with hirsutism, that is, male-
patterned body and face hair growth in female patients, and a clear sign of 
hyperandrogenism [1, 65]. Women with CS-related hirsutism have androgen levels 
higher than healthy controls [186]. Other signs of hyperandrogenism, such as voice 
changes or acne, are rare in female CS. 
Indirect evidence suggests that apparent hyperandrogenism is also present in 
children with hypercortisolism. In pediatric hypercortisolism, virilization signs such as 
change in voice, penile or clitoridian overgrowth, and hirsutism are common [187, 188]. 
Published studies do not describe muscle changes in these children, possibly due to 
difficulties in assessment and scarcity of cases. 
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In adult female CS, muscle catabolism increase contrasts with virilization and 
circulating androgens changes. This suggests that relative hyperandrogenism in some 
tissues is coincident with relative hypoandrogenism in others. For example, it has been 
shown that in cultured prostate cells excess GC improves the sensitivity of the androgen 
receptor (AR) [189], the nuclear receptor mediating the action of AAS. In contrast, in 
women’s muscle, short-term Dexa inhibits AR expression [190]. It may be the case that 
GCs interfere with Testo signals in a tissue- or sex-specific manner. 
In both sexes, the most concentrated circulating steroids are 
dehydroepiandrosterone (DHEA) and its ester, DHEA sulfate (DHEAS), which originate 
from the adrenal and, to a lesser degree, from gonads. Their most important role appears 
to be that of precursors for synthesis, in glands and peripheral tissue, of androgens and 
estrogens. DHEA has some affinity for the AR, which suggested it might be an AAS. 
Recent studies indicate that, in human female tissue, DHEA may in fact be a partial 
agonist, hindering the action of Testo [191]. DHEA and DHEAS, now termed adrenal 
androgen precursors (AAP), are upregulated by ACTH, through increased synthesis of 
DHEA in the adrenal and rapid bidirectional interconversion [192, 193]. Therefore, 
Cushing’s disease and other conditions associated with increases in ACTH will present 
with increases in AAPs, while primary hypercortisolism will be associated with ACTH 
repression and consequent AAP decrease [194, 195, 168, 196]. Both types of 
hypercortisolism are associated with GAML, despite opposite effects on AAPs, 
suggesting that AAPs changes do not cause GAML directly. Understanding causality in 
the case of simultaneous muscle loss and hirsutism is complicated by dose- and 
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compound-dependent crossconversion of GCs to AAS and interference of GCs in AAS 
synthesis and degradation. 
Loss of endogenous AAS is associated with loss of muscle mass and strength 
[197, 198]. Perhaps for this reason, muscle wasting is more common in males than in 
females with endogenous CS [199]. At least in adult males, muscle loss in CS may be 
aggravated by the reductions in endogenous AAP and AAS. An AAS replacement 
strategy in hypoandrogenic hypercortisolism appears intuitively beneficial for the muscle. 
Moreover, Crawford and colleagues observed the muscle protection by AAS as adjuvant 
to GC therapy extended to men who had low-normal circulating Testo [158]. Androgen 
therapy for muscle protection in CS is predicted to benefit adult males, especially in the 
frequent cases of patent hypogonadism. 
Molecular mechanisms of androgenic myoprotection in humans 
GC-associated muscle loss is a well-studied phenomenon, with its molecular 
mechanisms dissected in human studies. In contrast, the effect of AAS in GAML was 
studied in a few case reports, marred by the absence of objective physical outcomes and 
of molecular analysis. More information can be gleaned from the effect of AAS in other 
muscle-depleting conditions. 
Most commonly, studies of AAS on muscle are carried on hypogonadal men. In 
male primary hypogonadism, rates of cortisol synthesis and degradation are typically 
normal [200]. In this population, AAS therapy, even with low, “replacement” doses, 
causes an increase in muscle mass and force [201, 202]. The gain in muscle mass is 
caused mainly by an increase in protein synthesis, as evidenced by increased 
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nonoxidative uptake of labeled leucine [202]. Moreover, Testo causes an increase in FSR 
of myosin heavy chain (MyHC), indicating that protein accretion is localized in the 
myotubes. The referenced studies also measured leucine flux, a proxy for protein 
degradation, but failed to detect significant changes as a result to Testo therapy. 
Typical naturally-occurring male hypogonadism is usually associated with 
pleiotropic pathology, such as Klinefelter’s syndrome, where deficient androgen 
synthesis may be complicated by other peripheral defects. For this reason, some studies 
were conducted in males with iatrogenic hypogonadism, induced by administration of 
GnRH agonists, such as goserelin or leuprolide, which disrupts and eventually abolishes 
LH secretion. Leuprolide-induced hypoandrogenism causes loss of muscle mass in 
healthy volunteers and in prostate cancer patients [203, 204]. This form of chemical 
castration causes decreases in both protein synthesis and degradation [205], indicating 
that loss of muscle is caused by translation changes. In the prostate cancer study, 
correction of leuprolide-induced hypoandrogenism by co-administration of Testo 
reversed most of the muscle mass losses, although mechanisms were not studied. 
The protective action of AAS therapy in iatrogenic hypoandrogenism is not 
affected by co-administration of an aromatase inhibitor such as anastrozole [206]. 
Aromatase converts Testo in estradiol. The continuing muscle protection when Testo 
cannot be converted to estrogens demonstrates that muscle protection is an intrinsic 
ability of Testo. A more plausible mediator for AAS is the insulin-like growth factor I 
(IGF-I), whose muscle expression is decreased by iatrogenic hypogonadism [205]. 
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Another well-studies group comprises older men, whose Testo levels and muscle 
mass are naturally declining [207, 208]. An argument has been made about benefits of 
Testo replacement therapy in this population. Multiple clinical studies tested this 
hypothesis. In older men with low bioavailable Testo, muscle mass and strength is 
improved by 200 mg Testo every other week [209, 210]. As in hypogonadal men, muscle 
recovery can be localized to the contractile cells, as indicated by increases in the CSA of 
fast- and slow-twitching fibers [211]. No evidence of fiber type switching or fiber type-
specific effects in response to AAS therapy has been seen. Instead, histological studies 
reveal that elderly treated with AAS have significantly more satellite cells [211]. 
Testo improves the net balance between protein synthesis and degradation at 
muscle level [212]. The cause of protein accretion is an increase in protein synthesis, as 
shown by an augmentation of mixed-muscle FSR [213]. The increase in muscle fiber 
protein is correlated with an upregulation of circulating N-terminal propeptide of type III 
procollagen [214], indicating that cellular hypertrophy is paralleled by extracellular 
matrix remodeling. 
Ferrando and colleagues made the case for an anti-catabolic action of AAS in 
older men [215]. They tested a variable, moderate dose of Testo on normogonadal older 
men, with the goal of maintaining a physiological Testo level over six months. This 
moderate Testo therapy caused an improvement in muscle mass, strength, and net protein 
balance, in the absence of an improvement in protein FSR. Therefore, muscle protein 
accretion could be attributed to decreased protein degradation. Moreover, Ferrando and 
colleagues showed a significant decrease in the proteasome enzymatic activity following 
  
38 
Testo therapy. The same group found a similar pattern of net gain in muscle protein, 
correlated with reduced catabolism and unchanged protein synthesis, in a short-term trial 
of Testo on men with severe burns [216]. It is unclear why the anti-catabolic action of 
Testo did not garner more attention. The hypothesis that Testo inhibits protein 
degradation remains tempting, but better studies are needed. 
Perhaps provocatively, the protection of muscle force provided by Testo to the 
older hypogonadal men is not hindered by co-administration of finasteride, an inhibitor of 
5α-reductase, which causes the transformation of Testo to 5α-dihydrotestosterone (DHT) 
[217]. Similarly, Testo muscle protection was present when another 5α-reductase 
inhibitor, dutasteride, was co-administered to a younger, possibly less hypoandrogenic 
cohort [218]. In human males, conversion to DHT is not required or T’s regulation of 
muscle mass. Once more, a more plausible mediator of AAS is IGF-I, the peptide 
hormone upregulated by Testo in the muscle and in the serum of the older men [212, 
219]. 
There is no agreement on the balance of benefits and deleterious effects of Testo 
therapy for women [220, 221]. There is no FDA-approved Testo preparation for women. 
Therefore, the action of Testo in women remains an area of research requiring further 
investigation. 
The best molecular observations on the action of Testo on muscle loss have been 
obtained from studies of HIV-positive men, who have significantly lower circulating 
Testo levels [222]. AAS delays loss of muscle mass in AIDS wasting syndrome, leading 
to better quality of life [223]. Microarray analysis indicated that Testo-treated muscle 
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upregulated expression of genes from the IGF-I- and AR-stimulated signaling pathways 
[224]. Immunoblot confirmatory studies indicated that Testo caused the activation of a 
key component of the IGF-I signaling pathway, the protein kinase B, also known as Akt, 
by increasing its Ser-473 phosphorylation. Other genes upregulated by Testo are muscle 
development regulators, such as the myocyte enhancer factor 2A (MEF2A) and a host of 
macrophage-associated markers. In addition, Testo stimulated expression of genes from 
other pathways, including transcription factor 4 (TCF4) from the Wnt / β-catenin 
pathway, AMP kinase (AMPK), and the guanine nucleotide exchange factor Sos, 
involved in the mitogen-activated protein kinase (MAPK) pathway. In the same study, 
MAPK protein levels did not appear to be modulated by AAS therapy. The referenced 
microarray study failed to find a change in expression of the major muscle regulator 
myostatin (described in [225, 226]), or of the two E3 ligases typically associated with 
muscle loss, MAFbx and MuRF-1 (described in [227, 228]). 
The histological and molecular findings from hypogonadal and HIV-positive 
males receiving AAS have been confirmed in many other pathologies that cause loss of 
muscle. AAS therapy improves muscle mass and strength in males with chronic kidney 
disease and liver cirrhosis [229, 230]. In men with COPD, 100 mg Testo enanthate 
injected weekly led to improvements in muscle mass and strength, potentially 
augmenting quality of life [231]. These improvements are caused by an increase in fiber 
CSA, regardless of fiber type, and by an upregulation of the IGF-I mRNA isoforms IGF-
IEa and IGF-IEc [232]. In both COPD and HIV-positive men, Testo upregulated isoform 
3, also known as embryonic, MyHC. 
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A cross-sectional study split a cohort of males with heart failure, without cachexia 
and with normal circulating cortisol, Testo and ACTH levels in two halves based on their 
cortisol level. The subgroup with lower circulating cortisol achieved a higher peak work 
rate, suggestive of GC-induced muscle damage [233]. A randomized trial showed that 
heart failure patients improve their muscle force with AAS therapy [234, 235]. However, 
a series of recent studies found deleterious cardiovascular effects of AAS [236, 237], 
which will discourage the use of Testo in heart failure and, in general, in populations at 
risk. In 2014, FDA required manufacturers to include on Testo labels a warning regarding 
increased heart attack and stroke, thus pressing the need for more specific anabolic 
adjuvants. To this end, a deeper understanding of AAS therapy at molecular level is 
required. 
In various conditions that cause muscle loss, AAS benefits share a pattern 
including improved muscle mass and strength, fiber hypertrophy, tissue remodeling, and 
increased protein synthesis. In some conditions, AAS-driven muscle rehabilitation is 
associated with an increase in satellite cells and / or an inhibition of protein degradation. 
Putative molecular mediators known from animal models have not been confirmed in 
humans, with the exception of IGF-I upregulation. Better clinical studies are required. In 
their absence, our insights into glucocorticoid myopathy and AAS muscle protection 
come from animal and in vitro experiments, discussed in the next section. 
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BIOLOGICAL PREMISES 
Skeletal muscle histology 
Muscles are specialized for their main ability, contractility. For mammalians, 
ability to move is vital for survival, meaning that a large portion of their bodies is muscle. 
In a cohort of 300 borderline overweight US Americans, skeletal muscle as a proportion 
of body weight was on average 41% for men and 31% for women [238]. Three fifths of 
the human body’s protein is confined to the muscle contractile and support structures 
[239]. 
For the most part, the skeletal muscles confer the three-dimensional intricate 
conformation of the body, suggesting a complex, detailed organization, at least at 
macroscopic level. In contrast, at cell level, the relatively high specialization of the 
skeletal muscle leaves little space for diversity or inhomogeneity. Muscles’ diverse 
shapes are conferred by non-contractile proteinic auxiliary structures. The largest of these 
structures, tendons and aponeuroses, attach the muscle to other body structures (reviewed 
in [240]). The tendons are dense connective tissue structure, which extend into the 
epimysium, a connective tissue sheath surrounding the muscle. In turn, epimysium emits 
connective septing structures termed perimysium, splitting muscles into subunits termed 
fascicles. At an even lower level, a thin, sparse connective structure called endomysium 
coats each multinucleate, elongated cell (termed myofiber). The connective tissue inside 
the muscle provides mechanical anchoring between fibers, longitudinally, laterally and 
with the tendons. This is particularly true of perimysium, which is almost acellular, at 
95% collagen content [241]. Intramuscular connective structures carry terminal branches 
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of the nervous, circulatory and lymphatic systems. In addition, muscles include adipose 
and immune cells. Muscle mass changes require remodeling of all these connective 
structures, and may confound in vivo studies. For example, collagen synthesis or 
macrophage proliferation may misleadingly increase during slow muscle atrophy. 
The elongated, multinucleate myofiber is the histological base unit of contractile 
tissue. A large majority of the myofiber cytosol is the contractile apparatus, in the shape 
of bundles of protein filaments termed myofibrils. Within myofibrils, myosin and actin 
filaments alternate, held together by multi-protein complexes containing titin. Myofibril 
proteins are about two thirds of the total myofiber protein [242]. Therefore, any myofiber 
size change with functional relevance should correlate with changes in myosin II and 
actin protein content. The sizable actin content poses a challenge to muscle studies. 
Traditionally, in biological studies, actin is considered a housekeeping, unregulated, 
invariable protein, and is used in level normalization. In muscle, especially in atrophy, 
actin cannot be invariable. For example, in rat muscles atrophying due to streptozotocin-
induced acute diabetes, an actin degradation fragment becomes upregulated to detectable 
levels [243]. Therefore, in atrophy studies, normalization to actin may misleadingly 
reduce the apparent rate of depletion for other proteins. Similar issues govern the use of 
3MH as a marker for myofibril protein catabolism. Given that the main correlate of 
urinary 3MH is muscle mass [244], 3MH measurement may lack sensitivity when used as 
an indicator for muscle catabolic rate. On one hand, increased catabolism is expected to 
cause increased 3MH output, but on the other, an atrophic muscle has less 3MH to 
release. 
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Myofibers acquire nuclei by fusion with surrounding proliferative mononucleate 
cells, or with neighboring myofibers. Two classes of mononucleate cells are relevant for 
muscle structure and development. Satellite cells are Pax7-positive, mononuclear, nearly 
devoid of cytosol, sitting in close proximity to the fiber, under the proteinic external 
lamina (reviewed in [245]). In contrast to the above histological definition, myoblasts are 
defined in a functional manner, as proliferating cells able to fuse with myofibers. In vivo, 
myoblasts are derived from a subset of satellite cells. A transplant of seven satellite cells 
from an adult mouse is capable of yielding more than a hundred multinucleate myofibers, 
thus demonstrating former’s ability to regenerate muscle [246]. The transformation of 
quiescent satellite cells into proliferating myoblast is regulated by the interplay of growth 
factors, external lamina, and contact with myofibers [247]. Alternate extra-muscular 
sources of nuclei in the myofiber are subject of ongoing research, but their relative 
importance is expected to be minor at best (reviewed in [248]). 
Experimentally, α7 integrin is an effective marker for selecting proliferative 
precursors from muscle [249]. Many in vitro muscle models are based on the formation 
of multinucleate fibers from isolated myoblasts. In vivo, myofiber nuclei are typically 
peripheral, while in vitro multinucleate cells are characterized by central nuclei, akin to 
regenerating fibers. The latter are typically termed myotubes. 
The proliferative niche can play an important role in muscle atrophy and 
recovery. However, muscle hypertrophy may occur without cell division. For example, 
the muscles of mice receiving clenbuterol and of rats undergoing eccentric training gain 
20-30% muscle mass without apparent DNA changes [250, 251], suggesting hypertrophy 
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of existing fibers, but not additional cell division. Quail muscles depleted of proliferating 
cells by irradiation still undergo hypertrophy in response to stretch-overload [252]. These 
examples of amitotic hypertrophy demonstrate that, in some circumstances, the number 
of nuclei is not limiting muscle growth. Conversely, it is plausible that a moderate degree 
of muscle atrophy occurs without loss of nuclei. 
During experiments that perturb muscle mass equilibrium, the level of the 
regulators, of typical housekeeping proteins, and of non-myofiber proteins may fluctuate 
in manners that convolve their specific modulation with overall muscle protein kinetics. 
Investigation of recovery from muscle loss is burdened by the fact that it aims to dissect 
protein regulation, when the regulators are proteins themselves. 
Pre-adult muscle development 
In humans, immediately after birth, the number of satellite cells is much higher 
than in the adult, but drops by an order of magnitude between birth and 10 years [253]. 
This decay carries on throughout the lifetime at a slower rate. In mice, muscle growth at 
puberty is associated with a massive shift of nuclei from the satellite cells to the 
myofibers [254]. Perinatal Pax7 knockout reduces muscle ability to regenerate, while its 
genetic depletion in utero or at adulthood does not exhibit pathological traits [255], 
suggesting that juvenile muscle growth is distinct from muscle development at other 
ages. 
Even earlier, de novo muscle development is remarkable for its accretion of new 
nuclei to the myofiber. Pre-adulthood muscle growth appears reliant on hyperplasia, that 
is, cell proliferation. Cell proliferation regulators are crucial in determination of muscle 
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mass in before and soon after birth. In utero, the mesoderm, which is the source of 
muscle progenitor cells, undergoes segmentation and differentiation to form somites, 
dermomyotomes, and eventually myotomes (reviewed in [256]). The latter contain the 
earliest cells expressing muscle regulatory factors (MRF). These embryonic trunk 
muscles develop into trunk and limb muscles. Early on, limb muscle precursors express 
myogenic factor (Myf) 5, due to stimulation from the transcription factor Pax3 [257, 
258]. Myf5 is a strong inductor of the muscle phenotype, with the ability to convert 
embryonic fibroblasts to myosin-containing syncytia [259]. Cranial muscle formation is 
coordinated in a slightly different manner, through the transcription factors T-box (Tbx) 1 
and paired-like homeodomain (Pitx) 2 (reviewed in [260]). Once this early stage is 
completed, later fetal muscle progenitors converge to a phenotype remarkable for the 
expression of the MRF MyoD, due to stimulation by the transcription factor Pax7 [261]. 
MyoD knockout mice are normal, with Myf5 supplanting its absence [262]. In the Online 
Mendelian Inheritance in Man (OMIM) database, there is no reported case of human 
mutation of Myf5 or MyoD, further supporting the idea of duplicate function. 
Neither Myf5, nor MyoD induce muscle attributes. However, the expression of 
either will promote expression of another MRF, myogenin, which marks the transition 
from specification to differentiation. Initiation of myogenin expression marks the 
transition from specification to differentiation stage. In cultured cells, myogenin 
expression is followed by p21 expression, which removes the muscle precursor from the 
cell cycle [263]. Subsequent changes include expression of muscle-specific enzymes and 
contractile proteins [264], of a fourth MRF, the myogenic regulatory factor 4 (Mrf4) 
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[265], and, finally, acquisition of fusogenic abilities. In humans, by the seventh week of 
gestation, the initial wave of myoblast fusion slows down, and a second proliferative 
stage starts. The latter tapers off, leading to formation of secondary myotubes within the 
same laminar sheath with a primary myotube. Around the seventeenth week, some 
secondary myotubes migrate to form independent centers of coalescence for a third set of 
myotubes [266]. 
Overall, muscle formation in utero and in early childhood relies heavily on nuclei 
accretion and, as a consequence, on precursor proliferation. A series of other factors 
cooperate to improve embryonic muscle formation, including myostatin and IGF-I. 
Experimental perturbations of the negative muscle regulator myostatin in chicken 
embryos alter the number of muscle precursor cells [267]. Phenotypic differences 
between myostatin-null and wild-type mice develop by the second week of 
embryogenesis, prior to the moment when differences in protein synthesis would become 
relevant [268]. Similarly, the few reports of viable human mutations in the myostatin 
gene concern newborns with unusually large muscles [269]. Because myostatin defects 
cause even ampler increases in muscle mass after birth [270, 269], it is possible that 
myostatin acts through parallel, mitotic and non-mitotic, mechanisms. 
IGF-I has a similar composite effect. In chick embryos, overexpression of IGF-I 
induces a rapid increase in the ratio of myoblast to myofiber nuclei, while fiber density is 
unchanged [271]. In addition to the hyperplastic effect, IGF-I stimulates protein 
anabolism in prenatal muscle [272]. Defects in IGF-1R signaling determine low birth 
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weight and subsequent growth retardation in humans and transgenic mice [273, 274]. As 
in myostatin’s case, it is difficult to separate mitotic and non-mitotic effects of IGF-I. 
The adult satellite cells are derived from a subset of fetal Pax3+ Pax7+ cells. 
Because some cells, such as bone marrow stem cells and pericytes, have the ability to 
fuse with myotubes in vitro, the muscle stem cell population was hypothesized to include 
extra-muscular self-renewing cells [275, 276]. However, after the age of 20, human 
muscle nuclei maintain an almost constant length of telomeres, suggesting that mitosis 
and recruitment of extramuscular cells are rare phenomena [277]. Moreover, the 
proportion of resident satellite cells with proliferating abilities decreases with age, as 
more of them approach the Hayflick limit [278]. As evidenced by studies such as the 
New Mexico Elder Health Survey, 1993-1995, aging is associated with accelerated loss 
of muscle mass [279]. Muscle growth mechanisms based on mitosis become the 
exception, rather than the rule, in adult muscle. This may be underlie a difference 
between juvenile and adult in the atrophying effect of GC on muscle. The reduced rate of 
mitosis in adult muscle suggests that GAML and its alleviation by AAS should not be 
mediated by changes in nuclei density. 
Physiological muscle metabolism 
Muscle is a major energy user in the body, with a skewed use of fat during rest 
and glucose during exercise (reviewed in [280, 281]). Because its capacity to synthesize 
fatty acid is negligible, muscle is a consumer and a minor store, but not a generator, of 
fatty acids. During fast, more than half of infused non-esterified fatty acids (NEFA) are 
taken up by muscle, with a higher rate of incorporation in type I oxidative muscle [282]. 
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In contrast, after feeding, oversupply of NEFA is compensated mainly by increased 
uptake, in absolute terms, in the visceral adipose tissue, with minor contributions from 
other adipose tissue, liver, and muscle. After repeated exercise, muscle lipoprotein lipase 
expression is increased, indicative of an adaptive improvement in muscle ability to 
extract NEFA from circulating triglycerides [283]. Ongoing studies suggest that muscle 
oxidative (catabolic) uptake of NEFA is upregulated by peroxisome proliferator-activated 
receptor (PPAR) β/δ, which stimulates expression of the lipolysis rate-limiting enzyme, 
carnitine palmitoyltransferase I [284, 285]. This hypothesis is supported by fast- and 
exercise-induced upregulation of muscle PPAR δ [286, 287]. Moreover, PPAR δ 
overexpression leads to increase in type I fibers and subsequent resistance to high-fat diet 
[284]. Organ-level studies are impaired by the existence of nontrivial intramuscular 
adipose tissue. 
The work described in this dissertation relies extensively on the C2C12 cell line, 
an immortalized female mouse muscle progenitor line obtained from a muscle recovering 
after mechanical injury. Treatment of confluent C2C12 cells with Dexa and 3-isobutyl-1-
methylxanthine (IBMX) causes their differentiation into adipocytes [288]. Some pre-
adipocyte traits, such as upregulation of PPAR γ, Krüppel-like factor-15 (Klf15), and 
CCAAT-enhancer-binding protein (C/EBP) β and δ ( [289]; reviewed in [290]), may 
surface in cell culture experiments where muscle differentiation did not complete, and 
residual potential for adipogenesis remains (see, for example, [291]). An in vitro shift to a 
more adipose-like phenotype may be associated with diminished cell fusion ability, lower 
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protein synthesis, and lower mitochondrial content, which may be misinterpreted as 
muscle atrophy. 
In humans, up to 90% of the glucose absorbed after a meal is removed from 
circulation by the skeletal muscles [292, 293], meaning that muscles should have a 
paramount role in the development of insulin resistance and eventually diabetes mellitus. 
After normal feeding, muscle builds polysaccharides reserves, in part because it can 
synthesize and deposit the largest glycogen stores in the body, and because it cannot 
release glucose. 
Muscle work is generated at such high rates, that most glucose is processed solely 
through glycolysis, in the cytosol, to the three-carbon pyruvate. Some of the pyruvate is 
further oxidized in the muscle, through the tricarboxylic acid cycle, but a significant 
amount is converted to lactate and released in the blood stream. As part of the Cori cycle, 
circulating lactate is reassembled into glucose by the liver, and re-released into the blood 
stream, for muscle use. A similar gluconeogenetic mechanism employs the intramuscular 
transamination of excess pyruvate to the amino acid alanine. Muscle-released alanine is 
converted by liver to glucose, especially at times when dietary carbohydrate intake is 
inadequate. Pyruvate transamination requires the amino acid glutamate. Muscle uses 
glutamate for other metabolic processes, including the synthesis of non-essential amino 
acids, including proline and arginine. Therefore, at rest, human muscle uptakes 
significant amounts of glutamate, less serine, while releasing alanine, glutamine, and 
smaller amounts of the other amino acids [294]. Glutamine is synthesized in muscle in 
order to release the excess nitrogen yielded by amino acid release during protein 
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degradation. Muscle’s glutamine is then converted by the liver to urea and excreted. The 
aforementioned amino acids, with important roles outside protein metabolism, are not 
suitable for labeling and protein tracking experiments. 
Among the amino acids with a trend for release between meals, isoleucine, 
leucine, methionine, phenylalanine, threonine, and valine cannot be synthesized by 
humans. Their net release indicates that, at rest, basal level of protein degradation slightly 
surpasses protein synthesis. Conversely, for a steady muscle mass, there must be net 
protein synthesis in the fed state. Muscle protein synthesis is stimulated by feeding in 
multiple ways. One of these mechanisms employs effects of branched-chain amino acids 
(BCAA), that is, valine, isoleucine, and leucine. BCAA stimulate protein accretion in 
muscle through a complex mechanism. Some studies show that BCAA ingestion or 
infusion increase protein synthesis rate [295], while others claim that BCAA solely 
reduce protein degradation [296]. The effect of BCAA supplementation is three-fold, 
combining increased caloric intake, reflex hyperinsulinemia, and an autonomous, insulin-
independent effect. One study investigated the molecular effects of BCAA at clamped 
normal insulin levels [297]. In young, healthy men, BCAA alone were able to increase 
the fractional synthesis rate for myofibrilar protein. At the same time, BCAA caused 
intramuscular hyperphosphorylation of 4E-BP and of the ribosomal protein S6 kinase, 70 
kDa (p70-S6K). Both are substrates of mTOR complex 1 (mTORC1), an integrator of 
nutrients, energy, and growth factor signaling (reviewed in [298]). Hyperphosphorylation 
of 4E-BP is the canonical way by which mTORC1 stimulates protein synthesis, by 
abolishing the former’s ability to bind and inhibit the mandatory translation initiation 
  
51 
factor eIF4E. The activation of p70-S6K leads to the activation of a feedback 
phosphorylation of mTOR at Ser 2448 [299]. Some of these three posttranslational 
modifications are paradoxically found in acute atrophy settings, when BCAA sudden 
release increases their circulating levels. 
In vivo, BCAA are used by muscle as protein precursors, signaling molecules, and 
energetic substrates, when preferred energetic substrates are not available [300]. In 
studies that measure leucine disappearance from the bloodstream or culture medium, a 
distinction must be made between the leucine used in non-oxidative, anabolic reactions, 
and the alpha-ketoisocaproate-forming, ergogenic usage. An argument has been made for 
using phenylalanine as a tracer, because muscle catabolism is negligible, and because it 
has a lower insulin secretagogue effect [301, 302]. 
Adult muscle remodeling 
With aging, muscle gradually shifts from a mitotic to a postmitotic profile, with 
muscle growth achieved increasingly through hypertrophy, that is, cell size growth. 
While the typical middle-aged or elderly adult is undergoing net loss of muscle mass, 
muscle re-growth and remodeling is still possible in two common circumstances, exercise 
and injury. 
Humans achieve muscle mass growth following exercise. Some forms of exercise 
are more suitable at increasing strength or resistance than mass per se, but in most cases, 
mass will increase in pace with force. In animals, muscle growth is induced by muscle 
overload, or muscle unloading and reloading, which may be conceived as forms of 
aerobic exercise. In healthy volunteers, the acute response to exercise includes increased 
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intramuscular expression of MRFs MyoD and myogenin, and increased circulating IGF-I 
and IL-6 [303, 304, 305]. These signals are associated with increased proliferation of 
satellite cells and recruitment of neutrophils to the muscle [306, 307]. In the acute phase, 
the satellite cells co-localize with IGF-I [303]. The negative muscle regulator myostatin 
is not correlated with the phenotype, that is, it is not decreased by acute exercise [307, 
308]. Acute exercise increases the fractional protein synthesis rate in muscle [309, 310]. 
Interestingly, a single bout of exercise during fast leads to increases circulating cortisol 
levels and the release of 3-MH, indicative of increased stimulation of protein degradation 
[311]. Concomitant amino acid feeding counters GC and catabolic response to exercise. 
Variations in regimens of exercise and timing and composition of diet have led to a 
plethora of studies. Just as most of the short-term exercise routines do not lead to muscle 
hypertrophy, literature is rich with examples of short exercise studies, where molecular 
changes have not been detected (reviewed in [312]). An important future direction in 
exercise science is establishing what distinguishes an effective brief exercise routine from 
an ineffective one. In this context, GCs may be interesting noninvasive markers. 
In the long term, exercise increases fiber CSA, density of satellite cells, and the 
number of myofiber nuclei, while the level of intramuscular MyoD and IGF-I return to 
normal [313]. On the other hand, long-term exercise induces the expression of catabolic 
markers, such as the E3 ligases MAFbx and MuRF-1 [314]. Taken together, these 
molecular findings indicate exercise causes muscle remodeling, which manifests as 
increased muscle turnover, with upregulation of both protein degradation and synthesis. 
Moreover, post-exercise muscle accretion combines hyperplasia and hypertrophy. 
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A similar biphasic response is yielded by injury. In the immediate stage after 
injury, the muscle is infiltrated by pro-inflammatory M1 macrophages, while at later 
stage, anti-inflammatory (M2) subclass dominates (reviewed in [315]). Although the 
studies are rather incomplete, it appears that, similar to exercise adaptations, injury 
triggers a burst of growth factors, probably including IGF-I, basic fibroblast growth 
factor (bFGF), and transforming growth factor-beta (TGF-β) [316]. Most of the studies of 
regeneration provide circumstantial evidence, such as improved healing in the presence 
of a presumed mediator, rather than impairment in its absence. Still unidentified 
molecules from crushed muscle are able to cause myoblast hyperplasia, above the levels 
caused by stimulation with known growth factors [317]. 
Less than half of the C2C12 cells in their proliferating, undifferentiated, form 
express MyoD or Pax7 [318]. Limited evidence suggests these myoblast-like cells do not 
express Pax3 either [319]. Therefore, the C2C12 line is an incomplete model of 
hyperplastic muscle accretion. 
Generation and regeneration of muscle in common scenarios, such as 
development and adaptation, remain an object of study, due to their complexity. The 
variable importance of the immune cells, of MRFs, and of IGF-I, and concurring 
redundancy remain to be fully worked out to identify a common pattern for muscle 
hypertrophy. 
Hormonal control of muscle mass 
The variability of muscle mass within population is reflective of the variable 
needs for muscle strength. Muscle mass and strength are adjusted to the needs of the 
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organism mainly through hormonal mechanisms. Multiple classical hormones regulate 
muscle mass. The acute phase of insulin response poses a conundrum, with some studies 
showing it stimulates protein synthesis in human muscle [320], while others 
demonstrating that its effect is limited to anti-catabolism [321]. In male rat muscle, 30 
minutes in 30 nM insulin or IGF-I are equally able to stimulate protein synthesis and to 
inhibit protein degradation [322]. 
Insulin and IGF-I pathways overlap to some degree. For both hormones, 
physiological concentrations are tens of times higher than the half-maximal effective 
concentration (EC50) for their receptor, suggesting that physiological fluctuations cause 
marginal effects downstream [323, 324]. On the other hand, insulin has the ability to bind 
and activate IGF-I receptor (IGF-1R), with an EC50 of about an order of magnitude 
lower than physiological insulinemia. The converse is true, with IGF-I being able to bind 
and activate insulin receptor (IR), isoforms A and B. There is a small, but real, potential 
for interference between insulin and IGF-I signals. Therefore, IGF-I and insulin emerge 
as hybrids between metabolic stimuli and growth factors. The liver is the main source of 
circulating IGF-I, under the pituitary stimulation with growth hormone (GH). However, 
auto- and paracrine secretions fully supplant the absence of hepatic IGF-I in adult 
conditional knockout mice [325]. In contrast, insulin is secreted solely by one organ, the 
pancreas. This sets a more important distinction between insulin and IGF-I, with the 
former embracing a systemic, integrative role, while the latter carries more localized 
regulatory tasks. Our understanding of the regulation of insulin secretion is improving, 
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dispelling the simplistic view that nutrients alone are its sole modulators (reviewed in 
[326]). 
The levels of bioavailable IGF-I are under complex regulation (reviewed in [327, 
328]). IGF-I may be sequestered by IGF-I binding proteins (IGFBP), which are secreted 
by muscle under IGF-I stimulation [329]. The interaction with IGFBP may prevents IGF-
I from interacting with receptor, or it may extend its circulating half-life by protecting it 
from degradation. Depending on the isoform and location of IGFBP, the interaction may 
result in extinction or amplification of the IGF-I signal. IGFBPs levels are modulated by 
insulin, while their availability is modified competitively by insulin-like growth factor 2 
(IGF2). The latter can also stimulate IGF-1R, thus providing its own anabolic and pro-
myogenic signals [330]. IGF2 plays other, independent roles, suggested by the lethality 
of its knockout [331]. 
There is no consensus concerning the ability of GH to stimulate muscular 
secretion of IGF-I. Multiple studies found an upregulation of IGF-I mRNA in response to 
GH stimulation [332, 333], but protein data are lacking. Medium conditioned by GH-
stimulated C2C12 cells fails to elicit hypertrophy in other C2C12 myotubes [334], 
suggesting that IGF-I is not secreted in the cell culture medium. Alternatively, the 
hypertrophic action of IGF-I may be exerted by an intracellular autocrine mechanism. In 
addition to the indirect effect mediated by hepatic and the putative muscular IGF-I, GH 
has an IGF-I-independent effect on muscle. For example, knockout of GH receptor 
impairs body growth further beyond IGF-1R knockout [335]. In the context of pituitary 
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pathology associated with Cushing’s disease, the associated GH perturbations may 
contribute to loss of muscle. 
Hypothyroidism is often associated with muscle weakness and pseudohypertrophy 
[336]. Other hormones, such as the parathormone, have small effects on muscle protein 
metabolism, essentially irrelevant outside their respective pathologies [337]. In 
conclusion, muscle mass homeostasis is under a tight, multifactorial hormonal control, 
whose study is complicated by significant redundancy. The absence of third-party organs, 
such as glands, from reductionist cell-culture may limit their ability to replicate in vivo 
phenomena. 
Interaction of muscle mass and vascularization 
Muscle vascularization is a modulator of muscle mass and contractility. Mice 
whose muscle VEGF-A secretion was genetically depleted still express a tenth of the 
muscle VEGF-A protein, but have only half of the capillaries per muscle fiber, compared 
to their Cre-/- siblings [338]. The muscle-restricted VEGF-A-depleted mice have 12% 
lighter gastrocnemii, although the muscle loss disappears when muscle mass is 
normalized to total body weight. The loss does not affect specific fiber types. Therefore, 
the muscle depleted of VEGF-A is less able of endurance effort (80% shorter time to 
exhaustion on the inclined treadmill) and of brief anaerobic exercise (34% lower maximal 
running speed). 
Conversely, murine muscles injected with VEGF-A-expressing retroviruses 
display a higher proportion of hypertrophic fibers than those expressing bacterial β-
galactosidase [339]. Moreover, in the VEGF-A-overexpressing muscle, many of the 
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fibers have central nuclei, a sign of increased fusion with myoblasts. In the murine 
C2C12 cell line, VEGF-A causes faster differentiation, into longer myotubes, with more 
nuclei per fiber, although mitotic rates are in fact diminished. These observations are 
consistent with direct anti-apoptotic and profusogenic effects. 
It has been suggested that the most direct effect of VEGF-A depletion is partial 
segregation of muscle from blood-carried endocrine signals. For example, VEGF-A-
depleted muscle has lower glucose uptake, a defect that is reversed by explantation [340]. 
In addition, vascularization defects may induce relative intramuscular hypoxia, which is 
an independent atrophying, pro-proteolytic factor [341]. 
The relative importance of VEGF overexpression during myogenesis is still open 
to debate, as muscle-restricted VEGF receptor (VEGFR) knockout animals were not 
studied yet. Multiple effects concur to obfuscate VEGF action in hypertrophying muscle. 
First, VEGF promoter contains three binding sites for MyoD, meaning that growing 
muscle will express more VEGF [342]. Development of vasculature in growing muscle 
may be a physiologically meaningful way to ensure vasculature remains competent upon 
increase circulatory demands. Second, although the canonical positive regulator of VEGF 
is hypoxia-induced factor 1α (HIF 1a), muscle VEGF is also stimulated by PPAR γ 
coactivator 1 (PGC-1) [343, 344]. Even in the absence of VEGF, PGC-1 coactivators 
facilitate mitochondria biosynthesis, leading to oxidative fiber hypertrophy and 
improvements in endurance capacity [345]. Therefore, it is difficult to distinguish VEGF-
induced muscle changes from the common muscle remodeling program. Finally, VEGFR 
activation has multiple effects, including phosphorylation of Src family proteins [346], of 
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phospholipase C (PLC) γ [347], and, indirectly, of regulatory subunits of PI3K [348] and 
of the Signal Transducers and Activators of Transcription (STAT) STAT3 and STAT5 
[349]. Most of these VEGF effects overlap with the effects of many other muscle 
anabolic agents. It is possible that VEGF plays a central mediating role in muscle 
hypertrophy. Alternatively, VEGF changes may be reactive, merely adjusting the 
vasculature to fiber ratio to a constant level, after changes in either muscle or vasculature 
caused by other factors. 
Control of muscle mass through innervation 
Current understanding and future directions for the study of GAML are guided, to 
a large extend, by the data obtained in denervation experiments. From the earliest study 
of protein synthesis and degradation in atrophying muscle to the discovery of atrogenes, 
denervation has been compared with GAML in many studies. Denervation of a hindlimb 
or hemidiaphragm is a relatively simple procedure, with the advantage of having an 
animal as its own control. 
Limb and trunk muscles are controlled by the lower (alpha) motor neuron, located 
in the ventral horn of the spinal cord. Their main point of contact is a chemical synapse, 
the neuro-muscular junction (NMJ). In addition to the direct synaptic activity, muscles 
and lower motor neurons are involved in a mutually beneficial life-long interaction. 
Motor neuron precursors from the embryo spinal cord degenerate and die if they 
cannot engage in significant interactions with myofibers [350]. Eliminated motor neurons 
include neurons whose axons fail to reach myotubes, and neurons that eventually fail to 
maintain contact with myotubes, due to synapse elimination. The latter is a selective, 
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competitive process, whose molecular basis is still unknown, and which ensures 
injectivity of the correspondence between lower motor neurons and myofibers (reviewed 
in [351]). For a few days after birth, rat motor neurons go into a particularly sensitive 
state, when axotomy determines motor neuron death [352]. Thence, axotomy elicits the 
reprogramming of the neuron into a less differentiated state, followed by axonal regrowth 
(reviewed in [353, 354]). The re-establishment of contact between the motor neuron and 
muscle causes the reverse molecular changes, suggesting the existence of muscle-
secreted neurotrophic factors. The NMJ loses functionality with aging, although it is not 
clear whether NMJ cause or are caused by aging-related muscle loss [355]. Factors that 
improve muscle’s ability to exercise or even mimic exercise, such as IGF-I or androgens, 
have been shown to benefit NMJ recovery or to slow down its degradation during aging 
[356, 357, 358]. 
The loss of contact with the lower motor neuron elicits similar detrimental 
changes in muscle, with clinical relevance in the understanding and treatment of spinal 
cord injury and spinal muscular atrophy. Conceptually, denervation is distinct from 
disuse, such as that induced by damage to the upper motor neuron. Clinically, the latter 
manifests differently, through a syndrome termed pyramidal weakness, which mainly 
affects muscles opposing gravity [359]. In humans, after upper motor neuron damage, 
disuse response occurs in a few days after injury, and leads to exaggerated spasticity 
[360]. Understandably, literature does not describe any animal model of disuse by 
experimental damage to the upper motor neuron. In fact, literature contains multiple 
examples where “disuse” is taken to mean “absence of action potentials, due to 
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denervation”, “lack of work, due to denervation, unloading, immobilization”, or even 
both (see for example [361]). Consequently, there are no experimental attempts to 
disentangle muscle-maintaining effects of work, of the NMJ transmitter, acetylcholine, 
and of any other musculotrophic neuron-released factor. 
In utero, experimental destruction of motor neurons with bungarotoxin abolishes 
formation of secondary myotubes, although it has limited effect on the formation of 
primary fibers [362]. 
Experimental denervation causes rapid and ample loss of muscle mass. For 
example, three weeks after sciatic nerve removal, the tibialis anterior muscle halves in 
weight [363]. Fewer than one in 7,000 myofiber nuclei undergo apoptosis in this time 
[364], demonstrating how atrophy can occur without changes in nuclei density. 
In a seminal study, Goldberg demonstrated that denervation leads to increased 
loss of prelabeled muscle protein, proving that denervation upregulates protein 
degradation [365]. Moreover, denervation increases urinary 3MH, indicating activation of 
myofibril catabolism [366]. The rate of muscle loss in denervated muscle is halved by the 
proteasome inhibitor bortezomib [367]. Denervation stimulates persistently proteasome 
enzymatic activity [368], and upregulates all the ubiquitin-proteasome pathway 
components, including ubiquitin, the E3 ligases MuRF-1 and MAFbx, and the 
proteasome subunit A1 [369, 227]. The upregulation of the E3 ligases is induced by 
multiple independent transcription factors, including myogenin and the Foxo class [370, 
371, 372, 373]. 
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The temporal evolution of muscle loss following denervation comprises two 
stages. In the first few days of denervation, the atrophic response is correlated with 
myogenin upregulation by histone deacetylase (HDAC) 4 [374]. After the first week, 
Foxo activation is attributed to the downregulation of its negative regulator, Akt [372, 
375]. 
Because the mTOR inhibitor rapamycin prevents fiber hypertrophy that normally 
follows in vivo injections with a plasmid coding constitutively active Akt [375], the 
scientific community assumed, since the beginning of century, that atrophy is a mere 
reverse of hypertrophy. Commonly, reviews still state that atrophy, including 
denervation, requires Akt inactivation, followed by loss of downstream mTOR-mediated 
effects (for example, [376, 377]). Recent studies contradicted this paradigm. In 2013, 
Quy and colleagues found that denervation increased Thr 389 phosphorylation and 
catalytic activity of p70-S6K, indicating that denervation causes in fact activation of 
mTORC1 [378]. In 2014, Tang and colleagues proved that rapamycin, an inhibitor of 
mTORC1, which lacks intrinsic anabolic properties, abolishes denervation-induced loss 
of muscle mass [372]. These experiments prove that mTORC1 should be activated for 
denervation-associated muscle atrophy to proceed in its later stage. Tang showed that 
denervation causes phosphorylation of insulin receptor substrate (IRS) 1, proving that, in 
denervation, activated mTORC1 inhibits Akt through a p70-S6K - IRS 1-mediated 
negative feedback loop. Quy found that mTORC1 activation is lost upon proteasome 
inhibition with bortezomib. One can hypothesize the existence of an mTOR negative 
regulator, which is specifically targeted by the ubiquitin-proteasome system during 
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denervation. Alternatively, mTORC1 activation may be caused by the preceding 
upregulation of proteasome, which is stimulating BCAA release. The mechanism by 
which mTORC1 is stimulated by denervation remains to be established, but its 
consequences, including activation of p70-S6K, phosphorylation of IRS1, inhibition of 
Akt, and increased Foxo activity, appear well-supported by evidence. 
Establishing the role for mTORC1 in denervation-induced loss of muscle mass is 
crucial. In the conceptual frame before Quy and Tang experiments, mTORC1 inhibition 
was intuitively attractive, as it would simultaneously downregulate protein synthesis, and 
remove a restriction on autophagy. In particular, denervation-induced autophagy 
appealed to the muscle biologists of the 2000’s. For example, one group claimed that the 
lysosome inhibitor chloroquine prevents denervation-induced muscle loss [379]. Others 
showed that denervation upregulates lysosome enzyme cathepsin L [380]. A third group 
claimed that denervation causes buildup of the autophagosome marker, microtubule-
associated protein 1 light chain 3 (LC3) [381]. These studies were published even as 
others clearly refuted the role of autophagy in denervation. The lysosome inhibitors 
leupeptin, methylamine, and E64-c have minimal effects on the release of free tyrosine 
from denervated muscle [366]. Transgenic mice expressing LC3 fused with green 
fluorescent protein (GFP) exhibit a loss of autophagosomes in denervated muscles [378]. 
The example of denervation illustrates the barriers in the study of autophagy, a challenge 
equally present in GAML study. 
A similar debate surrounds protein synthesis regulation in denervation. In 
Goldberg’s 1969 experiment, the specific activity of the remaining muscle protein in 
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denervated limbs was essentially the same as in control limbs. He conjectured that 
increased or even unchanged protein synthesis rates would have caused a reduction in 
specific activity, as new, tracer-free protein would build up. By exclusion, Goldberg 
concluded that denervation causes protein synthesis decreases, thus opening a debate that 
is still unsettled. However, Goldberg’s observation could have been explained in other 
ways. For example, specific activity may be preserved if tracer amino acids increasingly 
released due to denervation would not freely diffuse out of muscle, but would be 
preferentially reused in new protein. More recent functional studies, including some from 
Goldberg’s group, found that denervation stimulates translation [382, 378, 368, 383, 
366]. Unlike the 1969 study, contemporary studies measured protein synthesis rate 
directly and over shorter time intervals (hours, rather than weeks). Both Tang and Quy 
found that denervation causes increased phosphorylation of 4E-BP, thus potentially 
causing protein synthesis upregulation. A sizable number of articles show that protein 
synthesis is either increased, decreased, or unchanged by denervation. 
Given that rapamycin has essentially no effect on adult muscle mass, it may be 
that mTOR is not the crucial effector of denervation-induced muscle atrophy once 
thought. Current evidence suggests that it is activated in late stages of denervation, with 
inconsequential, or perhaps compensatory, downstream activation of protein synthesis 
and inhibition of autophagy. In contrast, denervation-induced muscle loss is correlated 
systematically, and requires, the activation of ubiquitin-proteasome system. The 
predicaments of denervation research epitomize similar dilemmas in the study of muscle 
atrophy due to other, less studied etiologies, including GAML. 
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Animal models of glucocorticoid myopathy 
In the 75 years since the discovery of iatrogenic glucocorticoid myopathy, 
scientists attempted, with variable success, to develop multiple animal models. In dogs, 
seven days of 0.44 mg/(kg d) prednisone increased nitrogen excretion [384]. In horses, 
the action of Dexa on glycogen regulating pathways was replicated, but muscle mass was 
not measured [385]. In cows, GAML is undetectable at macroscopic level. Any putative 
change in myofibers is compensated by bovines’ unusually rich intramuscular adipose 
component, further hypertrophied by Dexa [386]. In rabbits, four days of 1 mg/(kg d) did 
not change muscle mass and reduced urinary 3MH, despite the upregulation of some 
catabolic markers [387]. For large animals, cats, or dogs, practical and humane reasons 
prevailed, meaning that experiments did not end with dissections, and data about muscle 
mass changes are unavailable. For many of these species, the genome was not known, 
and specific antibodies are not manufactured, meaning that signaling pathways could not 
have been analyzed. Especially in the early years, studies did not record most relevant 
outcomes, such as muscle mass and / or force, putting into question their validity. In 
conclusion, literature does not describe any effective non-rodent model of GAML. 
In the era of genome sequencing, studies of GAML focused on mice and rats. The 
first study of mouse GAML was published in 1964 [388]. However, for a long time, rats 
were the preferred model. Muscle mass in mice is smaller, making dissection harder and 
changes closer to detection threshold, compared to rats. In terms of glucose metabolism, 
mice are more GC-resistant than rats [389]. Mice studies became interesting with the 
advent of transgenic studies, starting with the MuRF-1 and MAFbx knockouts created by 
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Bodine and colleagues [227]. To my knowledge, at the start of this work, there was no 
published account of muscle atrophy in mouse, which showed changes in individual 
muscle mass, and which stated the effective Dexa dose. 
Myofiber-restricted knockout of GR abolishes GAML, while having no effect on 
denervation atrophy [390]. In rat muscle, chronic Dexa treatment upregulates expression 
of the NMJ essential component, muscle-specific nicotinic acetylcholine receptor, and 
resistance to NMJ-specific non-depolarizing muscle relaxants [391]. GAML appears 
associated with an improved NMJ, excluding the role of neurons, and confirming the 
phenotype that led to the “myopathy” designation in humans. 
There is no evidence of satellite cell dysfunction in GAML. In one report, Dong 
and colleagues hypothesize a “glucocorticoid-induced satellite cell dysfunction,” but 
describe solely that Dexa reduces the number of satellite cells in a post-injury 
regenerating muscle [392]. In conclusion, GAML is the direct effect of Dexa on 
myofibers. 
The perception that myotubes response to Dexa is a complete model of GAML 
inspired many reductionist in vitro models. Many published studies document the effect 
of Dexa on the mouse cell line C2C12 and the rat cell line L6. However, these and other 
myogenic cell lines have significant limitations, which may cause divergence between in 
vitro models and the glucocorticoid myopathy they aim to describe. As mentioned earlier, 
in the case of primary cells, experiments with Dexa are outright impossible, because 
primary cell survival is GC-dependent. Moreover, Dexa has hyperplastic and 
hypertrophic effects on myogenic cell lines. Commonly tested doses of Dexa, in the 
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range of tens of nM, have been shown to synergize with IGF-I [393] and even to act 
directly towards improved proliferation of L6 myoblasts [394, 395]. C2C12 fusion is 
more efficient when Dexa is added to IGF-I [90]. 
Until the end of the 1990s, Dexa was a common ingredient in myogenic culture 
media [396]. Even contemporary standard proliferation media, containing 10% fetal 
bovine serum, provide significant and unpredictable concentrations of GC, insulin, and 
IGF-I, impairing their study at physiological concentrations. In fusing C2C12 cells, IGF-I 
and Dexa synergize to amplify some Dexa catabolic signals, such as the expression of 
REgulated in Development and DNA damage responses-1 (REDD1) [90]. Conversely, 
the synergy with Dexa amplifies some of insulin and IGF-I effects, such as Akt 
phosphorylation on Ser 473 [396]. In addition to myotubes, C2C12 may differentiate into 
adipose-like or osteoblast-like cells. To avoid histological ambiguities, this chapter will 
refer mainly to in vivo studies. 
With this caveat, in vitro studies have been vital in excluding third-party organs, 
such as the pancreas, from the analysis of GAML, at the time when genome 
manipulations were not available. Some molecular features of GAML have been initially 
described in cell culture, and confirmed in vivo later. Fully differentiated myotubes from 
L6 and C2C12 cell lines lose more than a quarter of their diameter when treated with 100 
nM [397]. Evidence from in vitro studies on myogenic cell lines will be used in this 
chapter, but will be limited to studies where multi-nucleate myotubes were obtained and 
myoblasts were depleted. 
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The effects of 7-day, 5 mg/(kg d) treatment on rats allow the classification of GCs 
in two subsets [398]. Members of the short-acting subset, including prednisolone and 
corticosterone, cause net gains in body weight, through increased adiposity, MR-
mediated water retention, and a net neutral effect on muscle mass. Long-acting, specific 
GCs, such as Dexa, betamethasone, and triamcinolone, cause loss of body weight, and an 
even more rapid loss of muscle mass. The muscle mass loss is paralleled by reductions in 
maximal twitch and tetanic force [399]. GAML is an organized process, lacking the 
microscopic features of necrosis [400]. Although Dexa temporarily reduces food intake, 
possibly through stimulation of leptin secretion [401], pair-feeding experiments 
demonstrated that the GAML is not the effect of appetite changes [402, 403]. In response 
to Dexa, rat myofibers undergo reductions in CSA, to an ampler degree in fast twitch 
fibers [404, 405]. Dexa-induced loss of muscle mass is present, although less manifest, in 
female rats, possibly because, in males, hypercortisolism is compounded by a reduction 
in circulating Testo levels [404]. 
In rats, the nitrogen imbalance induced by Dexa slows down by the third day, and 
is compensated around the seventh day of treatment [406, 407]. Given that later time 
points are marred by feedback mechanisms and by animal mortality, almost no published 
experiment on rats extends past two weeks. For an animal weighing 300 times less and 
aging 20 times faster than humans, the common 5-10 days experiments should be 
comparable to chronic exposure in humans. Rats appear more resistant than humans to 
GAML, given that reported experiments start at about 0.5 mg/(kg d) Dexa, more than 
twice the muscle-impairing dose in humans. Illustrating the higher resistance to Dexa, 
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recently published mouse experiments used even higher doses (3 mg/(kg d) to 10 mg/(kg 
d) [408, 409]). 
Unless specified, the next sections refer to studies with chronic (5-10 days) Dexa 
on adult (not aged) male rodents, which are the best model from human male 
glucocorticoid myopathy. 
Glucocorticoid stimulation of ubiquitin-proteasome system 
The loss of muscle in the Dexa-treated adult rat is mainly the result of an increase 
in protein degradation. The 1969 Goldberg study on atrophy revealed that cortisone 
induced an even ampler upregulation of proteolysis than denervation [365]. His 
comparison of “fast-twitch” plantaris and “slow-twitch” soleus found that the latter did 
not exhibit lower muscle mass, not increased proteolysis. Goldberg found that cortisone 
increases in equal manner the degradation of older and newer proteins, and of myofibril 
and sarcoplasmic proteins. A search begun for an undiscriminating proteolytic machine 
stimulated by GC. 
In rats receiving 0.5 mg/(kg d) Dexa for six days, epitrochlearis muscle 
proteolysis rate increased by 50%, while protein synthesis was essentially unchanged 
[402]. Dexa-stimulated proteolysis affects the contractile apparatus, as indicated by the 
doubling of urinary 3-MH output [410]. The upregulation of proteolysis occurs even 
when explants, rather than animals, are treated with Dexa, suggesting that GAML does 
not require extramuscular inputs [411]. 
In vivo GAML is best correlated with an upregulation of the ubiquitin-proteasome 
system. The increase in proteolytic rate is unchanged when explants are treated with the 
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lysosome inhibitor methylamine and the lysosome / calpain inhibitor E-64. On the other 
hand, the Dexa-stimulated increase in proteolysis is abrogated when the explant is treated 
the proteasome inhibitor MG132 [412], or depleted of ATP by a combination of the 
mitochondrial decoupling agent dinitrophenol and the unlysable glucose homologue, 2-
deoxyglucose [413]. Proteasome chymotrypsin-like catalytic activity is doubled by Dexa 
[414]. Dexa upregulates proteasome subunits such as C1, C2, C4, C5 [402, 412]. 
In cultured myotubes treated with 100 nM to 1000 nM Dexa, the loss of diameter 
is reliably correlated with a 20% increase in protein degradation rate [415, 397]. Between 
78% and 95% of the Dexa-induced proteolysis augmentation is lost, when proteasome 
inhibitors, such as beta-lactone or MG-132, are co-administered [415, 416]. 
Demonstrating proteasome’s primacy, MG-132 has this overriding effect even co-
administered as an addition to a cocktail of lysosome and calpain inhibitors [412]. Co-
administration of dinitrophenol essentially abolishes Dexa-induced proteolysis [415]. 
GAML dependence on ATP reinforces the idea that GC-stimulated proteolysis takes 
place in the proteasome. In contrast, lysosome inhibitors had no effect, while E-64 has 
minimal effect [415]. 
In L6 myotubes, Dexa causes increased expression of the ubiquitin gene UbC, 
through a putative SV40 promoter-specific 1 (Sp1) response element [417]. In vivo, 
upregulation of UbC was confirmed only for acute Dexa treatment [411] and in diabetic 
rats [418]. 
One of the most tempting hypotheses attributed a role to nuclear factor kappa 
light-chain enhancer of activated B cells (NF-κB), a mediator of muscle loss in conditions 
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such as cancer cachexia (reviewed in [419]), and a regulator of multiple inflammatory 
genes (reviewed in [420]). However, the few published reports are contradictory. In L6 
myotubes, Dexa stimulates acetylation and nuclear translocation of the translational 
activator p65 [421], seemingly paralleling cancer cachexia. In contradiction to such 
parallels, Dexa was shown to inhibit NF-κB signals by upregulating inhibitory κBα 
(IκBα) [422]. Moreover, Dexa’s inhibition of NF-κB was shown to be necessary for 
proteasome subunit C3 upregulation in the same L6 cells [423]. 
Unbiased searches in atrophying mouse muscles revealed two upregulated genes, 
termed atrogenes, MAFbx and MuRF-1 [227]. Both are E3 ligases, pointing to an 
important role for the proteasome-ubiquitin system in muscle atrophy. Studies on 
cultured myotubes confirmed that GCs induce the two atrogenes directly, without a third-
party organ mediation [424]. In contrast to other muscle atrophy models, GAML is 
associated with stronger reliance on MuRF-1 than on MAFbx. Indicating a lower 
amplitude and / or higher variability in MAFbx, some unbiased searches in rat GAML 
failed to identify MAFbx as a target of Dexa [425]. While genetic depletion of either 
atrogene leads to muscle sparing in the denervation model [227], only MuRF-1, but not 
MAFbx genetic depletion spares muscle treated with Dexa [426]. The incomplete sparing 
of the MuRF-1 knockout indicates genetic redundancy. The main candidates for 
supplanting MuRF-1 are homologs MuRF-2 and MuRF-3, rather than MAFbx. 
One distinction between the two atrogenes is set by their promoters. MuRF-1 
promoter includes a GC response element, which MAFbx promoter appears to lack [427, 
428]. In contrast, MAFbx promoter is activated by myogenin [371], a MRF involved in 
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muscle regeneration. In C2C12 cells, MAFbx is upregulated by differentiation [429]. 
MAFbx is induced in muscle during hypertrophy from reloading [430]. Moreover, 
MAFbx knockout abolishes hypertrophy of loading [431]. Denervation leads to a stronger 
myogenin upregulation compared to GAML [432]. It is possible that GAML represses 
regeneration to a higher degree, thus leading to a less ample activation of the myogenin - 
MAFbx axis. 
Substrate specificity is also distinguishing the two ligases. The only two known 
MAFbx ubiquitination substrates are MyoD and the eukaryotic initiation factor 3f (eIF3-
f), identified in C2C12 ( [433, 434], reviewed in [108]). This suggests that MAFbx may 
be an initiator, neutralizing a few specific muscle-protecting factors, belonging to 
multiple metabolic pathways. Because MAFbx neutralizes a translation initiation factor, 
it has been suggested that MAFbx relative importance is augmented in conditions where 
muscle loss relies more on loss of protein synthesis. 
Two-yeast hybrid experiments revealed two classes of putative MuRF-1 
substrates [435]. The first includes structural myofibrilar proteins, such as titin, nebulin, 
troponin-I, troponin-T, myosin light chain 2. The second class comprises components of 
ATP-generating machinery, including NADH dehydrogenase 1a, NADH-ubiquinone 
oxidoreductase, pyruvate dehydrogenase, and ATP synthase beta-subunit. In transgenic 
mouse overexpressing MuRF-1, proteins from the second class were downregulated 
[436]. In vitro, MuRF-1 ubiquitinates myosin heavy chains [437] and actin [438]. MuRF-
1 is therefore a more plausible effector of bulk protein degradation, as it is a better fit for 
the “undiscriminating” proteolytic machine postulated by Goldberg. 
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The mechanisms by which MuRF-1 is induced are still under study. Transgenic 
mice with a defective GR still exhibit upregulated atrogenes in denervation and fasting, 
thus demonstrating the multiplicity of atrogene-stimulating mechanisms. A sizable body 
of indirect evidence suggests that the main positive regulators of atrogenes in GAML are 
FOXO transcription factors. Foxo transcripts are reliably upregulated by Dexa in muscle. 
In addition, Dexa may inhibit their kinase, Akt, thus protecting them from ubiquitination 
and degradation. Experimentally, atrogenes are also modulated by myostatin, through 
SMAD3 transcription factor, and by AMPK. The E3 ligase TRAF6, whose expression is 
increased by Dexa, appears necessary for GAML and atrogene upregulation [439]. 
In cultured cells, Dexa upregulates the nuclear cofactor p300 [440]. Dexa also 
upregulates acetylation and nuclear translocation of C/EBP β, in a p300 dependent-
manner [421]. Because atrogenes promoters contain putative binding sites for C/EBP 
transcription factors, p300 was hypothesized to be yet another mechanism by which GCs 
stimulate atrogenes. Interestingly, p300 is a histone acetyltransferase (HAT). Dexa 
increases HAT activity and reduces HDAC activity in muscle [441]. Because HDAC 3 
and 6 are repressed by Dexa and because trichostatin A, an HDAC inhibitor, upregulates 
MAFbx, it has been hypothesized that Dexa acts by increased histone acetylation. The 
importance of histone acetylation in in vivo GAML and the specific genes affected by 
epigenetic mechanisms are still to be determined. Therefore, the hypothesis that Dexa-
induced histone acetylation stimulates MuRF-1 remains a speculation. 
In conclusion, explant models suggest that GAML is, to a wide extend, but not 
exclusively, the result of upregulation of the proteasome-ubiquitin system. The absence 
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of specific anti-MAFbx and anti-MuRF-1 antibodies prevents the study of their protein 
flux and their intracellular localization [108]. Next sections will describe the various 
pathways that are hypothesized to upregulate the ubiquitin-proteasome system. Each of 
them has proteasome-unrelated side effects, including activation of other proteolytic and 
anti-translational pathways. 
Glucocorticoid-induced loss of sensitivity on the IRS - Akt axis 
Surprisingly, the most comprehensive account on GC-induced changes on protein 
metabolic regulation comes from the study of glucose metabolism changes. The latter is 
more easily measured in muscle, because it comprises only catabolic, but no anabolic, 
components (detailed in the dedicated section). 
Dexa causes systemic insulin resistance, manifested as uncompensated 
hyperglycemia [403]. Dexa induces concerted catabolic changes, which eventually 
converge to hyperglycemia, and consequent hyperinsulinemia. Together, these yield a 
higher index of homeostatic model assessment - insulin resistance (HOMA-IR) [442]. 
However, Dexa overrides insulin to reduce muscle glucose uptake [443, 322, 444]. Dexa 
does not alter expression and activity of hexokinase, and of glucose transporter (GLUT) 4 
expression [445], but inhibits GLUT4 recruitment to the cell membrane [443, 445]. 
Because translocation of GLUT4 in response to insulin is critically dependent on Akt 
[446], its suppression by Dexa is strong evidence for Dexa-induced Akt inactivation. 
Dexa-induced inhibition of Akt is surprising, because it occurs during hyperinsulinemia, 
which causes Akt activation in normal muscle. The disconnection between the 
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extracellular hyperinsulinemia and the intracellular signaling is achieved by Dexa in a 
multi-step process. 
The inhibition of Akt as result of Dexa interference was the subject of debates in 
the 2000’s. Proving Akt inactivation by Dexa is a complex endeavor, due to the 
extremely low Akt activation in basal state. Insulin or IGF-I, in concentrations close to 
the physiological levels, increase glucose uptake about 10-fold in muscle explants [443]. 
The fact that there is significant leeway for amplification of anabolic pathways 
demonstrates that, at basal state, muscle Akt-mediated signals are far below maximum. In 
immunoblots, active, that is, phosphorylated Akt is often below detection threshold in 
basal state [402]. Unsurprisingly, observations on basal state muscle frequently failed to 
identify further repression of Akt by Dexa. Many studies misinterpreted this failure to 
detect as an actual absence of effect. 
The opposite situation may also be true. Experimental studies on the Akt pathway 
are conceptually challenged by its extremely low basal activity. In a molecular biology 
experiment, in order to prove causality by inhibition, one must reverse the inhibition, and 
observe that the final effect is lost. In the case of a putative inhibition of Akt by Dexa, 
genetic reversal of inhibition will never be able to merely reverse the inhibition. Most 
often, overexpression of IGF-I, IGF-1R, Akt, or other mediators on this pathway 
overcompensates Dexa’s effect, thus causes overriding Akt activation far above the basal 
level. A long series of reports from overexpression studies mistakenly concluded that Akt 
pathway is the only mechanism by which Dexa causes atrophy, whereas in fact, they 
were describing non-specific hypertrophy. 
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Dexa interference on the Akt pathway begins at IRS 1. Dexa treatment does not 
change basal levels of autophosphorylated insulin receptor in absolute or stoichiometric 
terms [442, 447, 448]. Similarly, Dexa alone does not appear to change the basal level of 
phosphorylated IRS. However, in response to insulin, mice treated for 5 days with 1 
mg/(kg d) Dexa exhibit only a third of the IRS 1 and 2 phosphorylation, compared to 
untreated animals [449]. The mechanism by which Dexa interferes with IRS 1 is 
unknown. Based on observational studies, the interference was attributed to an improved 
protection of IRS by calmodulin [450], to an inhibitory phosphorylation on another 
residue, possibly by PKC [451, 448], or to the upregulated phosphatase C1-Ten [452]. In 
C2C12 myotubes, Dexa may downregulate IRS through caveolin repression [409]. 
The notion that Dexa interferes with IGF-I signaling suggested that GAML also 
attenuates downstream, IRS-independent, MAPK response (reviewed in [453]). Activated 
receptors for growth factors, such as IGF-1R, phosphorylate and assemble a transduction 
complex, including Src homology 2 domain containing (Shc) and Growth factor receptor-
bound protein 2 (Grb2). Dexa reduces insulin’s ability to cause Shc phosphorylation and 
association with Grb2 [454]. Paralleling the findings in sugar metabolism, Dexa has no 
detectable effect in basal state. Further downstream, the effect of Dexa wanes. The 
canonical MAPK pathway is activated when the complex including Shc and Grb2 binds 
and activates Son of sevenless homolog (Sos), the GTPase exchange factor for Ras. Ras-
GTP activates a cascade of kinases, including Raf, Mek, and Erk, eventually leading to 
cell proliferation. A report describes that Dexa upregulates phosphorylation of Mek and 
Erk in diabetic rats [418]. Others describe increased Erk phosphorylation in L6 myotubes 
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during acute Dexa [455]. No reports describe such changes in wild-type healthy animals. 
Measurements of changes in activation of another MAPK, p38, are contradictory [456, 
457]. Together with the limited role of hyperplasia in adult muscle, available evidence 
suggests that MAPK cascades do not mediate GAML. Moreover, absence of sizable 
changes in the MAPK cascades reinforces the idea that insulin and IGF-I signaling is 
extinguished by Dexa at IRS, rather than receptor, level. 
Next interference by Dexa occurs at the level of PI3K, whose recruitment to the 
membrane complex containing insulin receptor and IRS1 is hindered [442, 449]. One 
PI3K-inhibiting mechanism is based on transcriptional effects, with Dexa upregulating 
transcription of the PI3K regulatory subunit p85 α [425]. It was hypothesized that p85 α 
sequesters PI3K catalytic subunit, p110, in the cytosol, and away from the IRS-
containing membrane complex [442, 458, 459]. Another putative mechanism contends 
that activated GR binds p85 in a competitive manner, thus displacing it from IRS1 [460]. 
This non-transcriptional effect has not been fully explored in GAML in vivo, but is 
supported by the unusual persistence of IRS1-PI3K complexes during diabetes in GR 
knockout mice muscle [460]. 
The next step in the Akt pathway is the formation of a membrane complex 
comprising the receptor, IRS, p85, and p110 (reviewed in [461]). The latter acts on the 
membrane lipids to synthesize 3-phosphoinositides. In muscle cell lines treated with 
Dexa in vitro, the depletion of membrane-bound PI3K and of 3-phosphoinositides leads 
to lower activation of 3-phosphoinositide-dependent protein kinase 1 (PDK1). In turn, the 
reduction in PDK1 lowers the phosphorylation on its substrate, Thr 308 on the activation 
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loop of Akt. While Thr 308 phosphorylation is not detectable in rat muscle in basal state, 
its sensitivity to insulin is depressed by Dexa [462]. 
Akt has another important phosphorylation site at Ser 473. Historically, Ser 473 
phosphorylation was seen as a non-limiting step towards Akt activation, occurring 
automatically after Thr 308 phosphorylation. In GAML, Ser 473 appears to closely 
mimic Thr 308, with Dexa lowering insulin’s ability to upregulate Ser 473 
phosphorylation [462, 449, 463, 390]. The introduction of phospho-specific antibodies 
brought about the first distinction between Thr 308 and Ser 473 phosphorylation. The 
latter appears phosphorylated to a detectable degree even at basal state. In vivo, Dexa was 
shown to also repress Ser 473 phosphorylation in the basal state [464, 465, 466]. 
A second distinction between Thr 308 and Ser 473 is the difference in stimuli and 
enzymes causing their phosphorylation. Ser 473 phosphorylation is nominally stimulated 
by growth factors, through mTOR complex 2, and through little-known, mTOR-
independent, 3-phosphoinositide-stimulated mechanisms [467]. Extracellular stimuli that 
activate Thr 308 are expected to cause 3-phosphoinositide synthesis, and simultaneous 
Ser 473 activation. However, Ser 473 and Thr 308 phosphorylation may occur separately 
(see examples in the next section). In this case, it may be the case that Dexa impedes Ser 
473 phosphorylation through another, yet undiscovered, mechanism. 
The interdependence between Ser 473 and Thr 308 is illustrated by the fact that 
non-mutagenic in vivo experiments rarely describe Akt activation without 
phosphorylation at both residues (reviewed in [468]). In vivo, the scarcity of segregation 
reports leads to lack of knowledge regarding potential independent specializations for the 
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two sites. However, in vitro manipulations indicate that the two sites synergize for 
maximal Akt activation [469]. Mutagenic abolition of Ser 473 phosphorylation abrogates 
Akt activity on substrates belonging to the Foxo class, but does not change Akt ability to 
phosphorylate tuberin (Tuberous Sclerosis Complex 2; TSC2) and glycogen synthase 
kinase 3 (GSK3) [470]. Such changes in substrate imply that Ser 473 controls specificity. 
Because Foxo is at the core of atrogene regulation in muscle atrophy, Ser 473 status has 
been of greater interest for GAML studies. 
More evidence for Dexa-induced inhibition of Akt comes from its substrates, such 
as Ser 9 on GSK3-β. Chronic Dexa reduces GSK3-β phosphorylation at Ser 9, thus 
leading to GSK3-β activation [462]. The activation of GSK3-β in GAML is confirmed by 
increased phosphorylation of its substrate glycogen synthase at Ser 645, 649, 653, 657, 
and decreases intramuscular glycogen synthesis rate [471, 472, 462]. Among the many 
substrates of GSK3-β, the subunit ε of eukaryotic initiation factor 2B (eIF2B) may 
mediate an anti-anabolic effect [473]. In cultured myotubes, GSK3-β knockdown reduces 
Dexa ability to upregulate MAFbx [474]. While inactivation of GSK3-β is typically 
attributed to latent Akt inhibition, the Ser 9 site is also a target for ribosomal protein S6 
kinase, 90 kDa (p90-RSK), serum and glucocorticoid-inducible kinase-like kinase 
(SGKL), and p70-S6K [475, 476, 477]. The role of GSK3-β in muscle atrophy was 
briefly the subject of research at the turn of the century, in the context of a hypothesized 
atrophic mechanism involving calcineurin and nuclear factor of activated T-cells 
(NFAT). Since then, evidence that calcineurin is not involved in muscle anabolism [478] 
led to an unjustified neglect of GSK3-β. 
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In conclusion, Dexa interferes with IRS / Akt pathway in multiple ways, thus 
inhibiting glucose uptake. The inhibition of this pathway is difficult to detect in basal 
conditions, but consistently observed during challenge tests with insulin or IGF-I. 
Because the model of GAML centered on Akt is derived from experiments with acute 
states, cell models, and intrinsic anabolic interventions, it is perfectible. The best-studied 
downstream targets of Akt are mTOR and FOXO. 
Glucocorticoid inhibition of mTOR 
One of the most effective pathways for Akt to induce its anabolic program is 
mTORC1 (reviewed in [479, 480, 481]). The latter’s modulation in acute Dexa 
administration is proven by reduced phosphorylation in its substrates, 4E-BP (Thr 37/46) 
and p70-S6K (Thr 389) [482]. More commonly, 4E-BP and p70-S6K phosphorylation are 
reported to behave in a manner similar to Akt activation, with no detectable Dexa effect 
on their basal phosphorylation, and a Dexa-induced loss of sensitivity to insulin [483, 
444]. 
The mechanism by which mTOR is modulated by Dexa is not elucidated yet. Cell 
models established that activated Akt phosphorylates and inhibits proline-rich Akt 
substrate of 40-kDa (PRAS40), a negative regulator of mTORC1 [484]. The same cell 
models showed that activated Akt phosphorylates TSC2, thus causing its sequestration 
with a cytosol partner, 14-3-3, and away from its transmembrane partner, hamartin 
(Tuberous Sclerosis Complex 1; TSC1) [485]. The destruction of TSC1-TSC2 complexes 
relieves the negative regulation from Rheb, a small GTPase, which can induce activation 
of mTORC1. Therefore, in theory, Dexa-induced repression of Akt should inhibit 
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mTORC1 in two distinct ways. In practice, there is little evidence for TSC2 or PRAS40 
based mechanisms in GAML in vivo. 
The scarcity of evidence for PRAS40 or TSC2 mediation suggested that other 
mechanisms might lead to mTORC1 inactivation in GAML. Moreover, an Akt-mediated 
Dexa effect on mTORC1 would be subtle, with sizable amplitude only during 
hyperinsulinemia. Alternative Akt-independent pathways have been hypothesized. A 
well-studied negative regulator of mTOR is the energy sensor AMPK [486, 487]. 
However, Dexa inhibits muscle AMPK phosphorylation and activity [463, 488], probably 
as a consequence of intramuscular ATP upregulation [489]. The surge in intramuscular 
ATP is caused by Dexa-induced improvements in mitochondrial function, exemplified by 
upregulation of cytochrome c oxidase expression and activity [490] and of Na(+)-K(+)-
ATPase expression and maximal activity [491]. Chronic Dexa or corticosterone do not 
alter Liver Kinase B1 (LKB1) [463, 492], the main AMPK kinase, indicating that ATP 
availability causes AMPK inhibition by another, unknown mediator. In conclusion, in 
GAML, mTOR suppression does not employ AMPK. Moreover, GAML does not involve 
mitochondrial dysfunction. 
A third putative mTORC1 inactivating mechanism is centered on the stress sensor 
REDD1. Dexa upregulates REDD1 expression in muscle [425]. Demonstrating its key 
role, genetic depletion of REDD1 abolishes GAML and Dexa-induced myotube atrophy 
[493, 494]. In cell culture, REDD1 interferes with 14-3-3 in order to release TSC2, 
restore TSC1-TSC2 complexes, and eventually inhibit mTORC1 [495]. Moreover, 
REDD1 is in epistasis with AMPK [496], at times overriding its action on mTORC1. 
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Interestingly, a REDD1-based mechanism could explain the few observations on 
mTORC1 changes just as well as an Akt-centered model would. 
Finally, limited evidence suggests that Dexa impedes mTORC1 ability to act on 
its substrate p70-S6K, through the depletion of a putative scaffold, eIF3f [497]. 
Another way to gauge the role of mTORC1 is to use its inhibitor, rapamycin. One 
group reported that the Dexa-induced decrement in protein synthesis is unmodified, in 
absolute terms, upon rapamycin co-administration [444], suggesting that mTOR signaling 
is dispensable. In a C2C12 microarray study, interference of IGF-I transcriptional 
program with PI3K inhibitor was virtually identical to the interference induced by 
rapamycin [498], indicating that, on the contrary, mTOR is indispensable for PI3K 
effects. Most likely, both hypotheses are based on reductionist models that do not reflect 
true in vivo phenomena. 
Discovery of novel mTORC1 substrates such as UNC-51-like kinase 1 (ULK1) 
[499] led to speculations about additional contributions to the GAML phenotype from 
autophagy. In vivo evidence for mTOR-mediated autophagy upregulation in GAML is 
indirect and inconclusive (discussed in a later section). Similarly, Dexa-induced 
mTORC1 repression is expected to lead to simultaneous downregulation of protein 
synthesis via 4E-BP (discussed later). 
A recent study on acute Dexa [494] opens the perspective for a paradigm-
changing situation. It provides the most complete mechanistic explanation for Dexa-
induced inhibition of mTORC1. In wild-type mouse muscle, Britto and colleagues found 
that acute Dexa caused mTORC1 inhibition, as demonstrated by lower phosphorylation 
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of 4E-BP1. While Dexa reduced phosphorylation of PRAS40, it unexpectedly led to 
hyperphosphorylation of the other Akt substrate, TSC2. These mice also exhibited 
simultaneous hyperphosphorylation at Ser 473 and hypophosphorylation at Thr 308, thus 
providing a rare evidence for Akt specificity switching. Britto concluded that Dexa-
induced mTORC1 inactivation is mediated by hypophosphorylation of PRAS40, which is 
in turn caused by hypophosphorylation of Akt at Thr 308. Britto found more evidence for 
the REDD1 - Akt - PRAS40 axis in the REDD1 knockout mice, which are resistant to 
chronic Dexa. In these mice, acute Dexa fails to induce hypophosphorylation on 
PRAS40, and on Thr 308 of Akt. 
Britto’s model remains beset by incompleteness. In this report, acute Dexa failed 
to upregulate protein degradation, suggesting its extrapolation to chronic GAML may be 
debatable. Britto also speculated that Akt Ser 473 hyperphosphorylation is caused by a 
feedback loop responding to mTORC1 inhibition, a rather unlikely occurrence after only 
5 hours from oral administration. The mechanism by which REDD1 inhibits Akt activity 
on PRAS40 remains unknown. Studies on transformed cells support the hypothesis that 
REDD1 impairs Akt Thr 308 phosphorylation, while disagreeing on molecular 
mechanisms ( [500]; reviewed in [501]). 
The hypothesis that REDD1 suppresses Akt and mTORC1 is very attractive, 
because, in contrast to IRS1, REDD1 would be an active and permanent repressor. The 
mechanism by which Dexa stimulates REDD1 remains to be found. In neurons, the most 
robust inducer of REDD1 is hypoxia, through HIF transcription factors [501]. In contrast, 
in muscle, Dexa downregulates VEGF [502], a downstream effector of HIF (described in 
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the section on vascularization). This suggests that Dexa causes REDD1 upregulation 
independent of HIF1a and of hypoxia. Other putative positive regulators of REDD1 
include ATF4 and NFAT, discussed in other sections of this chapter. 
While it is certain that GAML is correlated with mTORC1 downregulation, it is 
still unclear how mTORC1 repression is achieved, and what is its relative importance. 
Based on the published evidence, the recent change of paradigm, which placed p70-S6K 
at the forefront of denervation atrophy, appears unlikely in GAML. For now, our 
understanding of GAML places Akt upstream of mTORC1.Better transgenic models, a 
deeper understanding of mTOR pathway, and more in vitro / recombinant experiments 
are required for a definitive conclusion. 
Glucocorticoid activation of Foxo transcriptional program 
The evidence for the role of Foxo in GAML is not as direct and compelling as that 
gathered in denervation atrophy. Given the partial redundancy between the three 
regulatable Foxo transcription factors, only a triple knockout will give the true measure 
of their relative importance. Nevertheless, an impressive body of indirect evidence 
supports their involvement in GAML. 
The importance of Foxo transcription factors is supported intuitively by their role 
as integrators of multiple atrophy signaling pathways. Multiple mechanisms converge to 
induce Foxo upregulation in GAML. First, chronic Dexa doubles Foxo expression [425]. 
Foxo1 promoter contains a GR response element [503]. In C2C12 myotubes, the response 
is biphasic, combining a short-lived ample and rapid increase, with a gentler long-term 
augmentation [429]. Foxo promoters contain GR-binding sites [504]. In vitro, Foxo 
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induction by GR is facilitated by the histone acetyl transferases p300 and CREB-binding 
protein, which are independently upregulated by Dexa [441]. Consequently, GR 
knockout reduces expression of FOXO1 and FOXO3a in muscle [427]. 
Second, Foxo transcription factors are thought to be potentiated by Dexa through 
post-translational means involving the earlier-described Akt pathway (reviewed in [505]). 
When active, Akt phosphorylates Foxo1 at Tyr 32 and Ser 253, thus creating binding 
sites for 14-3-3. Phosphorylated Foxo transcription factors are exported from the nucleus, 
and eventually marked for ubiquitin-proteasome-mediated degradation. Intuitively, Dexa-
induced impairment of Akt is expected to contribute to an increase in Foxo activity in 
GAML. Finding evidence for this mechanism has been challenging. In C2C12 myotubes, 
the expected Foxo hypophosphorylation in response to Dexa has been frequently reported 
[376, 506]. In vivo, evidence for Dexa-induced Foxo hypophosphorylation is limited to a 
few experiments, performed in unusual conditions, such as diabetes [507, 464, 508]. 
Given that phosphorylated Foxo is degraded, the ability to observe and quantify it is 
limited. 
Third, PGC nuclear cofactors may facilitate the Dexa-induced Foxo surge. Loss 
of sensitivity to insulin causes PGC-1 repression in muscle [509]. In particular, Dexa 
represses muscle PGC-1α [456, 508] and PGC-1β [510]. In cultured myotubes, PGC-1β 
overexpression and knockdown cause changes in the reverse direction for Foxo3a and 
atrogenes’ mRNA. Because PGC-1α overexpression drives conversion of fast to slow 
twitch fibers [345], it has been speculated that differences in PGC-1α levels make 
different types of muscle fiber more or less sensitive to Dexa [377]. A whole higher level 
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of regulation, centered on PGC-1α splicing, is yet to be studied. For example, isoform 1, 
and not 4, of PGC-1α is correlated with muscle hypertrophy [511]. 
Fourth, indirect evidence links Foxo1 to PPARβ/δ. Dexa stimulates 
simultaneously PPARβ/δ DNA binding and Foxo1 acetylation [512]. PPARβ/δ inhibition 
reduces GAML and, at the same time, prevents Dexa-stimulated acetylation of Foxo1. 
While the direct effects of this post-transcriptional modification is not elucidated 
(reviewed in [513, 514]), it was speculated that PPARβ/δ changes induce physiologically 
relevant alterations in Foxo1. 
Finally, the microRNA miR-182, whose expression is inhibited by Dexa, is a 
negative regulator of Foxo3 [515]. Other mechanisms, such as AMPK, have been 
hypothesized, based on the latter’s ability to upregulate atrogenes. 
The net result of these mechanisms is that Dexa treatments upregulates nuclear 
Foxo [456]. More convincing evidence towards Foxo activation comes from its 
downstream effects. For example, tens of reports describe how Dexa upregulates 
glutamine synthetase expression and activity [516]. Glutamine synthetase promoter 
contains a FOXO response element. Dexa-induced expression of muscle glutamine 
synthetase is absent in Foxo1 knockout [517]. 
Manipulations of Foxo have supported their role in GAML. Transfection with 
dominant negative Foxo3A partially prevents diameter reduction in disuse of rat soleus 
and Dexa-treated C2C12 myotubes [506, 518]. 
Among the Foxo-induced genes, a special importance was given to the E3 ligases 
associated with muscle loss, MAFbx and MuRF-1 [424]. Both atrogenes contain FOXO-
  
86 
binding regions in their promoter [506, 519, 427]. These Foxo-responsive elements are in 
close proximity of SMAD3-binding elements, in a shared response element, which 
facilitates synergistic interactions between the two classes of transcription factors [520]. 
MuRF-1 promoter facilitates another synergistic interaction, between FOXO1 and GR 
[427]. A positive feedback loop links MuRF-1 and FOXO1, as indicated by 
downregulation of FOXO1 in late GAML in the MuRF-1 knockout [408]. 
In both atrogenes’ promoter, a Klf15 response element is located, near the FOXO 
binding site [521]. Klf15 is a direct transcriptional target of GR, and interferes with 
mTOR signaling. A gene network is centered on Klf15, which upregulates expression of 
FOXO transcription factors, and synergizes with them to upregulate atrogenes. Overall, 
atrogenes appear to be under a strong control of Foxo, favored by concomitant activation 
of synergistic factors. Dominant negative Foxo3A transfection in rat soleus leads to loss 
of atrogene upregulation [522]. In cultured myotubes, transfection of constitutively active 
FOXO3a upregulates MAFbx [506], while knocking down FOXO1 causes a reduction in 
the atrogene response to GC [523]. 
A majority of the effectors described in this chapter appear to be under the control 
of Foxo pathway. In addition to atrogenes, Foxo targets include 4E-BP1, cathepsin L, and 
another effector of denervation atrophy, Growth Arrest and DNA Damage 45 (Gadd45) 
[524]. 
Glucocorticoid activation of myostatin 
In rodents, Dexa upregulates myostatin, a strong negative regulator of muscle 
mass [525]. In myostatin knockout mice, Dexa induces most of its transcriptional 
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program, including modulations of IGF-I, MuRF-1, MAFbx, FOXO3A, but Dexa-
induced muscle loss does not occur [414]. These findings suggest that myostatin is an 
important mediator of Dexa. 
Myostatin’s promoter contains GR response element [525], a FOXO responsive 
element [526], and a CCAAT sequence [527], all known to be stimulated by Dexa. 
Myostatin expression is also upregulated by the histone methyltransferase SMYD 3, 
which in turn is upregulated in muscle by Dexa [528]. The stability of the myostatin 
transcript is improved by Dexa-exerted repression of its negative regulators, miR-27 
[529]. 
Glutamine supplementation reduces GAML and myostatin expression in muscle 
[530]. This finding suggests that, in the context of GAML, myostatin may double as a 
nutrient sensor. 
Myostatin’s effects are manifold, and not completely understood. While 
myostatin inhibition in utero leads to doubling of muscle mass in adult animals [225], its 
overexpression in adult animals causes a more moderate effect [531]. This split in action 
indicates that myostatin modulates both hyperplasia- and hypertrophy-based pathways of 
muscle growth. In explanted adult mouse myofibers, where proliferation has been 
minimized, expression of a dominant negative form of activin A receptor, type IIB 
(ActRIIB), the receptor for myostatin, causes an increase in CSA, which is halved by 
rapamycin [532]. Therefore, proliferation-independent mechanisms of myostatin-induced 
atrophy may include both mTOR-dependent and -independent pathways. The extensive, 
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multifactorial action of myostatin on muscle suggests that it may override any atrophic 
stimulus, in non-specific ways. 
A series of experiments describe Akt inhibition in response to myostatin 
treatments. In vivo electroporation with myostatin-encoding plasmids led to 10% loss in 
tibialis anterior mass in the transfected muscle, in the absence of any changes at the level 
of atrogenes [533]. The atrophy was associated with loss of phosphorylation on TSC2 
and p70-S6K, suggesting that Akt was inhibited, and that myostatin affected protein 
metabolism. However, in regenerating, scarred, electroporated muscle, the number of 
proliferating cells is likely larger than in normal muscle, suggesting that myostatin might 
have acted through proliferative rather than anabolic means. This report is consistent with 
the well-documented myostatin-induced impairment of muscle regeneration [534, 535]. 
Repression of Akt in proliferating myoblasts is not expected to mediate GAML. 
Another study describes Akt inhibition in human myotubes differentiated from 
cultured myoblasts. In this system, myostatin treatments lead to reductions in diameter 
and atrogene downregulation [536]. In contrast, GAML is characterized by an 
upregulation of atrogenes, possibly facilitated by Akt inhibition. The authors of this study 
pinpoint the myostatin-induced Akt inhibition to changes in proliferating myoblasts. In 
conclusion, there is no evidence for adult GAML mediation through a myostatin - Akt 
axis. 
Myostatin-induced or -associated models of atrophy do not upregulate protein 
degradation. For example, microgravity atrophy is associated myostatin upregulation, but 
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no changes in 3MH excretion [537]. This contrasts again with GAML, which strongly 
relies on upregulation of protein degradation. 
Myostatin is particularly adept at modulating the fusion of myoblast to myotubes 
[538]. Myostatin’s action appears more relevant for processes where myoblasts or 
satellite cells are involved, such as muscle development and regeneration (reviewed in 
[539, 540]). However, normal adult muscle maintenance is more dependent on protein 
accretion than on satellite cells. In adult GAML, loss of satellite cells regenerative action 
may play a minor role, at most. 
Myostatin’s relative importance for GAML remains incompletely explored. The 
typical experiments, using qualitative alterations of myostatin, may override any 
endogenous mechanism, and yield non-specific anti-atrophic effects. 
Glucocorticoid modulation of protein synthesis 
Goldberg’s [365] 1969 study on cortisone-induced atrophy of rat muscle brought 
one more important theme for the field of GAML. In that experiment, the specific 
activity, that is, the ratio between tracer and total protein, was the same in GC-treated 
muscle as in control animals, despite decreased muscle mass and decreased total tracer in 
the GC-treated group. Goldberg conjectured that an equal rate of protein synthesis in the 
two groups would have caused a faster dilution of the tracer in the GC-treated muscle. 
Failing to find that was interpreted as evidence for decreased protein synthesis in 
cortisone-treated muscle. This was an elegant way of bypassing the denominator effect 
from the typical experiments, where synthesis rate would be measured over hours, in 
muscles that already underwent atrophy in the prior days. In these cases, a loss in protein 
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synthesis rate might be underestimated or even factored out, after normalization to a 
lower muscle mass. 
As in human studies, the role of protein synthesis modulation during chronic 
hypercortisolism is still debated, because chronic Dexa effect is superimposed by acute 
effects. A single 20 mg/(kg d) triamcinolone dose nearly halves incorporation of labeled 
precursors in rat muscle protein at 8 hours, yet has no effect after 24 hours [541]. Similar 
acute effects may be expected from feeding, which causes fluctuations of insulin and 
possibly of the Akt / mTOR / 4E-BP axis in muscle. 
Variability in the time from feeding and treatment to biopsy is a significant source 
of experimental noise, which must contribute to inconsistencies in literature. For 
example, some of the most exhaustive studies of protein metabolism in GAML came 
from Grizard laboratory. In two studies, they found that protein synthesis rate was 
unchanged after 0.5 mg/(kg d) Dexa for 6 days, compared to pair-fed animals, in the 
epitrochlearis muscle [402, 542]. In two other studies, assaying other glycolytic muscles 
or quadrupling the Dexa dose, led to observable reductions in protein FSR [543, 444]. 
In cell culture, studies of Dexa inhibition of protein synthesis are similarly 
equivocal, although Dexa causes 4E-BP hypophosphorylation directly, even in basal state 
[544]. In the most glaring example, the same group, using the same methods and working 
on the same L6 line, found that protein synthesis is “not altered” by Dexa in one article, 
and decreased in the next [397, 545]. 
Even when detected, the amplitude of changes in protein synthesis in vitro [545, 
546, 547] and in vivo [322] is lower than that on protein degradation, when Dexa is given 
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at the dose that causes muscle loss. In contrast, doses of Dexa below the apparent EC50 
are unable to change protein degradation rate, while still lowering protein synthesis rate 
[329]. 
In the MuRF-1 knockout mouse, Dexa fails to change FSR [426], suggesting a 
temporal order, with proteolytic processes preceding changes in protein translation. The 
temporal order is suggestive of a causal mechanism, where protein synthesis changes in 
GAML have a reactive, less central, nature, compared to protein degradation. 
While direct evidence has been rarely obtained, indirect evidence showing that 
Dexa modulates muscle protein synthesis is rich. For example, acute GC administration 
causes a reduction in the proportion of polyribosomes [548]. The proportion of 
polysomes recovers to basal level in less than 24 hours, when the GC is short-acting 
prednisone [398]. In contrast, polysome downregulation lasts about two days after Dexa. 
No published accounts describe polysome profile changes after longer GC exposure. 
Dexa has a dual effect on 4E-BP, the inhibitor of protein synthesis that binds and 
inhibits the eukaryotic initiation eIF4E. First, Dexa upregulates 4E-BP mRNA [425]. It 
was long believed 4E-BP induction is direct, and based on a Foxo response element in 
4E-BP promoter [549]. As of 2015, this response element is proven only in Drosophila. 
The only replication in mouse cells, in culture, was withdrawn during the preparation of 
this work, for unspecified reason. While the transcriptional upregulation of 4E-BP is 
certain, the mechanisms by which Dexa achieves it remain unknown. 
Second, Dexa may regulate 4E-BP through post-translational modifications. As 
shown earlier, Dexa reduces 4E-BP phosphorylation on residues that are usually 
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phosphorylated by mTORC1. The direct reduction is less salient, with reductions in 
response to insulin being more commonly reported. This mechanism is expected to 
impede protein synthesis rate mainly after feeding. The study of mTOR action is 
challenged by the existence of multiple phosphorylation sites, inability of antibodies to 
discern them, and inability of rapamycin to inhibit mTORC1 action on 4E-BP1 [550]. 
Dexa upregulates mitogen-activated protein kinase–interacting kinase 2 (MNK2) 
expression [551]. Dexa reduces eIF4G Ser 1108 phosphorylation in wild type mice, but 
not in MNK2 knockout mice. This posttranslational modification correlates with nutrient 
availability, but its role in GAML was not studied (reviewed in [552]). 
In C2C12 myotubes, GAML may repress protein synthesis by MAFbx-initiated 
neutralization of eIF3f [434]. Overexpression of eIF3f causes hypertrophy, and eIF3f 
knockout induces atrophy, supporting the hypothesis that loss of an initiation factor 
causes reductions in the rate of protein synthesis. Moreover, further data from the same 
group shows that loss of eIF3f impairs the ability of mTOR to bind and phosphorylate 
p70-S6K, suggesting that eIF3f pro-anabolic action is more complex [497]. The role of 
eIF3f in GAML has not been confirmed in vivo. 
Canonical control of protein synthesis includes translational derepression, a 
cytosol-based mechanism for sensing amino acid starvation (reviewed in [553]). Relative 
lack of amino acids enriches uncharged tRNA, which bind and activates General Control 
Nonderepressible 2 (GCN2) [554]. Activated GCN2 phosphorylates eIF2α at Ser 51, 
leading to the formation of an inactivating complex with eIF2B [555]. The inactivation of 
eIF2B, the guanine exchange factor for eIF2, leads to general translation shutdown [556]. 
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The lack of eIF2-GTP complexes leads to start codon skipping, which, for transcripts 
including multiple open reading frames (ORF), determines extraordinary translation from 
downstream start ORFs. In eukaryotes, a physiologically relevant downstream ORF is 
Activating transcription factor 4 (ATF4), which upregulates genes involved in transport 
of essential amino acids and synthesis of non-essential amino acids, such as asparagine 
synthetase [557]. Overall, the translational derepression pathway is a mechanism for 
inhibiting protein synthesis, initiated by apparent depletion of free amino acids, and 
leading to ATF4 upregulation. 
The study of translational derepression in mammalians is still in its beginnings. 
The ATF4 knockout mouse has normal weight, but exhibits some sparing from muscle 
atrophy in response to starvation [558]. ATF4 knockout mice exhibit a normal atrogene 
response to starvation, indicating that ATF4 is part of a novel atrophy pathway. The only 
study that measured chronic Dexa effect on phosphorylation of eIF2 reported negative 
results [123]. However, Dexa abrogated amino acid infusion ability to reduce eIF2 
phosphorylation, a situation reminiscent of Dexa’s action on Akt. In a fibroblastic cell 
line, Dexa upregulated ATF4 translation as long as insulin was withheld from the 
medium [559]. 
Unexpectedly, in C2C12 myotubes, ATF4 protein levels are upregulated by 
insulin in a rapamycin-dependent manner [559]. A plausible explanation is that ATF4 is 
upregulated by apparent amino acid deficits, including cases when mTOR-stimulated 
protein translation depletes the free amino acid pool. 
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Changes in 4E-BP1 and perhaps some other pathways regulating protein synthesis 
are induced by Dexa in a manner consistent with GAML. The mild alterations of 
translation molecular markers correlate with the moderate loss in protein synthesis rate. 
While the overall effect is not negligible, its reduced amplitude and its downstream 
relation to MuRF-1 indicate that anabolism adjustments play a complementary role to the 
activation of the ubiquitin-proteasome system in GAML. 
The effects of glucocorticoids on autophagy 
Proteasome inhibition does not abolish completely Dexa-activated proteolysis, 
indicating that some other catabolic mechanisms must be involved. Based on newly 
discovered role of mTOR as a major modulator of autophagy, the second most important 
effector of GAML was presumed to be autophagosome. Moreover, in L6 myotubes, 100 
µM chloroquine or 200 mM E-64 reduce the rate at which Dexa amplifies proteolytic 
tracer release [415]. 
A series of molecular markers further support the idea that autophagy is 
upregulated by Dexa. In C2C12 myotubes, Dexa may induce the formation of double-
membrane autophagic vesicles, although evidence is limited to unquantified micrographs 
[560]. 
Dexa reliably upregulates the family of lysosome proteases known as cathepsins. 
In vivo, Dexa doubles the lysosome proteases cathepsin L and D [402, 561, 429]. In L6 
myotubes, Dexa upregulates cathepsin B [415]. 
A new modality for investigating autophagy hinges on one of the longest-living 
markers on its surface, LC3. Transgenic mice with expressing LC3-GFP have been 
  
95 
developed, and are regularly used for tracking autophagosomes, including in denervation 
atrophy. Unfortunately, there are no reports of this model being used in the study of 
GAML. Alternatively, endogenous LC3 is tracked through immunofluorescence 
microscopy. Some reports describe an accumulation of punctate LC3-containing 
structures in L6 myotubes treated with Dexa for 6 hours [455]. Another way of tracking 
LC3 is based on immunoblot. A lipidated form of LC3, termed LC3-II, migrates faster 
than its precursor, LC3-I, during electrophoresis. Various indices, such as the amount of 
LC3-II, or the ratio between LC3 electrophoretic forms, are used for estimating the 
number of autophagosomes (reviewed in [562]). LC3-II is enriched in C2C12 myotubes 
overexpressing LC3 [560] and in L6 myotubes [455]. Similar to the microscopy 
experiments, these reports use acute Dexa treatments. Moreover, a time course reveals 
that in L6 myotubes, LC3-II peaks at 6 hours and is extinguished at 24 hours after Dexa 
administration [563]. Such findings are consistent with a rapid formation of 
autophagosomes, followed by a slower fusion with lysosomes and clearance. 
In vivo, LC3 changes are rarely documented. Acute Dexa causes accumulation of 
LC3-II protein [494]. Recently, the enrichment of LC3-II after chronic Dexa has been 
reported in rats [564]. 
In contrast with the limited body of evidence we have for autophagy upregulation, 
there is a significant amount of literature describing what would drive autophagy up in 
GAML. In C2C12 myotubes, overexpression of a constitutively active FoxO3 or 
chemical inhibition of Akt upregulate lysosome-attributable proteolysis [376]. As 
mentioned earlier, mTORC1 is a negative regulator of autophagy, whose inhibition in 
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GAML is hypothesized to stimulate autophagy. Acute Dexa administration reduces 
ULK1 phosphorylation at Ser 575, the mTOR-specific, inhibitory site [494]. 
Other lines of evidence provide indirect support for autophagy upregulation in 
GAML. Acute Dexa downregulates p62, one of the shortest-lived markers on the 
autophagosome, thus suggesting that autophagic flux is upregulated [494]. Acute Dexa 
increases expression of the mitophagy effector Bnip3 [494, 455]. In C2C12, acute Dexa 
upregulates expression of lysosome markers such as autophagy-related 12 (Atg12) [515]. 
Given the spatial segregation between lysosomes internal and outer space, 
autophagy must rely on a selective mechanism for any protein that it is processing. 
Therefore, it is likely that autophagy acts only on a few specific, perhaps limiting, 
proteins. For example, Dexa-induced depletion of sialidase Neu2 is prevented by 3-MA 
[560]. 
Autophagy may play a significant role in triggering and regulating GAML. 
Current evidence, based on cell culture experiments, is far from satisfactory. Given its 
limited amplitude in vivo, it is improbable that autophagy is responsible for bulk protein 
elimination. 
Other proteolytic systems modulated by glucocorticoids 
In 1986, it was discovered that proteolysis in muscle is increased when explants 
are soaked in 2.5 mM calcium [565, 566]. The calcium-stimulated proteolysis subsides 
upon co-administration of leupeptin, a wide-spectrum protease inhibitor. The discovery 
of a class of calcium-dependent proteases, called calpains, suggested that they might be 
contributing to muscle atrophy. The calpain system includes μ-calpain, which is activated 
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by micromolar concentrations of calcium, m-calpain, which is activated by millimolar 
concentrations of calcium, and their inhibitor, calpastatin (reviewed in [567]). Transgenic 
mice overexpressing calpastatin have 30% lower loss of muscle upon unloading [568], 
proving that the calpain system is important in some atrophy models. 
There is limited evidence for calpains involvement in GAML, beyond the 
experiments from 1980’s. In vivo, expression of the calcium-dependent protease m-
calpain is trebled by Dexa [402]. In L6 myotubes, calpastatin overexpression halves 
Dexa-induced proteolysis [569]. Also in L6 myotubes, Dexa promotes store-operated 
calcium entry, the mechanism by which intracellular Ca concentration is increased when 
ER stores are depleted [570]. 
It has been speculated that activations of calpains is an initial step in GAML, 
allowing myofibril protein to interact with MuRF-1 [571]. Calpains are important for 
some atrophy models, but their role in GAML is understudied. 
Many unbiased studies found that a family of proteases, metallothioneins, are 
upregulated in GAML [572]. However, they contribution to GAML has not been 
analyzed. 
With the advent of new genome technology, enzymatic and functional studies that 
brought the proteasome in the center of GAML have been abandoned. The example of 
calpains illustrates how non-transcriptional events can contribute to GAML, and testifies 
to a blind spot in GAML research. 
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Alleviation of glucocorticoid myopathy by IGF-I 
Upon finding that, in L6 myoblasts, Dexa-stimulated proteolysis is abated by co-
administration of insulin, Ballard hypothesized in 1983 that Dexa acts indirectly, by 
depleting the body’s supply of IGF-I [573]. While the use of non-fusing myoblasts is 
certain to introduce confounding changes in proliferation, and the equivalence between 
IGF-I and insulin lacks subtlety, his hypothesis captured the attention of many 
investigators. The interest it garnered was even more surprising given that another 
common research theme in those times was the hyperplastic synergy between IGF-I and 
GC [574, 575]. Many reports describe the easily measurable interaction between Dexa 
and IGF-I on muscle cells, rather than focus on the more subtle changes induced by Dexa 
alone. For example, the above sections on Akt and mTOR were informed mostly by 
studies of the interaction. Lately, the interpretation of such experiments shifted from 
mechanism-explaining to a therapeutic paradigm. In mice, electroporation of IGF-I 
plasmid in tibialis protected solely the transformed fibers from Dexa-induced atrophy 
[576]. In Dexa-treated rats, co-administration of IGF-I reduces loss of muscle mass, fiber 
atrophy, and 3MH release [577], thus providing a blueprint for the ideal anti-GAML 
therapy. 
Co-administration of IGF-I reverses upregulation of ubiquitin, and of proteasome 
subunits C2 C3, C8 [578, 579], thus blunting one of the major effectors of GAML, the 
ubiquitin-proteasome system. However, Dexa antagonizes IGF-I on many other 
downstream effects, such as glutamine synthesis [580]. 
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In vivo, Dexa reduces muscle expression of IGF-I [581, 190], and possibly 
interferes by altering IGFBP secretion [425]. Therefore, GAML manifests as an absolute 
loss of IGF-I exacerbated by a downstream inhibition. Intuitively, IGF-I supplementation 
may provide GAML alleviation. 
Despite the positive results seen in rodents, few studies analyzed molecular 
mechanisms by which IGF-I works in vivo. Because co-administration of GH cannot 
reverse muscle loss from Dexa or triamcinolone [582, 579], it was hypothesized that, 
similar to Dexa, IGF-I action on muscle is cell-autonomous, and may be modeled by cell 
cultures. In cell culture, IGF-I alone improves protein synthesis, but has no effect on 
protein degradation [583]. In contrast, on myotubes treated with Dexa, co-administration 
of IGF-I has an anti-proteolytic effect [583]. The reduction in proteolysis covers all 
domains, but, in acute settings, appears more effective in repressing lysosome than 
proteasome activity [584]. IGF-I co-administration reverses MAFbx and MuRF-1 
upregulation [478, 427], in a Foxo dependent manner. During co-administration, Foxo 
regulation is split. Dexa upregulates Foxo protein levels, while IGF-I counters by 
increasing their phosphorylation [424] and reducing its ability to bind MuRF-1 promoter 
[427]. 
The IGF-I-induced Foxo phosphorylation is consistent with upstream modulations 
of the Akt axis. Among those, myoprotective phosphorylation of Akt, GSK-3β, p70-S6K 
and 4E-BP1 is seen with IGF-I co-administration in cells [585, 586]. Studies with 
chemical inhibitors revealed that IGF-I protective effect is mediated by Akt and PI3K 
[585]. It is not known which of these downstream mediators is in fact relevant for 
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myoprotection. Muscle hypertrophy and recovery are halved by rapamycin, indicating 
that other anabolic mediators are as important as the mTOR pathway [587, 375, 588]. 
From the similarity between muscle protection conferred by IGF-I and by GSK-3β 
inhibitors, it was speculated that IGF-I acts by inhibiting GSK-3β [589, 465]. 
Based on the current evidence, it appears that IGF-I alleviating action is not 
completely overlapping with the wide spectrum of atrophic actions of Dexa. The putative 
mediator of muscle loss REDD1 is upregulated by acute insulin or IGF-I [590]. It is 
possible that REDD1 upregulation contributes to the incompleteness in reversal of 
GAML by IGF-I. 
IGF-I is only one of the many determinants of muscle mass. For example, 
myostatin knockout mice have double muscle size, yet lower circulating IGF-I levels, 
compared to wild type mice [591]. However, the changes induced by Dexa in IGF-I are 
consistent with its involvement in the atrophy program. As our understanding of GAML 
improved, studies on its alleviation by IGF-I are lagging. A large number of publications 
focus on the balance of GC and IGF-I on Akt in cultured cells. Given the reduced number 
of co-administration in vivo studies, our understanding of how IGF-I could alleviate 
glucocorticoid myopathy is incomplete. 
Alleviation of glucocorticoid myopathy by anabolic steroids 
Human studies demonstrated that AAS addition to chronic Dexa benefits male 
adult patients, by reducing their loss of muscle and improving their quality of life [158]. 
The idea of alleviating the CS by AAS therapy came two years after the discovery of an 
affordable source of Testo. In the case of exogenous hypercortisolism, the same idea 
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surfaced less than a year after the discovery of GC. Two years later, Courier and Marois 
report the first replication of the myoprotective effect in rats [592]. For a long time, 
during the second dark age of steroids, the combination of AAS and GC, with 
androgenic, but without anabolic potency, was investigated, in the hope that it would 
show the way towards splitting the anabolic from the androgenic principle in Testo. 
A related theoretic question was the nature of the nuclear receptor. At the time 
when it was not clear how many species of nuclear receptors there are, precise 
measurements tried to find putative interference between the various steroids, with Dexa 
and Testo among the most studied compounds. In vitro studies have quantified androgens 
ability to interfere with the binding of Dexa to GR. The dissociation constant (Kd) for 
GR-Dexa association is below nanomolar range [593]. In vitro Dexa doses used in 
muscle atrophy experiments range in the tens of hundred nanomolar. Similar 
concentrations are likely in the blood of mice injected with the 0.5 g/kg to 1 g/kg doses 
described before. At a concentration of 2 pM in rat skeletal muscle [594], virtually all GR 
should be bound to Dexa. On the other hand, inhibitory constant (Ki) for Testo competing 
with Dexa for binding to muscle protein extracts is 10 µM [595]. While the referenced 
report does not distinguish non-specific binding for Testo, Ki is tens or hundreds of times 
higher than typical Testo concentrations used in literature for biological reversal of 
GAML. Testo binding affinity to Dexa binding sites in rat muscle cytosol is less than 100 
times lower than Dexa’s affinity [596]. Therefore, barring allosteric effects, direct 
competition between the two steroids remains only of theoretical importance. 
  
102 
The experiments in the 1980’s and 1990’s tested the interaction of AAS and GC 
on the diaphragm. While these studies could not have measured the yet-undiscovered 
mediators of GAML, they established that myoprotection provided by AAS manifests in 
both muscle mass and force [597, 598, 599]. 
The mechanism by which AAS accomplishes muscle protection in GAML 
remains unknown to date. One early study found that, in vivo, Testo re-establishes the 
percentage of ribosomes that are involved in translation [600]. Two later studies on L6 
myotubes found that AAS could not reverse the downregulation of protein synthesis 
induced by Dexa [573, 601]. A study on C2C12 myotubes also rejected an action of 
Testo on protein metabolism, despite trends for restored protein synthesis and 
degradation when 1 µM Testo is added to 100 nM Dexa [546]. Given the limited number 
of attempts, the failure of in vitro systems to replicate in vivo benefits may be ascribed to 
reduced sensitivity rather than to fundamental shortcomings of the in vitro model. 
A few studies investigated the interaction of AAS and GC, by measuring the 
changes in one signal when the other is altered. An interaction at the level of receptors 
cannot be excluded. In skeletal muscle, GR mRNA and binding activity are increased 
upon castration [602, 603], suggesting a way by which castration causes muscle atrophy. 
Conversely, Dexa reduces the expression of AR in skeletal muscle [190]. 
Hypercortisolism reduces endogenous Testo levels in male rats, thus leading to ampler 
loss of muscle than in females, which experience Testo upregulation [404]. Sexual 
dimorphism in animal models confirms that males stand to benefit more from AAS 
therapy in GAML. 
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In the absence of direct interference, studies sought downstream effectors at 
which Testo could prevent Dexa’s program. One putative interaction is centered on 
myostatin. Myostatin promoter contains putative androgen responsive elements [525]. In 
intact animals and even in atrophic muscle after spinal cord injury, Testo does not alter 
myostatin [604, 605]. Myostatin changes in co-administration of AAS and GC has not 
been investigated. Given myostatin’s limited role in GAML, it is unlikely myostatin 
repression could contribute to the ample alleviation provided by Testo. 
Another promising point of interaction is at the level of the Akt axis. Testo 
upregulates IGF-I in muscle, potentially leading to reversal of Dexa-induced Akt 
inhibition. In other atrophy models, including castration, AAS administration had an IGF-
I-dependent myoprotective action [606]. Of note, this protection was correlated with 
increased Foxo3a phosphorylation, indicating restoration of Akt pathway. 
In the era of immunoblot, only three laboratories published studies of co-
administration of AAS and GC. All three converged towards describing a reversal of Akt 
pathway inhibition. Sheng laboratory describes the effect of 10-day 1 mg/(kg d) Dexa 
and/or 13-day 5 mg/(kg d) Testo on rat gastrocnemius [607]. With these regimen, Testo 
reliably, but incompletely, reverses losses in body weight, muscle mass, and fiber CSA, 
induced by Dexa. Molecular pathways largely confirm an Akt centered disruption of 
GAML. Muscle IGF-I expression is repressed by Dexa, and returned to basal level by 
Testo co-administration. Downstream, similar AAS-induced restorations are seen in Akt 
phosphorylation at Ser 473, p70-S6K phosphorylation at Thr 389, and atrogenes 
expression. The only difference from the canonical pattern is at GSK-3β level, where 
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Dexa has no effect. These findings are consistent with AAS-driven restoration of Foxo 
and mTORC1 pathways to basal level. 
Dalton laboratory account describes the effect of 8-day 600 µg/(kg d) Dexa and/or 
25 mg/(kg d) Testo on rat muscles [507]. This study is focused on the anabolic-
androgenic split, and therefore compares levator to extraperitoneal muscles. At these 
doses, Testo co-administration restores levator ani, but not other muscles. This is a 
surprising finding, given that muscle atrophy caused by a higher Dexa dose was reversed 
by a much lower dose of Testo, in the study from Sheng and collaborators. 
In Dalton’s study, the difference between levator ani and extraperitoneal muscles 
is ascribed to the fact that Testo co-administration upregulates IGF-I beyond basal levels 
in the former, and only partially in the latter. Possibly as a consequence, Testo addition 
reduces atrogene expression to a larger extent in levator ani. In levator ani and C2C12 
myotubes, Testo reverses Dexa-induced hypophosphorylation of Akt (Ser 473), GSK-3β 
(Ser 9), FOXO3a (Ser 253), and p70-S6K (Thr 389). 
The series of studies from Cardozo laboratory is the most informative. This was 
also the first group to show that 28 mg/(kg d) Testo reverses losses in rat gastrocnemius 
induced by simultaneous 700 µg/(kg d) Dexa [608]. They ascribed this alleviation to a 
reduction in proteolysis and atrogenes expression. In studies on L6 and C2C12 myotubes 
overexpressing AR, they found that Testo co-administration reverses transcriptional 
upregulation of REDD1 and MAFbx [609, 425]. 
Arguably, the most important contribution Cardozo made is the first microarray 
study on alleviation of GAML with Testo [425], using gastrocnemii treated as above. 
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This is also the first published microarray study of GAML, generating many hypotheses 
still untested. Many of the genes found in the unbiased approach are consistent with the 
above description of GAML, including transcriptional reversal at the levels of IGFBP, 
IRS1, FOXO1, p85, and 4E-BP1. These changes point to a pleiotropic program through 
which AAS re-establish signaling on the Akt axis. The overlap is not perfect, with 
important presumptive effectors, including IGF-I and MAFbx, failing to pass amplitude 
and statistical significance thresholds. The reversal of GAML is also correlated with a 
repression of REDD1 to basal levels, suggesting that mTOR is also restored by Testo. 
Testo also reversed the surge of MuRF-1, proteasome subunit D8, cathepsin L, LC3, M-
type calpain, C/EBP β and δ, and metallothionein 1, exhibiting a wide-spectrum anti-
atrophic action. 
Among the novel putative mediators, the microarray study revealed that Testo 
reversed Dexa-induced changes in B-cell leukemia/lymphoma 3 (Bcl3), IκB, and CD36. 
The latter is a fatty acid translocase. Its changes suggest that GAML and its reversal have 
opposite effects on muscle’s ability to use lipids as fuel [610]. 
Testo reversed the upregulation of the stress sensor Gadd45, isoform β. Recently, 
it has been shown that Gadd45β is an autophagy blocker [611]. This suggests that in 7-
day treated muscle autophagy could be downregulated, and goes against many other 
molecular markers that indicate the opposite. 
In conclusion, the mechanisms by which Testo prevents GAML appear manifold. 
Many of the putative myoprotective actions of Testo are only suggested by Cardozo’s 
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microarray, but have never been confirmed in quantitative assays and require further 
studies to clarify overall mechanism. 
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HYPOTHESES 
The example of Gadd45, at the end of the previous section, illustrates the issues 
GAML research is confronted with. On one hand, we have macroscopic certainties, such 
the loss of muscle mass following GC therapy. On the other, we have invariable 
molecular correlates of Dexa treatment, such as augmented proteolysis, increased Foxo 
transcriptional activity, reduced insulin sensitivity at Akt and mTORC1 level, and 
upregulation of MuRF-1 and REDD1. For many of these, inhibition or interference 
experiments showed a reduction in muscle atrophy, but none was found to be 
indispensable for GAML. The hierarchy of molecular events in GAML is not known. 
Progresses made in the study of denervation atrophy, greatly favored by the use of 
transgenic models, are yet to be replicated in the study of GAML. Our understanding of 
androgen alleviation of GAML is even more incomplete. 
One reason why key mediators of GC and AAS actions have not been identified is 
the lack of transgenic models. Muscle-localized conditional knockout experiments are 
needed. For this purpose, studies on the most common target of genome manipulation, 
the mouse, are needed. Surprisingly few studies describe GAML in the mouse. Moreover, 
to my knowledge, no study of AAS alleviation of GAML in mice has been published. 
While some parallels with rat studies may help, higher resistance to Dexa in mouse 
suggests there must be differences. This work sets out to determine whether AAS can 
alleviate GAML in mice. Upon identifying the conditions that lead to GAML and to its 
alleviation by AAS, the focus will switch to understanding of the molecular mechanisms 
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underlying them. Based on the published evidence available at the initiation of this 
project, I set forth the following hypotheses: 
1. Testosterone alleviates dexamethasone-induced muscle atrophy in mice. 
GAML has been frequently reported in rats and infrequently in mice. A series of studies 
describe reductions in CSA of mouse myofiber upon Dexa treatment. On the other hand, 
Testo has been used to reverse loss of muscle in mice and other species. Based on the 
information published prior to this work, there was a strong probability for Testo to 
prevent GC-induced loss of mouse muscle. 
2. Testosterone’s myoprotective action in the context of dexamethasone is 
based on inhibiting dexamethasone’s proteolytic effects. Studies of GAML suggest 
that it involved a strong upregulation of proteolysis, aggravated by a decrease in protein 
synthesis. Protein degradation mechanisms upregulated by Dexa are diverse, including 
the proteasome, the autophagosome, and soluble proteases. Microarray studies showed 
that Testo reverses GC-induced changes in markers of each of the three proteolytic 
pathways and of protein translation. Given that the amplest changes induced by Dexa are 
on the proteasome - ubiquitin system, there was a good probability that specific reversal 
of GAML by Testo will include proteasome’s repression. 
3. Testosterone’s myoprotective action in glucocorticoid-induced loss of 
muscle mass is facilitated by the activation of IGF-I / Akt / mTOR axis. The few 
studies on GAML reversal by AAS revealed that Testo action alters mTOR and Akt 
signaling. Based on the microarray studies that showed that Testo reverses changes in 
IGF-I and IGFBP induced by Dexa, and on the castration reversal studies indicating that 
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AAS replacement causes IGF-I upregulation, there was a good probability that the 
myoprotective action of Testo involved the modulation of IGF-I signaling. 
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METHODS 
Ethical considerations 
All animal procedures have been described in protocols drafted by the author, and 
submitted with Dr. Carlo Serra as principal investigator to the Institutional Animal Care 
and Use Committee at the Boston University School of Medicine and Harvard Medical 
Area Standing Committee on Animals. Experiments were performed solely after approval 
was obtained. 
Animal studies 
Male, 6-8 week old (young adult), C57Bl/6J mice were purchased from The 
Jackson Laboratories (Bar Harbor, Maine). Mice were acclimated for 3 d to 7 d between 
delivery and initiation of the experimental interventions. Before and during the 
experiments, mice were maintained in a temperature-controlled facility, at 21 ◦C, with 12 
h light / 12 h dark cycles. Mice were offered water and chow (Purina, Richmond, 
Indiana) ad libitum. 
Experiments involved steroid administration for 1, 3, or 7 days. Every morning, 
between 9 and 11 AM, mice were weighted, then injected subcutaneously with 200 µL 
corn-oil based solution, including 14 µL ethanol, which delivered either (A) 0.7 mg Testo 
propionate (T), or (B) 0.25 mg Dexa (D), or (C) both Testo and Dexa in the above doses 
(DT), or (D) neither drug. This latter group will be designated Vehicle (V). Testo 
propionate and Dexa were from Sigma-Aldrich (St. Louis, Missouri). Research-grade 
corn oil was purchased from MP Biomedicals (Solon, Ohio). Unless specified, chemical 
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reagents used in this work were from Fisher (Pittsburgh, Pennsylvania), including 
pharmaceutical-grade ethanol used here. 
Before the first injection and 24 h after the last injection, mice lean and fat body 
mass was measured by nuclear magnetic resonance (NMR), using an Echo-MRI whole 
body composition analyzer (Echo Medical Systems, Houston, Texas). In this procedure, 
mice were restrained inside a transparent methacrylate tube for 90 s, without sedation or 
anesthesia. 
Mice were euthanized humanely by Euthasol® (pentobarbital sodium and 
phenytoin sodium solution; 200 mg/kg pentobarbital; Diamond Animal Health, Des 
Moines, Iowa) intraperitoneal, followed by quick cervical dislocation. Blood was 
collected immediately after death through thoracotomy and cardiac puncture, incubated 
15 min at room temperature, centrifuged 15 min, at 10,000 g, 4 ◦C. Levator ani, 
gastrocnemius, tibialis anterior, quadriceps, and triceps brachii muscles were collected, 
weighted in wet state, flash-frozen by submersion in liquid nitrogen, and stored at −80 
◦C. 
Muscles were crushed under liquid nitrogen, using a mortar and pestle pre-chilled 
in liquid nitrogen, and muscle powder was stored at −80 ◦C. Small quantities of muscle 
powder (25 µg to 30 µg) were lyzed for enzymatic activity assays, immunoblot, or 
quantitative real-time polymerase chain reaction (qRT-PCR), as described in dedicated 
sections. 
  
112 
Enzymatic assays 
Chymotrypsin-like proteasome enzymatic activity was measured using the 20S 
Proteasome Activity Assay kit (Chemicon International, Temecula, California). For each 
animal and muscle, 25 mg powdered muscle was extracted with 8 mL/g tissue of lysis 
buffer containing 150 mM sodium chloride, 50 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonate HEPES (pH 7.4), 5 mM sodium ethylenediaminetetraacetate 
(EDTA), and 10 ‰ Triton X-100, by nutation at 4 ◦C for 30 min, with vortexing every 10 
min. The extract was clarified by centrifugation at 10,000 g, 10 min, 4 ◦C. The clarified 
extract was collected and stored at −20 ◦C for 1 h, while its total protein concentration 
was determined using the bicinchoninic acid (BCA) method (detailed in the immunoblot 
section). Next, the clarified extract was diluted to match the lowest total protein 
concentration with lysis buffer. Per kit manufacturer instructions, 80 µL clarified extract 
(depending on muscle, 300 µg to 600 µg total protein) were mixed, in 96-well plate 
wells, with 10 µL proprietary assay buffer and 10 µL fluorogenic proteasome substrate, 
Succynyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin, 500 µM stock. This was done in 
duplicates for each sample, and for a negative control (“background”), containing lysis 
buffer instead of muscle extract. The plate was sealed and incubated at 37 ◦C for 30 min. 
Next, fluorescence was measured with a Saphire multi-well plate reader (Tecan, 
Männedorf, Switzerland) with excitation at 380 nm and emission at 460 nm. Background 
fluorescence, including substrate, was subtracted from sample measurements. 
Preliminary tests with manufacturer’s positive control and muscle lysate indicated that 30 
min fluorescence measured with optimal gain and with background subtraction is 
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proportional with the rate of fluorescence change and with the amount of measured 
enzyme. Thus, more detailed kinetics were not needed. 
Lysosome enzymatic activity was measured in a similar protocol, using Cathepsin 
L Activity Fluorometric Assay kit (Abcam plc, Cambridge, England). For each animal 
and muscle, 25 mg powdered muscle was extracted with 8 mL/g tissue of proprietary 
lysis buffer, clarified, stored, and assayed for total protein, in the same manner as for the 
proteasome activity assay. Extracts were diluted to the lowest total protein concentration, 
using the same lysis buffer that was used to extract them. Per kit manufacturer 
instructions, 48 µL clarified extract (depending on muscle, 100 µg to 300 µg total 
protein) were mixed, in 96-well plate wells, with 50 µL proprietary assay buffer and 2 µL 
fluorogenic cathepsin substrate, FR-amino-4-trifluoromethyl coumarin, 10 mM stock. 
This was done in duplicates for each sample, and for a negative control (“background”), 
containing lysis buffer instead of muscle extract. The plate was sealed and incubated at 
37 ◦C for 30 min. Fluorescence was measured with excitation at 400 nm and emission at 
505 nm. Background fluorescence, including substrate, was subtracted from sample 
measurements. 
Calpain enzymatic activity was measured in a similar protocol, using Cathepsin L 
Activity Fluorometric Assay kit (Promega, Madison, Wisconsin). For each animal and 
muscle, 25 mg powdered muscle was extracted with 8 mL/g tissue of lysis buffer 
containing 150 mM sodium chloride, 10 mM HEPES pH 7.4, 10 mM dithiothreitol 
(DTT), 1 mM EDTA, and 10 ‰ Triton X-100, as described for proteasome activity 
assay. Extracts were clarified, and stored, as described for the proteasome activity assay. 
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Total protein was measured by Bradford assay. Briefly, 1 µL sample was mixed with 300 
µL Coomassie Plus (Life Technologies, Carlsbad, California) in duplicate wells of a 96-
well plate, incubated 10 min at room temperature, and measured spectrophotometrically 
for absorption at 595 nm. Extracts were diluted to the lowest total protein concentration, 
using the same lysis buffer that was used to extract them. Per kit manufacturer 
instructions, 50 µL clarified extract (depending on muscle, 100 µg to 300 µg total 
protein) were mixed, in 96-well plate wells, with 50 µL proprietary assay buffer, 
containing lyophilized luciferase, ATP, 80 µM pro-luminescent calpain substrate, Suc-
Leu-Leu-Val-Tyr-aminoluciferase, and 8 µM calcium chloride. This was done in 
duplicates for each sample, and for a negative control (“background”), containing lysis 
buffer instead of muscle extract. After 10 min of incubation at room temperature, steady 
state was reached, with a constant rate of free aminoluciferase production, which is 
immediately converted to free luciferin by the excess luciferase. Luminescence was 
measured with a GeniosPro multi-well plate reader (Tecan, Männedorf, Switzerland) set 
to integrate signal over 100 ms. Background luminescence, including substrate, was 
subtracted from sample measurements. 
Immunoblot 
For each animal and muscle, 25 mg powdered muscle was extracted with 4 mL/g 
tissue of radioimmunoprecipitation assay (RIPA) buffer, containing 150 mM sodium 
chloride, 20 mM Tris pH 7.5, 100 ‰ v/v glycerol, 10 ‰ v/v NP-40, 10 g/L sodium 
deoxycholate, 1 g/L sodium dodecyl sulfate (SDS), 1 mM EDTA, 1 mM sodium 
ethyleneglycol tetraacetate, 10 mg/L leupeptin, 10 mg/L pepstatin, 10 mg/L aprotinin, 1 
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mM phenylmethanesulfonylfluoride, 1 mM sodium orthovanadate, 5 mM sodium 
fluoride. The mixture was nutated at 4 ◦C for 30 min, with vortexing every 10 min. The 
suspensions were clarified by centrifugation at 12,000g, 15 min, at 4 ◦C. The supernatant 
was collected, aliquoted, and stored for months at −80 ◦C. 
Total protein content was measured with a BCA proprietary kit (Thermo 
Scientific Pierce, Rockford, Illinois). First, a 50:1 combination of reagents VW A and B 
was prepared. Next, 200 µL VW reagent mix was combined with 2 µL unknown solution 
in a 96-well plate well. This was done in duplicates for each sample, and for a series of 
standards of 0.5 g/L to 10 g/L bovine serum albumin (BSA) prepared with the same lysis 
buffer as the unknowns. The plate was incubated 30 min at 37 ◦C. Light absorbance was 
measured with a Saphire multi-well plate reader (Tecan, Männedorf, Switzerland) with 
absorption at 562 nm. The standard curve was fitted to a quadratic equation. Typically, 
extracts were diluted to the lowest total protein concentration, using the same lysis buffer 
that was used to extract them. 
The lysates were resolved by polyacrylamide gel electrophoresis (PAGE). The 
gels were cast in the morning of the electrophoresis. The stacking section was a 5 g/dL 
acrylamide gel, with 125 mM Tris pH 6.8. The separating section has a variable 
concentration of acrylamide (12 g/dL for low molecular weight unknowns, 8 g/dL for 
others), and 400 mM Tris pH 8.8. Both sections included 1 g/L SDS, and polymerized by 
the addition of 1 g/L ammonium persulfate and 0.4 ‰ v/v tetramethylethylenediamine. In 
order to settle and migrate, lysates were mixed 1:1 with PAGE sample buffer, which 
contained 30 mM Tris pH 6.8, 10 g/L SDS, 100 ‰ v/v glycerol, 50 mg/L bromophenol 
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blue, and 350 mM DTT. The mixture of sample and sample buffer was incubated for 5 
min at 95 ◦C, then loaded on the gel, with equal volumes and masses of total protein in 
each well. Electrophoresis was performed in a Miniprotean Tetra cell (Bio-rad, Hercules, 
California), at constant 80 V, using an electrode buffer with 14.4 g/L glycine, 3 g/L Tris 
base, 10 g/L SDS. 
From the gel, resolved proteins were transferred to nitrocellulose membranes 
using a Bio-rad Mini-trans blot cassette, at 8 V/cm constant overnight at 4 ◦C. The 
Towbin transfer buffer had 200 ‰ v/v methanol, 25 mM Tris pH 8.3, 192 mM glycine. 
Quality of transfer was assessed by temporary Ponceau staining (20 g/L Ponceau 
S in 300 g/L trichloroacetic acid and 300 g/L sulfosalicylic acid). At this time, using 
indications from the molecular weight standards, the membrane was sectioned, thus 
allowing probing with multiple antibodies. 
Ponceau was removed by washing twice, with shaking 5 min at room temperature, 
in TBST (130 mM sodium chloride, 20 mM Tris pH 7.5, 1 ‰ v/v Tween-20). The 
membranes were blocked by shaking for one hour in blocking solution (TBST with 5 
g/dL fat-free instant milk) at room temperature. Next, membranes were probed by 
shaking overnight at 4 ◦C in TBST with 50 g/L BSA and primary antibodies of choice 
(listed later). Next day, the membranes were washed in TBST, twice briefly and three 
times with 5 min shaking at room temperature. The washed membranes were then probed 
by shaking at room temperature for an hour in a solution with TBST, 5 g/dL fat-free 
instant milk, and the secondary antibody of choice (listed later). The membranes were 
washed as before. 
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Next, the membranes were probed with proprietary Amersham ECL Western 
Blotting Detection Reagent (GE Healthcare, Wilmington, Massachusetts). Briefly, the 
two reagent components were warmed to room temperature, mixed 1:1, and layered on 
the nitrocellulose membrane. The membrane was incubated for 1 min, and then excess 
liquid was drained. The membrane was placed in the film cassette. In a dark room, under 
red light, a X-Omat photographic film (Kodak, Rochester, New York) was placed on the 
nitrocellulose membrane. Exposure was between 10 s and 5 min, depending on the 
strength of the signal. After developing the first image, longer or shorter exposures were 
used, as needed. 
Photographic films were digitized using a FluorChem-SP Imaging System (Alpha 
Innotech, San Leandro, California), using automatic exposure. Band densitometry was 
performed with the Image Studio Lite application (Li-Cor, Lincoln, Nebraska). 
At times, antibodies were stripped by incubation with shaking for 45 min at 50 ◦C 
in a tight container with pre-warmed stripping buffer (20 g/L SDS, 60 mM Tris pH 6.8, 
100 mM beta-mercaptoethanol). Stripped membranes were rinse with water, washed with 
TBST, re-blocked, and re-probed. 
Primary antibodies used were: anti-myosin heavy chain (in-house, from MF20 
hybridoma cells), anti-GAPDH (Pierce), anti-calpain 1 (Abcam), anti-eIF3f (Rockland), 
anti-LC3, anti-phospho-eIF2, anti-4EBP, anti-phospho-4EBP, anti-ATF4, anti-cathepsin 
L, anti-calpastatin, anti-IGF-1R, anti-phospho-IGF1-R, anti-Akt, anti-phospho-Ser473 
Akt (all from Cell Signaling Technologies). Anti-mouse and anti-rabbit secondary 
antibodies were from Cell Signaling Technologies. 
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Quantitative real-time polymerase chain reaction 
Total RNA was purified by a combination of phenol-chlorophorm fractionation 
and spin column chromatography. For each animal and muscle, 25 mg powdered muscle 
was homogenized briefly in 1 mL Trizol (Life Technologies). The suspension was 
incubated 5 min at room temperature, then supplemented with 200 µL chloroform. The 
tube was shaken vigorously for 15 s, and then incubated 3 min at room temperature. 
Phase separation was induced by centrifugation, 15 min, 12,000 g, at 4 ◦C. The top, 
aqueous fraction (500 µL) was collected, and then passed through a gDNA exclusion 
column, by centrifugation for 30 s, 8,000 g. The recovered solution was supplemented 
1:1 with 700 ‰ v/v ethanol, and then passed through an RNeasy column, by 
centrifugation, 10 s at 8,000 g. The column was washed with 700 µL proprietary, 
guanidine and ethanol-containing, RW1buffer, and twice with 500 µL proprietary RPE 
buffer, each time by centrifugation, 15 s at 8,000 g. The column was dried by 
centrifugation 2 min at 8,000 g. RNA was eluted with 40 µL water, by centrifugation, 1 
min at 8,000 g. 
Total RNA concentration was measured with an ND-1000 spectrophotometer 
(Nanodrop, Wilmington, Delaware) at 260 nm, using its Windows proprietary 
application. 
To obtain cDNA using AccuScript 1st Strand cDNA synthesis kit, 320 ng total 
RNA was combined with 300 ng random primers, 20 nmol of each triphosphate 
nucleotide, and the proprietary AccuScript RT Buffer 10×. After incubation for 5 min at 
65 ◦C, and cooling towards room temperature another 5 min, the RNA mix was 
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supplemented with 2 nmol DTT, 20 units RNAse Block ribonuclease inhibitor, and 1 µL 
reverse transcriptase (“AccuScript RT”) proprietary stock. For negative control purposes, 
the same mixture was prepared, while withholding the RT Buffer and the RT stock. This 
no-RT tube provided a measurement of the leaked DNA, which, in the course of this 
work, was negligible. Reverse transcription was performed by incubating 10 min at 25 
◦C, then 60 min at 42 ◦C. Reverse transcription was terminated by incubating 15 min at 
70 ◦C. The product was stored at 20 ◦C between measurements. 
Specific cDNA amounts were measured with an 7500 Fast Real-Time PCR cycler 
(Applied Biosystems, Foster City, California), using 96-well plates. Each unknown was 
measured in duplicates. Each well contained 1 µL cDNA stock, 10 pmol each sense and 
anti-sense primer (listed later), and proprietary SybrGreen 2X. The qRT-PCR cycler 
incubates samples 2 min at 50 ◦C, then 10 min at 95 ◦C. Then, 40 cycles were run, 
comprising 15 sat 95 ◦C, and 60 s at 60 ◦C, with measurements of DNA after each cycle. 
The amount of specific cDNA was estimated from the number of cycles (Ct; cycle 
threshold) required to reach a DNA concentration threshold, automatically chosen by the 
Applied Biosystems software at midway between the lag phase and the end plateau DNA 
concentrations. Moreover, the Applied Biosystems software may interpolate the number 
of cycles, thus providing, for each well, a non-integer number of cycles that will yield the 
threshold DNA concentration. 
Duplicates were averaged for each unknown. Next, from the cycle count required 
to reach the threshold DNA concentration for the specific cDNA of interest, the cycle 
count for a housekeeping gene was subtracted, thus providing a relative measurement of 
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expression for the gene of interest within the transcriptome of that animal. Statistics were 
computed on these differences, also known as ΔCt. To enable comparisons, these ΔCt 
measurements were further re-based, by subtracting from each the average measurement 
in the V group. (This double-rebasing method is also referred to as the ’ΔΔCt’.) 
Primers used are listed in table 2. 
Gene Primers 
Trim63 Forward: TCTCTCAGCTGGAGGACTCC 
Reverse: CTGTACTGGAGGATCAGAGC 
Fbxo32 Forward: GGGAAGCTTTCAACAGATTGG 
Reverse: AATGTTCATGAAGTTCTTTTGGG 
Igf1 (IGF-IEa) Forward: GCTTGCTCACCTTTACCAGC 
Reverse:AAATGTACTTCCTTCTGGGTCT 
Foxo1 Forward: CACCCTGTCGCAGATCTAG 
Reverse: CGAATAAACTTGCTGTGAAGG 
Foxo3a Forward: GACAAACGGCTCACTTTGCC 
Reverse: GACAGGTTGTTGTGCCGGATGG 
Foxo4 Forward: GCCCTACTTTCAAGGACAAGG 
Reverse: CATCCACCAGAGCTCTTC 
Ddit4 Forward: CTGCGAGTCCCCTGGACAGC 
Reverse: CACTGAGCAGCTCAAAGTCG 
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Igf1r Forward: GGGCTGACTGGTGGATGC 
Reverse: CGCTGGGCACGGATAGAGC 
Becn1 Forward: CCACAGCCCAGGCGAAACC 
Reverse: GATGAATCTTCGAGAGACACC 
Map1lc3b Forward: GGAAGATGTCCGGCTATCC 
Reverse: CTCATGTTCACGTGGTCAGG 
Ctsl Forward: AACCGCTGATGCTTAAGATCC 
Reverse: CACTCAGTGAGATCAGTTTGC 
Klf15 Forward: ACAGGCGAGAAGCCCTTGC 
Reverse: CTCGCACACGGGACACTGG 
Gapdh Forward: GCTCACTGGCATGGCCTTCCG 
Reverse: GTAGGCCATGAGGTCCACA 
Table 2. List of RT-PCR primers. 
Cell culture studies 
C2C12 cells were obtained from ATCC (Manassas, Virginia). They were grown 
on solid substrate, on cell culture coated plates, in atmospheric air, supplemented to 5% 
CO2, at 37 ◦C. During proliferation, cells were maintained under 500 µL/cm2 growth 
medium, that is, Dulbecco’s Modified Eagle Medium (DMEM; VWR International, 
Radnor, Pennsylvania), supplemented with 100 ‰ fetal bovine serum (FBS), 100 
units/mL penicillin, and 100 mg/L streptomycin, changed every other day. DMEM 
contained 400 µM phenylalanine, 4.5 g/L glucose, 4 mM glutamine, and lacked pyruvate. 
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Confluence and multiple passages reduce their ability to proliferate and 
differentiate. Therefore, cells were propagated in an undifferentiated state, by splitting 
1:40 at confluence, about every 5 days. Early on, frozen stocks were made, at 1 million 
cells/mL in growth medium supplemented with 100 ‰ dimethyl sulfoxide (DMSO), 
stored under liquid nitrogen. For detachment, cells were rinsed twice with pre-warmed 
200 µL/cm2 phosphate buffered saline (PBS), then incubated at 37 ◦C for about 5 
minutes with 50 µL/cm2 pre-warmed 0.05% trypsin / EDTA (Life Technologies). After 
detachment, cells were tested for viability with trypan blue, counted on a hemocytometer, 
and re-seeded at about 5,000 cells/cm2. 
For experiments, cells were differentiated into myotubes by seeding at higher 
density (about 5,000 cells/cm2). Next day, when cells were nearly confluent, the medium 
was changed to differentiation medium, that is, DMEM supplemented with 20 ‰ horse 
serum (HS), which was charcoal / dextran stripped of hormones (Gemini Bio-Products). 
After two days in differentiation medium, myotubes form, while myoblast become 
quiescent. The medium was then changed every day for five more days, leading to nearly 
complete elimination of undifferentiated and mononuclear cells. 
Dexa and Testo were delivered from 400X stocks in ethanol, at various 
concentrations, as indicated at each experiment in the results section. 
Protein synthesis was inhibited with 100 µM cycloheximide from 360X water-
based stock, or 5 µM puromycin dihydrochloride from 500X water-based stock. 
proteasome activity was inhibited in cell culture with 5 µM MG132 from an 80X 
working stock in differentiation medium, which in turn was derived from an 8,000X 
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DMSO-based stock. lysosome activity was inhibited with 25 µM chloroquine from a 
2,000X water-based stock. Calpain and cathepsin activity was inhibited by 10 µM E-64, 
from a 100X water-based stock. IGF-1R was inhibited by 50 nM picropodophyllin (PPP), 
from a 200X working stock in differentiation medium, which in turn was derived from a 
1,000X DMSO-based stock. 
Immunofluorescence microscopy 
After the experimental treatments, the adherent cells were washed twice, on ice, 
with ice-cold PBS. The cells were covered with cold 1:1 v/v ethanol:acetone, and 
incubated at 20 ◦C for 20 minutes. This process both fixated and permeabilized the cells. 
The liquid was removed, and the cells were rinsed with PBS. 
On the first day of staining, PBS was removed, and cells were washed briefly 
twice with PBS. For blocking purposes, cells were incubated for 40 min at room 
temperature under 1% BSA in PBS. The blocking liquid was then replaced with the 
primary antibody solution, that is, the same blocking solution, supplemented with 1:20 
hybridoma cell culture medium containing the anti-myosin heavy chain antibody MF-20. 
Cells were probed with the primary antibody overnight at 4 ◦C. 
Next day, the cells were incubated twice 5 min each with the blocking solution, to 
wash unbound primary antibody. Cells were then probed with the secondary antibody, 
that is, blocking solution supplemented with 1:500 anti-mouse antibody conjugated with 
rhodamine, and with 1 mg/L DAPI. The cells were incubated 60 min at room temperature 
in the dark, and then briefly washed 4 times with PBS. Cells covered in PBS were store at 
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4 ◦C or observed with an Eclipse TE2000-E fluorescence microscope (Nikon 
Instruments, Melville, New York). 
Cell contours were obtained using Magnetic Lasso in Adobe Photoshop CS4. All 
the cell outlines that could be recognized by Photoshop from two randomly chosen fields 
were pasted in another file, which was read in Matlab 8. An automated script determined 
multiple estimates of the diameter, and calculated an average diameter for each fiber. 
Measurement of muscle protein synthesis and degradation 
Cells were labeled by incubation in differentiation medium supplemented with 0.2 
mCi/L radioactive (³H- [ring]) phenylalanine (126 Ci/mmol; PerkinElmer, Shelton, 
Connecticut), starting at the times and for the durations specified at each experiment in 
the results section. For removal of non-specific tracer at the end of labeling stage, cells 
were rinsed with PBS twice, and then incubated with 2 mm PBS for 15 min at 37 ◦C, 5% 
CO2. 
For chase experiments, PBS was then replaced with non-radioactive 
differentiation medium, for the durations specified at each experiment. Chase 
experiments ended with a double rinse with PBS. Preliminary studies revealed that 
supplementation of differentiation medium with 10 mM phenylalanine made no 
difference to the rate of tracer release, compared to differentiation medium alone (data 
not shown). This is plausible, because differentiation medium already contains 0.4 mM 
phenylalanine, and suggested that additional osmotic stress could be avoided at no cost to 
sensitivity of the method. 
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In all cases, cells and media were collected separately, and each was fractionated 
with trichloroacetic acid (TCA). Medium was removed from the plate, and then 
supplemented with 6 M TCA, to a final 0.6 M TCA. Cells were covered with 0.6 M TCA. 
Both media and cells were then incubated overnight at −20 ◦C. Next day, cells and media 
were thawed at 4 ◦C over two hours. Cells were scraped. The cell culture wells were 
further scraped and rinsed with 0.6 M TCA. Protein suspensions were centrifuged at 
15,000 g, for 15 min, at 4 ◦C. Pellets were washed with 0.6 M TCA, by resuspension, 
incubation at 4 ◦C for 15 min, and centrifugation as above. Next, pellets were washed 
once more with acetone, by the same procedure. All two TCA-based supernatants and the 
acetone supernatant were pooled. Pellets were dissolved in 1 M NaOH / 1 ‰ Triton, with 
sonication 15 min at 50 ◦C, followed by incubation 15 min at 50 ◦C. 
From the supernatant or from the resuspended pellet, 100 µL was mixed with 5 
mL Econo-lite scintillation fluid, and then counted in a TriCarb 3100TR liquid 
scintillation counter (PerkinElmer) for 3 min per sample. Counts per minute were 
converted to disintegrations per minute using a standard curve generated using 1 µCi/L to 
80 µCi/L labeled phenylalanine dissolved in the same solvents as the samples (2:1 
TCA:acetone, or 1 M NaOH / 1 ‰ v/v Triton). 
From the same protein pellet suspension, aliquots were used to measure total 
protein concentration by BCA method, as described in the immunoblot section, but with 
standards prepared in the same solvent as the unknowns. 
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Statistics 
Statistics and plots were generated in R 3.2 with ggplot2, knitr, and Lyx [612]. 
Raw data, with LibreOffice Calc and R calculations, is publicly available on Github. 
Results are presented as means ± standard error of the mean. In plots, points represent 
means, while error bars are standard error of the mean. In both cases, error bars include 
only biological variability. 
. In the cases where data passed the Shapiro-Wilk test of normality at significance 
level of 0.05, parametric tests were used. Experiments with two conditions were analyzed 
using Student’s t-test. Experiments with more than two conditions were analyzed by 
analysis of variance (ANOVA). Within these experiments, pairs of conditions were 
contrasted with post-hoc Tukey’s honest significant difference (HSD) test. In cases where 
data normality could not be proven, non-parametric tests were used, as follows. 
Experiments with two conditions were analyzed using Mann-Whitney U-test. 
Experiments with more than two conditions were analyzed by Kruskal-Wallis test. 
Within these experiments, pairs of conditions were contrasted by post-hoc Dunn’s test 
with Bonferroni correction for multiple comparisons. 
In a plot, means with the same letter are not significantly different from each 
other. Tests were considered statistically significant when the null hypothesis could not 
be rejected at any level of significance greater than or equal to 0.05. 
Literature review 
The introduction section was based on review of all literature indexed by 
PubMed. Search expressions included ‘testosterone OR androgens‘, ‘dexamethasone OR 
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betamethasone OR triamcinolone OR prednisone OR prednisolone OR hydrocortisone 
OR cortisone OR triamcinolone OR fludrocortisone‘, ‘Cushing‘, ‘ribosome OR polysome 
OR lysosome OR autophagosome OR proteasome OR ligase OR cathepsin OR FOXO 
OR IGF1 OR calpain OR mTOR OR AMPK OR Akt‘, and combinations thereof. 
Relevant primary data were summarized. 
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IN VIVO EXPERIMENTS 
Testosterone reverses dexamethasone-induced muscle atrophy 
At the time when the project started, no published study on mice described a dose 
of Dexa that would induce muscle atrophy. To date, there is still no published report of 
the effective Testo dose that would prevent GAML in mice. I attempted to repeat the 
daily injections protocol described by Jones as effective on rats [507] (Fig.1 ). 
 
Figure 1. Experimental protocol for the in vivo studies. 
Mice treated with the Dexa doses that were reported to induce muscle atrophy in 
rats did not exhibit significant muscle loss based on muscle dissection and NMR (data not 
shown). Higher doses of Dexa were used. Effect size on wet muscle weight became 
stronger than experimental error at a dose of 10 mg/(kg d) Dexa. In contrast, Testo doses 
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that could reverse GAML were found to be similar to those effective in rats (28 mg/(kg 
d)). 
 
Figure 2. Body weight at sacrifice, following 10 mg/(kg d) Dexa with / without 28 mg/(kg d) Testo 
treatments. Treatments designated by the same letter do not differ significantly from each other 
(n=5-6). 
Upon finding the Dexa dose effective in inducing muscle atrophy, I analyzed the 
body weight at sacrifice. There was no difference between groups in terms of absolute 
weight, due to the large variability of the initial body weight (Kruskal-Wallis p = 0.777) 
(Fig. 2, right). The difference became apparent when percent change in body weight was 
compared (Fig. 3, top, last time point). In this case, the three treatments (vehicle, Dexa, or 
the combination Dexa + Testo) were significantly different (Kruskal-Wallis p = 0.00385). 
Instead of the expected unchanged body weight over the seven days of treatment with 
vehicle alone, there was a trend for growth, with an apparent gain of 0.212 grams every 
day during the treatment. A similar trend has been seen in the other repetitions of the 
experiment, as well as in other published studies on young rodents. A sizable contribution 
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to this growth was brought by the 200 µL vehicle injected every day. Once this artifact is 
taken into account, the gain of a negligible 0.0333 grams per day in the Dexa-treated 
group is in fact indicative of an actual massive loss of body weight. 
 
Figure 3. Time course of body weight Dexa with / without Testo treatments (n=5-6). Stars indicate 
statistically significant differences between Veh and Dexa (p <0.05). Daggers indicate statistically 
significant differences between Dexa and Comb (p <0.05). 
Seven-day weight gain in Dexa-treated group (1.05 ± 1.14% of initial body 
weight) was significantly smaller than that of the vehicle-treated group (6.12 ±0.879%; 
Dunn’s test p = 0.0447). Conversely, co-administration of Testo, hereafter and in plots 
abbreviated Comb, brought back the body weight gain over seven days to levels similar 
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to those in vehicle-treated animals (8.62 ± 0.674%; Dunn’s test vs. Dexa alone, p = 
0.00167). 
The time course of body weight changes suggested that both drugs’ action had a 
rapid onset (Fig. 3; Kruskal-Wallis for first day percent change in body weight, p = 
0.0239). Specifically, mice receiving vehicle alone gained 2.28 ± 0.485% body weight in 
the 24 hours, due to accretion of nonresorbable vehicle. In contrast, mice receiving Dexa 
lost 1.86 ± 0.485% body weight (Dunn’s test p = 0.0387). Mice receiving a combination 
of Dexa and Testo were essentially indistinguishable from those receiving vehicle alone, 
having gained 2.61 ± 0.767% body weight. This demonstrated an advantage of the 
combination treatment over Dexa alone (Dunn’s test p = 0.0213). 
Based on the whole time course, I hypothesized that body weight changes and 
muscle atrophy occur in a gradual manner, with significant metabolic and molecular 
changes preceding the seven-day end of experiment. Accordingly, I repeated the above 
experiment on different cohorts of mice, which were sacrificed after only 1 or 3 days of 
treatment. Once more, absolute changes in body weight could not be correlated with the 
muscle changes (Fig. 2, left and middle). When normalized, relative changes in body 
weight for these groups of mice were less ample than those seen with 7 days of treatment, 
to the point that most parameters (body weight, lean body mass, individual muscles mass) 
were not changed in a statistically significant manner (Fig. 3, bottom). These shorter 
treatments provided insight into the molecular development of atrophy, but, because they 
were run as independent experiments, they will not be analyzed in conjunction. Because 
this work is focused on longer-term effects of Dexa, most of the reported data in the 
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remainder of the section will be either from mice treated for 7 days with Dexa with / 
without Testo, or comparisons of the 1, 3, and 7 day samples. 
 
Figure 4. Changes in water, lean, and fat body mass, after Dexa with / without Testo treatments 
(n=5-6). 
Body composition analysis indicated that all animals included in these 
experiments progressively lost total water. There was no difference between water loss in 
the three experimental groups (Fig. 4, top; Kruskal-Wallis for seven day mass of water 
lost, p = 0.302). This uniform loss of water negates a scenario in which the observations 
could be ascribed to increased water retention due to non-specific action of either steroid 
with MR. In all cases, the losses of total water track the loss of lean body mass, indicating 
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that muscle atrophy, rather than renal dysfunction, underlies the loss of water. Fat mass 
analysis indicated that in the vehicle-alone treated group, the rate of apparent fat gain was 
essentially equal with the mass of injected vehicle accrued over the seven days. This 
demonstrates that experiments manipulations, in the absence of pharmacological 
treatments, have no effect on lipid metabolism. Dexa-treated mice accrued an additional 
0.73 g fat, compared to vehicle (Dunn’s test, p = 0.0681. Similarly, mice treated with the 
combination accrued 0.922 g additional fat, compared to vehicle (Dunn’s test, p = 
0.0172). Therefore, Testo co-administration had no effect on lipid accretion (Dunn’s test, 
Dexa vs. combination, p = 0.802). 
Ampler changes were induced by the two drugs on lean body mass (Fig. 4, 
bottom; Kruskal-Wallis for seven day lost lean mass, p = 0.000811). Vehicle alone has no 
effect on lean body mass (0.327 ± 0.203 grams lost over seven days, that is, 1.65% of the 
total lean body mass). Dexa alone induce a massive loss of lean body mass (3.21 ± 0.166 
grams lost over seven days; Dunn’s test p = 0.000242). When Testo was co-administered, 
the loss of lean body mass persisted, but there was a trend towards a lower loss rate (1.57 
± 0.133 grams lost over seven days; Dunn’s test vs Dexa, p = 0.108). 
The loss of lean body mass induced by Dexa was apparent even in the 3-day 
experiment (1.45 ± 0.152 grams lost over three days; Dunn’s test vs. vehicle, p = 
0.00961). Interestingly, in that experiment, Testo protective effect was very small and not 
statistically significant (1.28 ± 0.369 grams lost over three days; Dunn’s test vs. Dexa, p 
= 0.675). 
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Figure 5. Effects of Dexa with / without Testo treatments on the wet weight of le- vator ani, 
quadriceps, gastrocnemius, triceps brachii, and tibialis anterior muscles (normalized to body weight; 
n=5-6). 
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Dissection of individual muscles confirmed that Dexa achieved widespread 
muscle atrophy (Fig. 5). Despite the small sample size (n=5-6), the atrophying effect of 
Dexa became statistically significant at day 3 on gastrocnemius (Dunn’s test, p = 0.0369). 
At day 7, statistical significance is also achieved in triceps brachii (Dunn’s test, p = 
0.0209), quadriceps (Dunn’s test, p = 0.00205), and levator ani (Dunn’s test, p = 0.0245). 
In terms of amplitudes, the five measured muscles ranged from extremely responsive, 
such as quadriceps (22.7% muscle weight loss), triceps (18% muscle weight loss) and 
gastrocnemius (16.5% muscle weight loss), to the refractory tibialis anterior (6.2% 
muscle weight loss). For each muscle and time point, the average muscle weight in the 
Dexa group was smaller than the average weight of the controls. 
Upon Testo co-administration, four out of five muscles measured were exhibited a 
trend towards restoration to their basal weight (Fig. 5). The amplitude of restorative 
response to Testo co-administration was strongest in quadriceps (15.2% restoration in 
muscle weight; Dunn’s test, p = 0.27), followed by levator (10.2% restoration in muscle 
weight; Dunn’s test, p = 0.134), and gastrocnemius (9.07% restoration in muscle weight; 
Dunn’s test, p = 0.199) appear the most responsive. 
At the seventh day, Testo co-administration led to an additional 3.12% loss in 
tibialis weight (Dunn’s test, p = 0.523). A similar trend indicating Testo’s inability to 
rescue tibialis mass is also present in the three-day data (2.63% loss; Dunn’s test, p 
=0.975). The small amplitude and the complete absence of statistical significance suggest 
that observations describe lack of Testo effect, rather than a true atrophic effect. Because 
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tibialis is not manifesting GAML at macroscopic level, molecular analysis will not 
include it. 
 
Figure 6. Changes in atrogenes MuRF-1 / Trim63 and MAFbx / Fbxo32 expression following Dexa 
with / without Testo treatments, in quadriceps and gastrocnemius muscles (n=3-5, normalized to 
GAPDH). 
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In conclusion, 10 mg/(kg d) Dexa injection led to rapid onset of muscle atrophy. 
Similar to humans with hypercortisolism, total body weight had limited use in assessing 
atrophy progression. Based on the time course of lean body mass and individual muscle 
changes, the atrophy develops throughout the first week, indicating that this murine 
model replicates chronic GC exposure. Some muscles are more responsive than others, 
with tibialis a notable refractory exception. In contrast, 28 mg/(kg d) Testo co-
administration reduced the loss of muscle throughout the seven days course. While rat 
experiments have described a series of pathways by which Dexa can achieve muscle 
atrophy, it was unclear which of them, if any, is reversed by Testo co-administration. 
Testosterone reverses glucocorticoid-induced activation of the ubiquitin-proteasome 
system 
The rapid loss of muscle mass induced by Dexa in mice exceeds the rate of 
protein turnover in normal adult rodent muscle (about 2.5% per day [613]). Therefore, 
Dexa’s action cannot rely exclusively on translational shutdown. I attempted to establish 
which protein degradative pathways could be mediating the atrophic effect of 
dexamethasone. Experiments on rats suggest that Dexa causes protein degradation by 
stimulating the proteasome-ubiquitin-related transcriptional program, whereas Testo 
represses it. 
In normal circumstances, the rate-limiting factor in proteasome-mediated protein 
degradation is target protein conjugation with ubiquitin, catalyzed by E3 ligases. In mice 
treated with Dexa, the E3 ligase more commonly associated with loss of muscle mass, 
MuRF-1 (Fig. 6, top), was upregulated by Dexa at day 1 in gastrocnemius (1.9-fold 
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amplification; Dunn’s test, p = 0.116) and in quadriceps (61.5-fold amplification; Dunn’s 
test, p = 0.00906). The effect was even more consistent at day 3, with MuRF-1 transcript 
in gastrocnemius being 7.58-fold amplified (Dunn’s test, p =0.0154), and in quadriceps 
4.71-fold amplified (Dunn’s test, p =0.0726). The effect was insignificant statistically, 
and in amplitude, by the seventh day of Dexa administration. 
Testo co-administration had an inhibitory effect on MuRF-1, with a later onset. 
No significant effect of Testo co-administration was seen in day 1. In day 3 samples, 
MuRF-1 was repressed by Testo in gastrocnemius (1.97-fold reduction; Dunn’s test, p 
=0.591) and in quadriceps (5.82-fold reduction; Dunn’s test, p=0.0268). Testo repression 
of MuRF-1 strengthened in the day 7 samples, with transcripts reduced in gastrocnemius 
(2.11 fold reduction; Dunn’s test, p = 0.116) and in quadriceps (2.13 fold reduction; 
Dunn’s test, p = 0.0748). 
A similar pattern, although with lower intensity, was seen in MAFbx gene 
regulation by the two steroids. MAFbx was reliably upregulated by Dexa at day 1 in 
gastrocnemius (2.45 fold amplification; Dunn’s test, p = 0.175) and quadriceps (50.1 fold 
amplification; Dunn’s test, p = 0.00906). At day 3, only the quadriceps MAFbx response 
was still present to a significant degree (4.32 fold amplification; Dunn’s test, p = 0.113). 
The effect became insignificant statistically across muscle groups by the seventh day of 
Dexa administration. 
Testo co-administration had no statistically significant effect on MAFbx at days 1 
and 7. By day 3, MAFbx was repressed by Testo in gastrocnemius (1.34 fold 
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amplification; Dunn’s test, p = 0.616) and in quadriceps (6.29 fold amplification; Dunn’s 
test, p = 0.0154). 
The other component of the ubiquitin-proteasome system is the proteasome itself. 
In cases where E3 ligases are upregulated, it may be the case that availability of 
proteasomes is limiting the ubiquitin-proteasome system. However, in day 3 samples, 
where atrogene upregulation was at its peak, Dexa upregulated proteasome 
chymotrypsin-like enzymatic activity in quadriceps (18.7% increase; Dunn’s test, p = 
0.157) and triceps (111% increase; Dunn’s test, p = 0.0884; Fig. 7). This component of 
atrophy was also inhibited by Testo, whose co-administration reduced proteasome 
activity in quadriceps (24.2% reduction; Dunn’s test, p = 0.435) and triceps (30% 
reduction; Dunn’s test, p = 0.609) at day 3. 
 
Figure 7. Changes in proteasome chymotrypsin-like enzymatic activity following Dexa with / without 
Testo treatments, in quadriceps and triceps muscles (n=4-6). 
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Overall, the good correlation with the macroscopic loss of muscle suggests that 
the proteasome-ubiquitin system is an effector of GAML and a target of its alleviation by 
AAS. 
 
Figure 8.Changes in autophagy-related genes following Dexa with / without Testo treatments, in 
quadriceps and triceps muscles (n=3-4, normalized to GAPDH). 
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Figure 9. Changes in cathepsin L enzymatic activity following Dexa with / without Testo treatments, 
in quadriceps and triceps muscles (n=4-6). 
Autophagy markers during dexamethasone and testosterone treatments 
Rat microarray studies indicated that a series of genes related to autophagy are 
upregulated by Dexa and downregulated by Testo. However, these findings have never 
been tested in vivo in mice. Having established a model of GAML, I investigated whether 
the autophagy markers are correlated with muscle loss. A panel of three genes indicated 
that Dexa-induced gastrocnemius atrophy is associated with a reduction in autophagy-
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related transcription (Fig. 8) The repression is ampler in day 3 samples, with mRNA for 
beclin / Becn1 reduced 9.81-fold (Dunn’s test, p = 0.0213), cathepsin L / Ctsl reduced 
3.89-fold (Dunn’s test, p = 0.304), and LC3 / Map1lc3b reduced 5.61-fold (Dunn’s test, p 
= 0.359). Across muscle groups and time points, Testo co-administration lacked 
detectable effect. 
I tested the hypothesis that autophagy mediates protein degradation in GAML by 
measuring lysosome enzymatic activity in muscle lysates (Fig. 9). Unexpectedly, 
cathepsin L enzymatic activity was reduced in all the assayed muscle, in a progressive 
manner. At day 1, cathepsin L activity was suppressed by Dexa in gastrocnemius (16.4% 
reduction; Dunn’s test, p = 0.02), quadriceps (14.5% reduction; Dunn’s test, p = 0.0294), 
and triceps (26.8% reduction; Dunn’s test, p = 0.00219). At day 3, cathepsin L activity 
was further suppressed by Dexa in gastrocnemius (19.7% reduction; Dunn’s test, p = 
0.223), quadriceps (44.5% reduction; Dunn’s test, p = 0.00201), and triceps (44.5% 
reduction; Dunn’s test, p = 0.00107). In day 7 samples, Dexa-induced repression of 
cathepsin L activity reached 36.3% in gastrocnemius (Dunn’s test, p = 0.00365), 44.4% 
in triceps (Dunn’s test, p = 0.0486), and 44.9% in quadriceps (Dunn’s test, p = 0.0091). 
Testo co-administration had no statistically significant effect on cathepsin L enzymatic 
activity, although a trend of reversal to baseline can be seen in day 1 and 3 samples. 
In literature, another line of evidence for the putative upregulation of autophagy 
during GAML was the increase in lipidated, fast migrating LC3 protein (also known as 
LC3-II). In murine muscle, detecting this form has been difficult, because it is 
significantly less frequent than its slower migrated counterpart (Fig. 10). In 
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gastrocnemius at day 7, there was a trend towards enrichment of LC3-II in absolute terms 
upon Dexa treatment (91.6% increase, when normalized to GAPDH; Dunn’s test, p = 1). 
However, LC3-II changes become negligible, when LC3-II is normalized to its precursor, 
LC3-I (-0.339% increase; Dunn’s test, p = 1). 
 
Figure 10. Changes in hyperlipidated (fast-migrating) LC3 isoform following Dexa with / without 
Testo treatment in gastrocnemius muscles (n=4). 
The trend towards increased absolute LC3-II in gastrocnemius is reversed by a 
trend towards basal levels upon Testo co-administration (29.8% decrease, when 
normalized to GAPDH; Dunn’s test, p = 1). 
 
Figure 11. μ-calpain enzymatic activity, during 7 days of Dexa with / without Testo treatments, in 
gastrocnemius muscles (n=3-6). 
Findings like the upregulation of LC3-II may have suggested to other authors that 
GAML relies on autophagy. However, the overall evidence suggests that GAML is 
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correlated with rampant autophagy downregulation, while AAS co-administration has a 
limited effect on autophagy. Immunoblots and enzymatic assays indicated a similar 
disconnection between the calpain / calpastatin system and the AAS-induced muscle 
sparing (Fig. 11). The ubiquitin - proteasome system emerges as the main effector of 
GAML and the main target of its alleviation by AAS, in this model system. 
 
Figure 12. Levels of phosphorylated eIF2α (Ser 51) following Dexa with / without Testo treatment in 
gastrocnemius muscles (normalized to simultaneously resolved GAPDH; n=4). 
Protein synthesis modulation during Dexa-induced muscle atrophy 
Often, literature reports describe how upregulation of muscle catabolism 
following Dexa treatments is compounded by repression of protein synthesis. In order to 
discern putative changes in protein synthesis in this model, I investigated a series of its 
translation regulators. A well-documented manner of translational shutdown upon various 
conditions, such as endoplasmic reticulum stress, is phosphorylation of the initiation 
factor eIF2α by a diverse set of kinases. In agreement with published studies, there was 
no statistically significant change in phospho-eIF2α in the gastrocnemius of mice treated 
with Dexa (Dunn’s test, p = 1; Fig. 12). Another regulator of proteins synthesis that was 
shown to play a role in muscle atrophy upon starvation is eIF3f. In levator muscles of 
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mice treated with Dexa, there was no statistically significant change in the levels of eIF3f 
(Dunn’s test, p = 0.971; Fig. 13). 
 
Figure 13. Levels of eIF3f following Dexa with / without Testo treatment in levator ani muscles 
(normalized to simultaneously resolved GAPDH; n=4). 
 
Figure 14. Levels of total (left) and phosphorylated (right) 4E-BP following Dexa with / without Testo 
treatment in gastrocnemius muscles (normalized to GAPDH; n=4). 
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Finally, Dexa was hypothesized to achieve protein synthesis inhibition by 
stimulating the negative regulator 4E-BP. In Dexa-treated mice, gastrocnemius 4E-BP 
protein levels were upregulated (25.6% increase, when normalized to GAPDH; Dunn’s 
test, p = 0.428; Fig. 14, left). However, Dexa also stimulated phosphorylated, that is, 
inactive 4E-BP (62.5% increase, when normalized to GAPDH; Dunn’s test, p = 0.00669; 
Fig. 14, right). The effect of Dexa on active, that is, unphosphorylated 4E-BP could not 
be clearly estimated from these immunoblot data. 
After 7 days of Testo co-administration, levels of total 4E-BP were essentially 
identical to those yielded by Dexa alone (5.6% increase; Dunn’s test, p = 0.428; Fig. 14, 
right). At the same time, Testo co-administration was associated with lower 
phosphorylated 4E-BP (9.83% increase, when normalized to GAPDH; Dunn’s test, p = 
0.49; Fig. 14, left). The combination of increase in total 4E-BP and decrease in 
inactivated 4E-BP suggests an unexpected increase in active 4E-BP, which could have 
led to reduction in the rate of protein synthesis. The amplitude of Testo-induced changes 
in 4E-BP is small, and the direction opposite to what would be required to upregulate 
protein synthesis and facilitate muscle recovery. 
Overall, regulators of protein synthesis appeared largely unchanged by Testo at 
the 7-day stage of their administration, in this model system. 
Foxo pathway response to dexamethasone and testosterone 
Previous studies on C2C12 cultured cells showed that the atrogene response is 
crucially stimulated by Foxo transcription factors. The review section describes a series 
of five hypothetical means by which Dexa is thought to stimulate Foxo transcriptional 
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program. Most of them converge on upregulation of Foxo transcripts. I set to test the 
hypothesis that muscle Foxo expression is modulated by Dexa and Testo in muscle. 
 
Figure 15. Changes in the expression of Foxo3a (top) and Klf15 (bottom) transcription factors, 
during 7 days of Dexa with / without Testo treatments in quadriceps muscles (n=4, normalized to 
GAPDH). 
In this study, Foxo transcription factors were strongly induced during the early 
stages of GAML (Fig. 15). In quadriceps at day 1, Foxo3a RNA was 78.1-fold 
upregulated (Dunn’s test, p = 0.00906). In day 3 samples, Foxo3a activation was less 
ample (3.17-fold; Dunn’s test, p = 0.0529). In the samples from day 7, Dexa treatment 
was associated with a non-significant downregulation of Foxo3a (Dunn’s test, p = 0.175). 
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In contrast, Testo downregulated Foxo transcription factors at later stages of 
GAML. In day 3 samples, Testo co-administration repressed Foxo3a 2.99-fold (Dunn’s 
test, p = 0.195). The trend was present in day 7 samples too, with Foxo3a repressed 2.04-
fold (Dunn’s test, p = 0.304) by Testo co-administration. Similar patterns of modulation 
were seen in Foxo1 and Foxo4 transcripts (data not shown). 
The changes in Foxo transcription factors were mirrored by similar changes in 
their positive regulator Klf15. Dexa stimulated Klf15 expression at day 1 (13.9-fold 
upregulation; Dunn’s test, p = 0.00906), and day 3 (2-fold upregulation; Dunn’s test, p = 
0.222). Testo co-administration reversed Klf15 changes, with the strongest repression, 
3.28-fold, in day 3 samples (Dunn’s test, p = 0.017). 
Akt pathway response to dexamethasone and testosterone 
An alternative way to achieve Foxo modulation is through their neutralization by 
Akt. As described in the literature review section, activation of Akt is dependent on its 
phosphorylation on two residues, Ser 473 and Thr 308, with the former being the most 
important regulator of Foxo specificity. I therefore investigated the effect of the two 
steroids on Ser 473 phosphorylation. 
After 7 days, neither drug changed the level of total Akt in levator, nor 
gastrocnemius (Fig. 16, left). At the same time, Dexa repressed phosphorylation of a 
large degree in gastrocnemius (35.6% reduction in absolute densitometry of phospho-
Ser473 Akt, when normalized to GAPDH; Dunn’s test, p = 0.304), and levator ani 
(46.2% reduction; Dunn’s test, p = 0.146). However, Testo co-administration had no 
significant effect on phospho-Ser473 Akt in gastrocnemius (0.842% increase, p = 1).  
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Figure 16. Levels of total and phosphorylated Akt following 7 days of Dexa with / without Testo 
treatment in gastrocnemius (top) and levator (bottom) muscles (normalized to GAPDH; n=4). 
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Figure 17. Changes in Redd1 transcripts, during 7 days of Dexa with / without Testo treatments in 
gastrocnemius muscles (n=4, normalized to GAPDH). 
Interestingly, in this model system, Testo co-administration repressed phospho-
Ser473 in levator ani, an extremely AAS-sensitive muscle (33.1% decrease; Dunn’s test, 
p = 0.823). 
The other relevant phosphorylation on Akt, Thr 308, is controlled by REDD1. I 
investigated the effects of the two steroids on REDD1 / Ddit4 transcription (fig. 17). 
Dexa upregulated Redd1 expression in gastrocnemius collected at days 1 (7.48-fold; 
Dunn’s test, p = 0.0362), 3 (27.8-fold; Dunn’s test, p = 0.0912), and 7 (2.64-fold; Dunn’s 
test, p = 0.255). Confirming the rat microarray studies, at day 7, Testo co-administration 
induced a sizable repression of REDD1 (1.85-fold; Dunn’s test, p = 0.143). 
IGF-I changes during dexamethasone and testosterone administration 
As explained in the review section, IGF-I was one of the few genes whose 
expression was changed in opposite ways by Dexa and Testo in rat microarrays. I tested 
the hypothesis that Dexa and Testo alter IGF-I expression in mice, in vivo (Fig. 18). 
In gastrocnemius, Dexa downregulated IGF-I expression in samples collected at 
days 1 (4.35-fold; Dunn’s test, p = 0.0213), 3 (4.03-fold; Dunn’s test, p = 0.0105), and 7 
  
151 
(2.25-fold; Dunn’s test, p = 0.0362). Dexa-induced downregulation of IGF-I was also 
detected in quadriceps at days 3 (2.87-fold; Dunn’s test, p = 0.0319), and 7 (2.41-fold; 
Dunn’s test, p = 0.0213). 
 
Figure 18. Changes in the expression of IGF-I, during 7 days of Dexa with / without Testo treatments 
in gastrocnemius muscles (n=4, normalized to GAPDH). 
Testo reliably reversed this change. In gastrocnemius, Dexa downregulated IGF-I 
expression in samples collected at days 1 (2.23-fold; Dunn’s test, p = 0.421), 3 (2.55-
fold; Dunn’s test, p = 0.0825), and 7 (1.85-fold; Dunn’s test, p = 0.175). A similar trend 
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was seen in quadriceps, but the amplitude was smaller, perhaps owing to the fact that 
Dexa-induced changed in IGF-I were smaller. 
Throughout this section, the molecular correlates of GAML, as found in rats, were 
confirmed in this novel mouse model. However, few of the effects of Dexa were reversed 
by Testo, at the resolution of my experimental design. However, among the putative 
mechanisms of alleviation of GAML, there is good evidence for the repression of the 
proteasome - ubiquitin system and for restoration of intramuscular IGF-I. In the next 
section, I describe my efforts to better understand these myoprotective mechanisms, 
using an in vitro model. 
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IN VITRO FINDINGS 
Testosterone alleviates dexamethasone-induced atrophy of cultured cells 
In mouse explanted myofibers and C2C12 cultured myotubes, muscle atrophy is a 
cell-autonomous phenomenon, with all its essential manifestations present in vitro. I 
hypothesized that the muscle protection by Testo could be replicated in C2C12 cells. 
Indeed, fully differentiated C2C12 myotubes treated for 48 h with 50 µM Dexa lost 
8.66% in diameter (Tukey’s HSD, p = 0.000316). Co-administration of 300 nM Testo re-
established basal diameters (Tukey’s HSD vs. Dexa alone, p = 1.02e-05). 
 
Figure 19. Changes in C2C12 myotube diameter following Dexa with / without Testo treatments. 
Micrographs are representative for cells receiving (top left) vehicle, or (top right) 50 µM Dexa, or 
(bottom left) 50 µM Dexa and 300 nM Testo. Bottom right image compares average myotube 
diameters for the three treatments (n=510-740). 
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Figure 20. Changes in C2C12 myotube total protein content following Dexa with / without Testo 
treatments (Top) Absolute total protein density. (Bottom) The same data, after normalization to the 
average of the initial time point for each condition (n=5-6). 
In another experiment, I tested the ability of Testo to preserve protein content in 
C2C12 cells. In order to determine the time course of protein content, cells were treated 
with (A) vehicle, (B) 1 µM Dexa, (C) 1 µM Dexa and 100 nM Testo, or (D) 1 µM Dexa 
and 500 nM Testo, for up to three days, in increments of 24 h (Fig. 20, top). All the 
treatments led to loss of total protein starting from the third day, presumably due to 
senescence and / or loss of viability (ANOVA treatment x time, p = 0.000463 for time 
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variable). When all the samples were analyzed together, treatment had no significant 
effect (ANOVA treatment x time, p = 0.0943 for treatment variable). 
However, there were differences in total protein density prior to the third day, 
which mimicked the in vivo findings. These trends become apparent when data is 
represented after normalization to the initial time point (Fig. 20, top), or when data is 
analyzed only across days 1-3. In the first two days, there were no relevant changes in 
total protein content in cells treated with vehicle. Total protein concentration was 81.8 
µg/cm2 in the first day, 81.1 µg/cm2 in the second, and 81.6 µg/cm2 in the third 
(ANOVA p = 0.957). In contrast, Dexa-treated cells lost protein, declining from 83.3 
µg/cm2 in the first day to 81.4 µg/cm2 in the second and 78.9 µg/cm2 in the third day of 
the experiment (5.32% loss; ANOVA p = 0.957). Co-administration of Testo more than 
compensated the effect of Dexa. Rather than losing protein, cells receiving a combination 
of 1 µM Dexa and 100 nM Testo gained 4.99 % total protein over the first two days of 
the experiment (ANOVA p = 0.957). Moreover, increasing the Testo dose to 500 nM 
further improved protein accretion, leading to a 7.16 % protein gain during the first two 
days of the experiment (ANOVA p = 0.957). 
Overall, the changes in cell diameter and total protein content are similar to 
changes observed in muscle in vivo. 
Protein synthesis in cultured cells treated with dexamethasone and testosterone 
In preliminary experiments, I found that tracer uptake is minimal during the first 
two hours. In addition, tracer uptake rate became essentially equal to the rate of tracer 
release due to protein synthesis after the first 18 h of labeling. Therefore, I performed a 
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series of assays where the rate of protein synthesis was estimated through the rate of 
tracer uptake over an intermediate 6 h (Fig. 21, top). In each case, cells were 
differentiated over seven days, then treated with (A) vehicle, (B) 1 µM Dexa, or (C) 1 
µM Dexa and 500 nM Testo, for either 6, 24, 48, or 72 hours. The media with steroids 
was refreshed every 24 hours. The tracer was added with a final medium change, six 
hours before lysis. 
After lysis, cells were assayed for protein-bound tracer. There was no effect of 
treatment on the amount of tracer taken up by the cells (Fig. 21, middle). To avoid the 
confounding influence of the atrophy, data was also analyzed as specific activity, that is, 
protein-bound intracellular tracer normalized to the mass of cell protein (Fig. 21, bottom). 
The same qualitative observations could be made after normalization. There was a 
significant effect of time on the rate of protein synthesis (ANOVA treatment x time, p = 
2.45e-08 for time variable). The time variable was significant due to a downward trend 
form days 2 through 4. This trend adds to the notion that C2C12 fully differentiated 
myotubes quickly lose their viability. When all the samples were analyzed together, 
treatment had no significant effect (ANOVA treatment x time, p = 0.302 for treatment 
variable). There is no statistically significant difference between treatments at each time 
point. The amplest difference in translation rate between treatments is in day 4, when, in 
Dexa cells, protein synthesis rate is higher than in all other conditions (specific activity 
10.6% higher than vehicle, and 13.5% higher than the combination with testosterone). 
The trend toward increased protein synthesis with Dexa cannot explain the observed 
myotube atrophy induced by Dexa. Moreover, the late onset of protein synthesis 
  
157 
upregulation indicates that this may be a compensatory response to the earlier loss of 
protein. 
 
 
Figure 21. Estimates of protein synthesis rate in C2C12 myotubes treated with Dexa with / without 
Testo. (Top) Experimental timeline. (Middle) Amount of tracer incorporated into protein per well. 
(Bottom) Amount of tracer incorporated into protein per gram of total protein (n=6). 
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Within the limits of the C2C12 model utilized in these experiments, protein 
synthesis changes do not appear to mediate Dexa-induced loss of protein, nor its 
alleviation by Testo. 
Testosterone prevents protein catabolism upregulation induced by dexamethasone 
A series of complementary experiments estimated the rate of protein degradation 
in C2C12 myotubes. In each case, cells were differentiated over seven days, then treated 
with (A) vehicle, (B) 1 µM Dexa, (C) 1 µM Dexa and 100 nM Testo, or (D) 1 µM Dexa 
and 500 nM Testo, for either 6, 24, 48, or 72 hours (Fig. 22, top). The media with steroids 
was refreshed every 24 hours. The tracer was added three days before the addition of 
steroids, and was maintained in the media until 6 hours before lysis. Because the rate of 
incorporation of tracer slows down before the first 24 hours, and therefore it may be 
assumed that, with some approximation, the ratio of tracer to tracee in culture medium is 
equal to that in the pool of rapid-turnover intracellular protein. 
Preliminary experiments revealed that scintillation data were not completely 
additive. In this experiment, the amounts of free tracer from cell extract and protein-
bound tracer in the medium proteins are tens of times lower than the free tracer in the 
medium, and the protein-bound tracer in the cells. In order to avoid addition of non-
additive data, protein degradation rate was estimated from the ratio of free tracer in the 
cell culture medium to protein-bound tracer in the cell extract (Fig. 22, middle). 
However, the results are essentially identical when free tracer from cell extract and 
protein-bound tracer in the medium proteins are taken into account. This scintillation-
based method is semi-quantitative, meaning that a doubling of the ratio of free tracer in 
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the cell culture medium to protein-bound tracer in the cell extract does not indicate a 
doubling in protein degradation rate, but merely its upregulation. 
 
 
Figure 22. Estimates of protein degradation rate in C2C12 myotubes treated with Dexa with / 
without Testo. (Top) Experimental timeline. (Middle) Ratio of tracer in medium to tracer in cells, 
across time points. (Bottom) Ratio of free tracer in medium to protein-bound tracer in cells, at day 2 
(n=5-6). 
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Overall, due to sample size, the treatments were not statistically significant across 
time points (ANOVA time X treatment, p = 0.401 for time; p = 0.259 for treatment). 
Nevertheless, the effects of the two steroids were ample and dose-dependent at the 24 
hour time point (ANOVA between treatments, p = 0.144; fig. 22, bottom). For 24-hour 
vehicle-treated cells, the ratio of free medium tracer to protein-bound intracellular was 
0.0968. When cells received 1 µM Dexa, the ratio of free medium tracer to protein-bound 
intracellular increased to 0.661 (Tukey’s HSD vs. vehicle, p = 0.202). Co-administration 
of Testo had a dose-dependent inhibitory effect on protein degradation. When Dexa was 
supplemented with 100 nM Testo, the ratio of free medium tracer to protein-bound 
intracellular was reduced to 0.388 (Tukey’s HSD vs. Dexa alone, p = 0.776). When Dexa 
was supplemented with 500 nM Testo, the ratio of free medium tracer to protein-bound 
intracellular was further reduced to 0.0713 (Tukey’s HSD vs. Dexa alone, p = 0.173). 
A similar trend was recorded at the 48-hour time point. For 48-hour vehicle-
treated cells, the ratio of free medium tracer to protein-bound intracellular was 0.062. 
When cells received 1 µM Dexa, the ratio of free medium tracer to protein-bound 
intracellular increased to 0.0699 (Tukey’s HSD vs. vehicle, p = 0.182). Co-administration 
of 100 nM Testo reduced the ratio of free medium tracer to protein-bound intracellular to 
0.0607 (Tukey’s HSD vs. Dexa alone, p = 0.12). 
Overall, Dexa myotube atrophy is correlated with an increase in tracer release, 
indicating an upregulation of protein degradation. Testo protection of myotubes is 
correlated with an inhibition of protein degradation. 
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Mechanisms of androgenic myoprotection in cultured myotubes treated with 
dexamethasone 
In previous experiments, I established that loss of C2C12 myotube protein during 
Dexa treatment is associated with an increase in protein degradation at 24 hours after the 
initiation of steroid. Using a series of chemical inhibitors, I investigated the molecular 
mechanisms that could mediate this catabolic upregulation (Fig. 23, top). As in the 
previous experiment, cells were differentiated over 7 days. In the final three days of 
differentiation, medium with tracer was refreshed daily. For the final 24 hours, the tracer 
was removed, and cells were treated with (A) vehicle, (B) 100 nM Dexa, or (C) 100 nM 
Dexa and 300 nM Testo. In order to interfere with putative proteolytic pathways, other 
sets of cells were treated with (D) 100 nM Dexa and 25 µM chloroquine, an inhibitor of 
autophagy, or (E) 100 nM Dexa and 5 µM MG132, an inhibitor of the proteasome. 
Finally, in order to interfere with IGF-I signaling, another set of cells were treated with 
(F) 100 nM Dexa, 300 nM Testo, and 50 nM picropodophyllin, an inhibitor of IGF-1R. 
The medium and the cells were fractionated as in the previous experiment. Protein 
degradation rate was estimated via the ratio of free tracer in the medium to protein-bound 
tracer in the cells. When cells were treated with vehicle alone, the ratio of free medium 
tracer to protein-bound intracellular was 0.826. When cells received 100 nM Dexa, the 
ratio of free medium tracer to protein-bound intracellular increased to 1.55 (Tukey’s HSD 
vs. vehicle, p = 0.000104). 
The upregulation in catabolism was dependent on both proteasome and lysosome 
actions. When the lysosome was inhibited with chloroquine, the ratio of free medium 
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tracer to protein-bound intracellular was brought back to basal levels (0.614; Tukey’s 
HSD vs. Dexa, p = 1.44e-06). However, proteasome inhibition had a more ample result, 
with the ratio of free medium tracer to protein-bound intracellular depressed to 0.132 
(Tukey’s HSD vs. Dexa, p = 2.4e-10). 
 
 
Figure 23. Interference of protein degradation in C2C12 myotubes treated with Dexa with chemical 
inhibitors. (Top) Experimental timeline. (Bottom) Ratio of tracer in medium to tracer in cells (n=5-
6). 
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Testo repressed the upregulation of catabolism brought by Dexa to basal levels 
(free medium tracer to protein-bound intracellular tracer 0.714; Tukey’s HSD vs. Dexa, p 
= 2.35e-05). The protective effect of Testo was not apparently altered by the inhibition of 
the IGF-1R pathway (free medium tracer to protein-bound intracellular tracer 0.701; 
Tukey’s HSD vs. Dexa, p = 1). 
Overall, in C2C12 cells, Dexa upregulates protein degradation, mainly through 
the activation of the proteasome. Testo reverses the activation of proteolysis in an 
apparently IGF-1R-independent manner, based on the experimental sensitivity used in 
these assays. 
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DISCUSSION 
Testosterone alleviates dexamethasone-induced muscle atrophy in mice 
The present work investigated the molecular mechanisms mediating androgen 
attenuation of GC-induced muscle atrophy in mouse. While the myoprotective action of 
Testo was demonstrated in humans and rats, to date the role of Testo in GC-mediated 
atrophy has not been studied in the mouse. In fact, although some studies investigated 
transcriptional changes in mouse muscle in response to Dexa, surprisingly few have 
described macroscopic (organ level) atrophy. 
In this dissertation, I demonstrated that a dose of 10 mg d/kg Dexa induced a 
significant loss of muscle, as evidenced by decrements in lean body mass and changes in 
the weight of individual muscles. The effect was progressive, with the losses of lean body 
mass at day 3 being roughly half of the losses at day 7. The observed time dependence is 
evidence for a Dexa-specific effect. As expected, lean body mass was essentially 
unchanged in mice treated with vehicle alone. The measurement of fat body mass 
indicated that the mice treated with vehicle had essentially unchanged tissue fat during 
the experiment. The unchanged lean and fat tissue content is evidence for the fact that the 
experimental manipulations had no effect by themselves. The robustness and quality of 
the study design of the study animals was further supported by the fact that Dexa exerted 
its expected stimulatory effect on accretion of body fat. 
The observed change in total body mass was approximately equal to that in lean 
body mass. This may explain why changes in body weight (Fig. 3), rather than body 
weight at sacrifice (Fig. 2), were significantly altered by Dexa treatment. No other organ 
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appeared to undergo atrophy upon Dexa treatment. Dissection revealed no significant 
changes in the size of viscera. No detectable changes were seen in the wet weight of the 
heart (data not shown). 
Gastrocnemius and quadriceps were the more sensitive muscles to Dexa, whereas 
tibialis was essentially unchanged. The lack of response in tibialis was surprising, given 
how common mouse tibialis manipulation, such as electroporation of DNA, has been 
described in literature. A report published during this work similarly failed to observe 
tibialis anterior atrophy following 14 days treatment with a slightly lower Dexa dose 
[426]. With 54% fast glycolytic fibers in gastrocnemius, compared to 59% in tibialis 
anterior [614], the two muscles appear very similar in fiber type distribution. Therefore, 
even if fiber typing was not evaluated in my model, it is unlikely that differences in 
muscle sensitivity stem from differences in fiber type. The lack of sensitivity in tibialis 
may have been due to the fact that the tendinous component is weighing more in relative 
terms, compared to large fleshy muscles. 
There was a remarkable similarity between the first 3 days of the in vivo 
experiment and the in vitro findings at 48 hour time point. Whereas quadriceps lost 6% of 
their weight, C2C12 myotubes lost about 5% of their total protein upon Dexa treatment. 
This rate is similar to that indicated by Desler for C2C12 myotubes that had been 
differentiated over three days and then treated with Dexa [546]. 
In contrast to the in vivo studies, the in vitro study could not have been extended 
beyond the early days. Cells ability to thrive degraded towards their third day of Dexa 
treatment, that is, their ninth day of differentiation. The significant reduction in protein 
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synthesis seen at the 72-hour time point suggests that the cells became less metabolically 
active compared to the 48-hour time point, perhaps due to senescence. Therefore, the in 
vitro model appears inadequate beyond the 48-hour time point. Moreover, the atrophic 
fibers’ diameter becomes comparable with that of the nucleus after the first two days 
(Fig. 19). Further reductions in cell diameter would have required a shrinkage of the 
nucleus, which has not been observed in the first two days of myotube atrophy. It was 
therefore not possible to develop a longer term in vitro model of muscle atrophy. 
Co-administration of Testo alleviated all macroscopic Dexa effects. Similar to the 
profile of Dexa action, in absolute terms, the recovery in lean body mass was 
approximately equal to that in total body weight. The percentage by which total body 
weight, lean body mass, and individual muscles recovered were similar, indicating that 
Testo action was limited to muscle. 
The experimental protocol may not have been ideal for observing the time course 
for Testo action. On the one hand, the body weight changes during the 7-day experiment 
(Fig. 3, top) suggest that the protective action of Testo begins with the first day of 
experiment. On the other hand, the time course was not reflected in the individual muscle 
weight (Fig. 5). While 7-day samples appear effectively protected by Testo, 3-day 
samples displayed a more limited anabolic response. This discrepancy may be due to the 
fact that the mice analyzed in the 7-day study were slightly more developed than those 
used in the 3-day sample. This was indicated by the difference in levator muscles at 
sacrifice between vehicle-treated animals at each time point. Moreover, the detection of 
the Testo protective effect on muscle mass may be strained by its incomplete nature. 
  
167 
Because Dexa effect is progressive, its amplitude in the early stages is necessarily small. 
When Dexa-induced atrophy is hard to detect, its incomplete reversal will be even harder 
to demonstrate. I could not exclude a temporal dissociation between the actions of the 
two steroids, as the changes surrounding the acute onset of GAML were not investigated 
in more detail, which was beyond the scope of this work. At the 7-day time point, which 
is the more representative model of chronic glucocorticoid myopathy, the alleviation of 
GAML has been well established. 
The alleviation following Testo was incomplete in terms of lean body mass and 
individual muscle weights. In contrast, total body weight completely recovered. The 
source of this discrepancy remains unclear. Dissection revealed no other viscera with an 
appearance of hypertrophy following Testo co-administration. The dose of Testo used 
here was shown to be effective in rats. However, the Dexa dose used in the rat studies 
was much smaller, suggesting that mice studied here may have benefited even more from 
an increased dose of Testo. Moreover, mice may be intrinsically less responsive to Testo 
than rats, as the former appear to be more resistant to many pharmacological treatments, 
such as Dexa (reviewed here) or streptozotocin [615]. The most effective dose of Testo to 
fully prevent GAML should be pursued in future studies. Within the limits of the present 
data, it may be the case that no Testo dose would have overcomed the Dexa-induced 
atrophy, which would then imply that atrophy inducing mechanisms of Dexa potentially 
include pathways outside the scope of anabolic stimuli. 
Notably, there were differences in the responsiveness to Testo between muscle 
groups. Similar to Dexa sensitivity, an important component appears to be the tendinous 
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content. Levator ani is more responsive to Testo than to Dexa, perhaps being explained 
by the increased presence of AR compared to other muscles [616]. The apparent 
dependence of Testo response amplitude to the expression of AR indicates that 
alleviation of GAML by AAS is a specific effect, rather than an interaction at the GR 
level. 
In vitro, myoprotective action of Testo was similarly present at late time-points. 
The protection of C2C12 myotubes was dose-dependent, based on the total protein assay. 
Paralleling the in vivo system, the myoprotective effect in C2C12 cells was more 
pronounced when the data were normalized to the first time point in the experiment (fig. 
20 top versus bottom).  
Testosterone’s protective action was driven by the inhibition of the dexamethasone-
induced proteasome upregulation 
The mouse model of GAML largely replicated what was known from rat 
experiments, where a strong upregulation of the proteasome system is followed by 
alterations in protein synthesis. 
In vivo, the E3 ligases also known as atrogenes were upregulated in this model 
system. The upregulation of MuRF-1 was robust, and reached statistical significance 
despite a small sample size. Upregulation of MuRF-1 was confirmed at early stages in 
gastrocnemius, quadriceps, and triceps (Fig. 6; the latter not shown). In agreement with 
published studies, the more specific ligase, MAFbx, was upregulated by a lesser 
percentage than MuRF-1. In combination with the practical limitations on sample sizes, 
the low-level activation of MAFbx limited my ability to obtain statistical significance. 
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Nevertheless, the consistent trend across muscle groups of increased MAFbx expression 
in response to Dexa indicates that the second atrogene was also part of the atrophic 
transcriptional program. The massive proteasome upregulation observed in day 3 samples 
increased the probability of the hypothetical scenario in which protein degradation is 
limited by proteasome availability, rather than E3 ligases. However, day 3 also marks the 
peak of proteasome catalytic activity ( 7). The synchronized stimulation of the 
proteasome and of the atrogenes indicates that the proteasome - ubiquitin system may be 
at the center of GAML. 
All these catabolic changes were inhibited by Testo co-administration. In vitro, 
atrogenes expression was reduced to basal levels, and, in the case of day 7 samples, even 
below baseline levels. The inhibitory effect of Testo on MuRF-1 was predicted by the 
microarray study on rat muscle. Similar to the rat study, the changes in MAFbx were also 
in agreement with the phenotype, but of a lesser amplitude. In addition, the proteasome 
activity was suppressed at its day 3 peak. This aspect of muscle atrophy, already 
demonstrated as a component of male post-castration muscle atrophy [606], has never 
been investigated in GAML, nor in its attenuation by Testo. 
Upregulation of proteasome activity, independent of atrogene status, has been 
reported by others [431]. It is unclear how Dexa achieves this upregulation. In this study, 
limited evaluation of transcripts for proteasome subunits A6, B10, or D4 were 
inconclusive (data not shown). 
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In vitro, proteasome inhibition led to nearly complete suppression of proteolysis, 
beyond the basal levels seen in vehicle-treated cells. This finding indicates that most of 
the proteolytic activity in C2C12 cells is dependent on the proteasome. 
A study by Baehr and colleagues [426], which was published while my 
experiments were under way, showed that MAFbx knockout did not reduce the amplitude 
of GAML, while MuRF-1 knockout reduced GAML to about half of its amplitude in 
wild-type mice. My data show that, instead of rejecting the proteasome-centered model of 
GAML, future studies should focus on finding alternative ways by which the proteasome 
promotes catabolic activity. For example, the simplest scenario fitting today’s data is one 
where the proteasome performs the clearance of the bulk of dispensable proteins. An 
alternative explanation, which takes into account the subsiding evolution of the atrogene 
surge, is that atrogenes ubiquitinate, and target for degradation, a yet unidentified 
myoprotective intracellular factor, thus unleashing a cascade of proteasome-independent 
mechanisms. Some limited attempts to detect multiple ubiquitination states for MuRF-1’s 
putative substrate, myosin heavy chain, were inconclusive (data not shown). If MuRF-1 
has only this limited and limiting action, disruption of MuRF-1 in Baehr’s knockout mice 
could have been supplanted by partially homologous genes, such as MuRF-2 or Fbxo40 
[617, 435]. The distinction between the two scenarios is difficult, especially in the in vivo 
approach. In either scenario, the role of the proteasome is indispensable for GAML. 
Nevertheless, proteasome inhibition by Testo co-administration emerges from this work 
as an important mechanism of GAML alleviation. 
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The experiments performed in this study clearly exclude a role for the 
autophagosome - lysosome system in digestion of bulk myofiber proteins. The in vivo 
data indicate a persistent suppression of autophagy-related genes across muscle groups 
and time points. Moreover, lysosome-associated cathepsin L enzymatic activity is 
suppressed by Dexa in a statistically significant manner at all time points. The 
downregulation of cathepsin activity and expression was more ample than the loss of 
muscle protein, indicating that an active process of cathepsin degradation is activated by 
Dexa in vivo. 
The finding of Dexa-induced downregulation of autophagy was unexpected. 
Some atrophic conditions, most notably starvation, lead to autophagy regulation. The rat 
microarray findings found cathepsin L among the set of genes upregulated by Dexa. Even 
in this study, a narrow measurement, the accumulation of lipidated LC3 appeared 
upregulated by Dexa (Fig. 10, middle). However, the microarray results were never 
validated by qRT-PCR. In the present work, when the hyperlipidated LC3 form is 
normalized to its precursor, its levels appeared essentially unchanged in response to Dexa 
(Fig. 10, right). The accumulation of LC3 protein, both in precursor and mature form, 
indicates reduced capacity in the autophagolysosome compartment, especially in the 
present context of downregulated LC3 protein expression. This line of evidence 
corroborates the downregulated enzymatic activity to collectively exclude a putative role 
for autophagy in bulk GAML. 
Intuitively, it is more likely for bulk protein catabolism to be mediated by the 
smaller proteasome and atrogenes than the larger autophagosome. However, autophagy 
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may play a regulatory, initiating role in GAML. In the in vivo studies, the amplitude and 
invariability of autophagy inhibition prove its modulation by Dexa. One could speculate 
that such changes, ampler than those in muscle mass, cannot be simple inconsequential 
side effects. While the present data solidly exclude a role for bulk protein digestion, 
further studies are needed to elucidate which proteins are spared from autophagy during 
GAML, and what is the regulatory effect of their sparing from autophagy. 
While the in vivo data suggested that downregulation of autophagy is part of 
GAML, I found the opposite phenomenon in cell culture experiments. There, inhibition 
of lysosomes with chloroquine had a significant protective effect. The differences 
between the in vivo and in vitro data underscore the limitations intrinsic to cell culture 
models. Many factors absent from the cell culture experiment may explain the observed 
contrast, including myoprotective influences of the motor neuron at neuromuscular 
junctions and vascularization of muscle tissue. Moreover, the advanced quiescence of the 
cultured myotubes contrasts with the ample in vivo ability for muscle to regenerate. 
Given the reductionism of the culture cell experiment, the in vivo experiment is likely 
more reflective of what occurs in human glucocorticoid myopathy. The fact that Testo 
reversed most of the in vivo effects of Dexa on autophagy suggests that this pathway may 
be relevant for GAML attenuation. 
Prior to this work, the calpain system was the least likely effector of GAML. In 
agreement with the literature, this study could not substantiate Dexa-induced changes in 
calpain enzymatic activity, calpain, or calpastatin protein levels (data not shown). 
Overall, the absence of Dexa-induced amplification in catabolic activity in the cathepsin 
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and calpain pathways reduces the scope for AAS myoprotection through inhibition of 
these pathways. Moreover, Testo had no reliable effect on the Dexa-induced changes in 
the autophagosome - lysosome pathway. Therefore, Testo protection is unlikely to be 
mediated by inhibition of cathepsin or calpain. 
Studies on protein synthesis rate have been strained by the limited technical 
abilities of measuring protein synthesis in mice. No study that I am aware of measured 
changes in the rate of protein synthesis in mice prior to this work. The studies on rats 
indicated that such measurements are fraught with high variability, and would therefore 
likely fail to detect any effect. I did not measure protein synthesis directly in vivo. The 
measurements of protein synthesis rate in vitro failed to identify any significant change in 
response to Dexa. C2C12 cells are surprisingly dependent on protein synthesis, with 
either translational inhibitor cycloheximide and puromycin leading to cell death and 
detachment within hours (data not shown). Overall, the lack of detectable changes in 
protein synthesis rate agrees with findings in rat L6 cells [397] and explanted muscle 
experiments [322]. 
In order to detect subtle changes in protein synthesis, I investigated a series of its 
regulators. I failed to identify changes in levels of phosphorylated eIF2α and eIF3f in 
response to either Dexa or Testo (Figs. 12, 13). I could not detect ATF4 protein in muscle 
lysates (data not shown). In the 7-day samples, both total and phosphorylated 4E-BP 
were upregulated by Dexa. With these data, it was unclear whether the active negative 
regulator of protein synthesis, unphosphorylated 4E-BP was increased or decreased by 
chronic Dexa exposure. The changes in total and phosphorylated 4E-BP induced by Testo 
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are small, and would be unlikely to lead to increased inactivation of 4E-BP. Therefore, 
based on these data and the limitations of the model system, there was no evidence that, 
at 7-day time point, that the protective action of Testo benefited from increased protein 
synthesis. 
While the reported experiments were ongoing, Baehr and colleagues reported that 
Dexa decreased protein synthesis rate at day 3 and increased it at day 14 in mouse triceps 
[426]. Baehr et al. findings suggest that acute Dexa represses protein synthesis, whereas 
chronic Dexa is associated with a compensatory restoration of translational capacities. At 
the 7-day time point analyzed in this study, a measurement of protein synthesis by 
Baehr’s method would have been indecisive, as the muscle would have been midway in 
the switch from a low to high translation rate. 
In conclusion, Testo induced muscle protection through multiple mechanisms, 
among which inhibition of the proteasome system stood out by amplitude and 
persistence. 
Molecular mechanisms linking dexamethasone and testosterone to protein 
metabolism 
In agreement with the rat studies, the present work demonstrates that Dexa-
induced upregulation of atrogenes is coordinated with increased expression of Foxo 
transcription factors (Fig. 15, top). A Foxo3a surge was even more robust than the 
increase in MuRF-1, with a statistically significant presence in day 1 samples. Moreover, 
the transcription factor Klf15, which is a target of Foxo, and their synergistic partner in 
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the upregulation of MuRF-1, underwent an equally rapid intensification (Fig. 15, 
bottom). 
In addition to repression of atrogenes, Testo reverses other actions of Dexa. This 
efficient, multi-directional action of Testo suggests that it may act on a higher-level 
mediator of GAML. Two molecular levers responded in a uniform, consistent manner to 
the two steroids, and therefore may be high-level mediators of AAS and GC. The first is 
REDD1 / Ddit4, the negative regulator of mTORC1. Dexa consistently upregulated 
REDD1 expression in samples from days 1, 3, and 7. The amplitude of upregulation 
decreased with time. A time course where Dexa amplifies REDD1 only for the first week 
could explain Baehr’s observations on protein synthesis changes during GAML. As 
REDD1 inhibition of mTORC1 subsides, the 4E-BP-mediated brake on protein synthesis 
is gradually reduced. Testo co-administration reversed REDD1 upregulation to a 
significant degree at 7-day time point, when Dexa-induced amplification was at its 
lowest. Further experiments are needed to analyze the relationship between REDD1 and 
protein synthesis, especially at later time points, which have not been investigated here. 
The transcriptional upregulation of Foxo by Dexa may have been compounded by 
Akt inhibition. GC caused a large decrement in Ser 473 phosphorylation of Akt (Fig. 16), 
which in turn is expected to protect Foxo from export to cytosol and proteasome-
mediated destruction. AAS had no apparent effect on Ser 473 phosphorylation. The 
discrepancy between Ser 473 phosphorylation and muscle recovery may be explained 
within the model described by Britto [494], who showed preliminary evidence that Ser 
473 is not involved in Akt inactivation during GAML. Another explanation is based on 
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the ability of Dexa to disconnect Akt from insulin and IGF-I signals (discussed in a 
dedicated section). The only other trait shared between mice receiving Dexa with versus 
without Testo is accumulation of fat mass, suggestive of whole-body insulin resistance. 
At the level of muscle, Dexa induces insulin resistance by interference at IRS 1 and p85 
levels. 
The other reliable change in GAML and its alleviation by Testo was observed in 
IGF-I expression. In agreement with studies on rats, Dexa reduced IGF-I expression, 
while Testo co-administration restored reduced IGF-I expression to basal levels (Fig. 18). 
In agreement with all previous studies, I could not substantiate changes in the 
phosphorylation of IGF-1R that would correlate with the IGF-I upregulation (data not 
show). It is unclear to what extent IGF-I would mediate AAS myoprotection given the 
aforementioned interference by Dexa at IRS 1 and p85. 
In vitro, I attempted to gauge the role of IGF-1R in Testo myoprotection. A novel 
IGF-1R inhibitor, picropodophyllin, had no effect on Testo protection. However, the 
same experiment uncovered a series of other shortcomings of the cell culture experiment, 
including a higher reliance on autophagy compared to the in vivo model. Better causal 
inferences could be made by employing in vivo transgenic models of interference within 
the IGF-I / Akt / mTORC1 axis. 
Future directions 
This work demonstrates that Testo protects mouse muscle in vivo and in vitro by 
reversing the Dexa-induced upregulation of proteasome activity. On the other hand, the 
set of E3 ligases that cause GAML is incomplete. The role of candidates such as Fbxo40 
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remains to be investigated. Future studies will need to determine whether Testo 
suppresses the other E3 ligases. 
At this time, the mechanisms by which Dexa upregulates Foxo transcription 
factors is a subject of speculation. Even less is known about the way in which Testo 
represses Foxo. Chromatin immunoprecipitation tests using Foxo promoters would help 
resolve this question. 
The in vivo experiment suggest that Testo also reversed Dexa-induced repression 
of autophagy. The role of autophagy in GAML would be better understood by observing 
the effects of GC and AAS on muscle from LC3-GFP transgenic mice. 
Both autophagy and protein synthesis appeared to have changed in time, during 
the in vivo experiment. Because they were performed as three independent experiments, 
an ability to infer the time course of changes was limited. A direct exploration of time-
dependent changes is required, in order to establish which changes in protein metabolism 
are late-onset, reactive adjustments. 
I was not able to observe the effect of IGF-I modulation, due to an overarching 
suppressive effect of Dexa which disconnects the transmembrane receptors from their 
Akt effector. The mechanisms by which Dexa achieve this disconnection are largely the 
subject of speculation. Future studies that establish if and how GR interferes with the 
IGF-I / Akt pathway are needed. 
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Figure 24. Mechanisms of AAS alleviation of GAML 
Transgenic models, such as the triple Foxo knockout, are needed, in order to 
determine the relative importance and the eventual interaction between Foxo and the 
mTOR pathway. 
Conclusions 
Testo co-administration attenuates the loss of muscle mass induced by GC 
administration in mice. Based on the model systems used in this thesis, Testo 
myoprotection was exerted through an inhibition of the proteasome, mediated by Foxo 
and REDD1. Changes in these, as well as in IGF-I intramuscular expression, indicate that 
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the two classes of steroids counter each other’s effect on the Akt signaling pathway (Fig. 
24). AAS therapy may be beneficial for a subset of male adult patients receiving chronic 
GC as a treatment, especially if they present with biochemical and clinical signs of 
hypogonadism. The relative importance of the proteasome in glucocorticoid myopathy 
suggests that in addition to Testo, other more direct proteasome inhibitors such as 
bortezomib, may be useful as adjunctive therapy. 
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